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ABSTRACT  
 
Autoimmune thyroiditis is a chronic disease characterized by mononuclear cell 
infiltration in the thyroid gland and production of anti-thyroglobulin (Tg) antibodies. In 
this thesis, we have used the murine models of experimental autoimmune thyroiditis 
(EAT) and iodide-accelerated spontaneous autoimmune thyroiditis (ISAT) to investigate 
the immunoregulation of the disease. 
 
In the EAT model, we have examined whether putative H2Ak-binding Tg epitopes, 
located adjacent to cathepsin cleavage sites within mouse Tg would have 
immunopathogenic properties. The peptides, p2369 and p2439, elicited significant 
proliferative T cell responses and production of IL-2 and IFN-γ in recall assays using 
lymph node cells from peptide-primed mice. Both peptides were pathogenic in CBA/J 
mice after direct challenge with the peptide in CFA and by adoptive transfer of peptide-
primed lymph node cells into naïve recipient hosts. 
 
In the ISAT model, we have examined whether NOD.H2h4 thyrocytes are highly prone to 
iodide-mediated apoptosis since such an event could theoretically trigger ISAT in this 
strain. Our data showed that NOD.H2h4 thyrocytes cultured with low NaI concentrations 
had significantly higher apoptotic rates compared to CBA/J thyrocytes. Increased 
apoptosis was associated with an impaired control of oxidative stress mechanisms since 
the expression of only two genes involved in ROS metabolism and/or anti-oxidant 
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function were upregulated in iodide-treated NOD.H2h4 thyrocytes vs. 22 genes in iodide-
treated CBA/J thyrocytes. Next, we examined the immunopathogenicity of the Tg 
epitope, a.a. 2549-2560 (T4p2553) in NOD.H2h4 mice. The epitope was 
immunopathogenic in this strain after direct challenge with peptide in CFA. In ISAT, 
peptide-specific proliferative responses were recorded using only cervical lymph node 
cells (CLNC) from iodide-fed mice before the onset of the disease. Also, selective 
enrichment of CD4+ IFN-γ+ T4p2553-specific cells was observed among CLNC and 
intrathyroidal lymphocytes.  T4p2553 was equally detectable on dendritic cells from 
CLNC regardless of iodide intake whereas spontaneous T4p2553-specific IgG responses 
were not detectable. Our data identified for the first time a Tg T-cell epitope as a 
spontaneous target in ISAT. 
 
Lastly, we have examined whether a high salt diet can exacerbate autoimmune thyroiditis 
because previous studies by other groups had suggested this diet as a predisposing factor 
for autoimmune diseases in general. Our data showed that high salt intake failed to 
significantly affect the incidence and severity of SAT in NOD.H2h4 mice or EAT in Tg-
primed C57BL/6J and T4p2553-primed CBA/J mice relative to mice on a normal diet. 
No difference was detected at the Tg-specific IgG levels between the two groups. These 
data demonstrate that a high salt diet is not a risk factor for all autoimmune diseases. 
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Chapter 1   
Introduction & Overview 
 
1.1. Thyroid gland and function 
The thyroid is the largest endocrine gland in humans and it is located in the middle of the 
neck. It consists of two lobes that are connected by the isthmus, normally located on the 
second or third ring of the trachea. The thyroid is comprised of follicles and a small 
number of parafollicular calcitonin-producing cells, the C-cells, which make up about 
10% of the thyroid mass. The thyroid follicles are composed of an outer layer of 
epithelial cells called thyrocytes, while the interior of the follicle, the lumen, contains 
thyroglobulin (Tg), a protein produced only by thyrocytes. Tg acts as a prohormone for 
the thyroid hormones thyroxine (T4) and triidothyronine (T3). T4 and T3 are eventually 
secreted by thyrocytes into the bloodstream, following Tg proteolysis in the thyrocyte 
(Santisteban 2005). 
 
The thyroid hormones are involved in the regulation of the cellular metabolic rate, heart, 
digestive and muscle function, brain development and bone maintenance (Chi et al. 
2013). Due to their crucial role in many biological activities, the levels of the thyroid 
hormones are regulated by a negative feedback loop (Santisteban 2005). Disturbance of 
this regulatory mechanism can lead to overproduction or decreased production of the 
thyroid hormones, causing the pathological conditions hyperthyroidism and 
hypothyroidism, respectively.  
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1.2. Hashimoto’s thyroiditis  
One of the most common causes of hypothyroidism is the autoimmune disease of the 
thyroid gland called Hashimoto’s thyroiditis (HT) (Farwell, Braverman 1996), also 
known as lymphocytic thyroiditis or struma lymphomatosa. HT, described for the first 
time in 1912 by Dr. Hakaru Hashimoto (Hashimoto 1912), is a chronic disease 
characterized by thyroid infiltration of hematopoietic mononuclear cells, mainly 
lymphocytes, plasma cells and macrophages, as well as by the presence of serum 
antibodies (Abs) against Tg and thyroid peroxidase (TPO) (Caturegli et al. 2014). 
Intrathyroidally, lymphocytes can either form lymphoid follicles resembling germinal 
centers or come in close contact with thyrocytes to mediate their destruction (Caturegli et 
al. 2014). Tissue injury can be mediated by cytotoxic T cells or by cytokines release by T 
cells (Weetman, McGregor 1994). Also, thyroid-specific Abs can cause injury either 
through complement activation (Chiovato et al. 1993) or by ab-dependent cellular 
cytotoxicity (Bogner et al. 1984). Patients with HT can display a wide spectrum of 
clinical symptoms ranging from formation of germinal centers in the thyroid, fibrosis, 
thyroid cell hyperplasia and/or enlargement of the thyroid gland (goiter), usually leading 
to hypothyroidism (Weetman 1996). 
 
HT can occur alone or in association with other autoimmune diseases like type I diabetes 
mellitus or Sjögren’s syndrome. Also, HT has been associated with papillary thyroid 
cancer in 0.5 to 30% of the cases (Caturegli et al. 2014). The prevalence of HT is 
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reported as 8 cases per 1000 persons (Jacobson et al. 1997) and it is 8 times more 
frequent in women than men in white and Asian populations (Caturegli et al. 2014). 
 
So far, there is no cure for HT. Patients with hypothyroidism receive synthetic T4 orally, 
the only effective drug available, daily for life. In cases where severe cervical 
compression has occurred or thyroid cancer is also present with HT, thyroidectomy is 
performed (Caturegli et al. 2014). Therefore, treatment for HT deals only with the 
symptoms of the disease and not with its pathogenesis. 
 
1.3. Autoantigens in autoimmune thyroiditis 
1.3.1 Thyroglobulin 
Tg is a large dimeric glycoprotein with a molecular mass of 660 kiloDalton (kDa) and 
comprises the most abundant protein of the thyroid gland (~75% of the protein content) 
(Vali et al. 2000). Tg is produced in the cytoplasm of thyroid epithelial cells and is stored 
inside the follicular lumen at concentrations as high as 500 mg/ml (Berndorfer et al. 
1996, Herzog et al. 1992). Two known physiological functions of Tg are: 1) to serve as a 
scaffold protein for the synthesis of the thyroid hormones, T4 and T3; and 2) to store 
available iodide. 
 
Tg consists of two identical polypeptide chains each of which has 2749 amino acids (a.a.) 
(Carayanniotis 2003). This protein is highly conserved among different species; the 
identity between human and bovine is 77.3%, human and mouse 71.8% and 73.5% 
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between bovine and mouse (Vali et al. 2000). The N-terminal region of Tg (residues 1-
2170) contains three types of cysteine-rich repetitive domains, type I, II and III with 
unknown functions (Dunn J.T., Dunn A.D. 2000). The type I domain, about 60 a.a. long, 
is repeated 10 times and may participate in Tg degradation by reversible inhibition of 
proteases (Molina et al. 1996). The type II domain, 14-17 a.a. long, is repeated 3 times, 
whereas the type III domain is repeated 5 times. The C-terminal 250 a.a. segment of the 
protein has a high content of tyrosine residues compared to the other regions. This part of 
the protein shows a striking similarity to the enzyme acetylcholinesterase, a member of 
the type B carboxylesterase family (Dunn J.T., Dunn A.D. 2000). Interestingly, the lack 
of homology between the N- and C-terminal regions as well as the difference in the size 
of the introns between the two regions suggest that they may have been derived from 
different genes that were either fused or condensed to generate the Tg gene (Mori et al. 
1987). 
The Tg gene in humans, mice, rats and cows is located on chromosomes 8, 15, 7 and 14, 
respectively (Dunn J.T., Dunn A.D. 2000). In humans, the Tg gene spans 300 kb and 
contains 48 exons, which are separated by introns of various sizes, up to 64 kb (Mendive 
et al. 2001). Expression of the Tg gene is highly restricted to thyroid cells and is 
controlled by the thyroid-specific transcription factors 1 and 2 as well as the paired-box 
protein, via binding to the highly conserved promoter region (Rubio, Medeiros-Neto 
2009). Exogenous factors such as thyrotropin (TSH), insulin and insulin-like growth 
factor-1 have been shown to stimulate Tg gene expression whereas factors such as 
epidermal growth factor, interferon-γ (IFN-γ), tumor necrosis factor-α (TNF-α) and 
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retinoic acid inhibit Tg gene expression (Dunn J.T., Dunn A.D. 2000). Interestingly, Tg 
itself has been shown to limit expression of Tg as well as TPO and the sodium iodide 
symporter (NIS) gene in FRTL-5 cells (Suzuki et al. 1998). 
The biosynthesis of Tg occurs within the cytoplasm of thyrocytes. The full length of the 
Tg messenger RNA (mRNA) transcript is 8.7 kb (van de Graaf et al. 2001) and is 
translated on polyribosomes bound on the endoplasmic reticulum (ER) of thyrocytes 
(Dunn J.T., Dunn A.D. 2000). The newly synthesized protein undergoes several 
posttranslational modifications, such as glycosylation, sulfation, phosphorylation (Vali et 
al. 2000), in different intracellular organelles before it acquires the proper dimeric 
conformation and becomes stable. First, Tg monomers are transported to the ER via their 
19 a.a. signal peptide in the N-terminus. In this organelle, the first carbohydrates are 
added to Tg and the protein undergoes dimerization with a number of enzymes such as 
protein disulfide isomerase, peptydylpropyl isomerase as well as molecular chaperones 
facilitating the folding of the protein; misfolded protein is transferred back to the 
cytoplasm for degradation. After formation of stable dimers, Tg is transported to the 
Golgi complex for incorporation of the final carbohydrates and sulfation of these units. 
Phosphorylation of Tg also occurs in the cytoplasm of thyrocytes but the organelle in 
which this modification occurs has not been defined. At this stage, a stable form of Tg is 
transferred via exocytotic vehicles to the apical surface of the cells for iodination and 
generation of thyroid hormones (Dunn J.T., Dunn A.D. 2000). 
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Inside the lumen, iodination of Tg occurs in certain tyrosines (25-40 tyrosines out of 140 
available) forming monoiodotyrosine (MIT) and diiodotyrosine (DIT) residues (Vali et 
al. 2000). The iodination reaction is catalyzed by TPO located at the luminal surface in 
the presence of hydrogen peroxide. TPO catalyzes the intramolecular coupling of two 
DIT leading to T4 formation or one DIT and a MIT leading to T3 formation in Tg 
(Arvan, Di Jeso 2005). The thyroid hormone reaction generates T4 or T3 at specific sites, 
called acceptor or hormonogenic sites, while a dehydroalanine is formed at the 
iodotyrosine residue that contributed the outer ring, called donor site. It is unknown 
whether intramolecular coupling occurs in an intrachain or interchain fashion or both. So 
far, four major hormonogenic sites have been identified in the Tg monomer; sites A, B, C 
and D, located at the 5th, 2,554th, 2,747th and 1,291st residue of Tg.  In addition, three 
minor sites, designated as G, N and R, may be generated in certain species under variable 
physiological conditions, i.e. iodide availability (Dunn J.T., Dunn A.D. 2000, Arvan, Di 
Jeso 2005). 
After the thyroid hormones have been generated within Tg, the protein is reabsorbed by 
the thyrocytes and undergoes extensive proteolysis to allow the release of T4 and T3 
from its polypeptide backbone. Proteolysis of Tg starts within the lumen by cathepsins B, 
K and L allowing the solubilization of Tg and extracellular release of T4 (Friedrichs et al. 
2003). Subsequently, thyrocytes take up Tg via receptors expressed on their apical 
surface or by macropinocytosis or by a combination of both in endocytic vehicles (Dunn 
J.T., Dunn A.D. 2000). These vehicles fuse with lysosomes and degradation of Tg 
continues. Lysosomal Tg proteolysis is a complex procedure since many pH-dependent 
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enzymes have been reported to participate in the process: the cysteine endopeptidases, 
cathepsins B, L, H, S (Dunn et al. 1991, Nakagawa, Ohtaki 1984, Petanceska, Devi 
1992), the aspartic endopeptidase cathepsin D (Dunn, Dunn 1982) and the exopeptidases 
dipeptidyl II and lysosomal dipeptidase I (Dunn et al. 1996). Studies, however, have 
highlighted the role of cathepsins B, L and D in Tg processing, since specific inhibition 
of all these proteolytic enzymes blocked the release of iodopeptides from rabbit [125] Tg 
incubated with lysosomal extracts from human thyroids by 80-90% (Dunn et al. 1991). 
Once thyroid hormones are released from Tg, they are secreted from the basal cell 
membrane into the bloodstream. Intracellular Tg fragments are deiodinated by an 
iodotyrosine-specific deiodinase (Rosenberg, Goswami 1979) and iodide is either reused 
for hormone synthesis or it enters the circulation.  
Tg uptake by thyrocytes can follow an alternative pathway mediated by megalin, a 
receptor expressed on the apical surface of thyrocytes. Tg internalized by megalin is 
transported from the apical to the basal surface of the cell through transcytosis, avoiding 
lysosomal processing (Marino et al. 2001). Tg is finally released to the bloodstream 
reaching concentrations of 5, 10 or 133 ng/ml in humans, mice and rats respectively 
(Carayanniotis, Rao 1997). The presence of Tg in the circulation shows that Tg is not a 
sequestered antigen.  
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1.3.2. Thyroid peroxidase and thyrotropin receptor 
TPO is a thyroid enzyme that catalyzes oxidation of iodide, its incorporation to Tg as 
well as the intramolecular coupling of MIT and DIT leading to T4 and T3 generation 
within Tg. TPO is a glycosylated homodimer (~ 107 kDa) containing a heme group and it 
is located at the apical membrane of thyrocytes (McLachlan, Rapoport 2007). 
Purification of TPO has been challenging, since this protein is not as abundant as Tg 
within the gland. TPO has been purified from human thyroid tissue (Czarnocka et al. 
1985) as well as expressed as recombinant protein in Chinese hamster ovary cells, insect 
cells and yeast cells (Taurog 2000). Recently, mouse TPO was expressed in Chinese 
hamster ovary cells after transfection with a plasmid carrying complementary DNA 
(cDNA) for full length TPO (Chen et al. 2010). TPO is involved in HT and anti-TPO Abs 
are used as a serological marker for diagnosis of the disease since approximately 95% of 
patients develop them, whereas these Abs are rarely detected in healthy individuals 
(Caturegli et al. 2014).  
 
TSH, a critical factor for the function and survival of thyrocytes can be sensed through 
the TSH receptor (TSHR) localized to the basal membrane of the epithelial cell. TSHR 
contains a glycosylated extracellular region, a transmembrane domain and an intracellular 
carboxyterminal region. The extracellular domain of the protein is connected to the 
transmembrane region via the so called hinge region (Rapoport 2000). Patients with 
Graves’ disease develop TSHR-stimulating and/or inhibiting Abs that stimulate 
9 
 
overproduction of thyroid hormones leading to hyperthyroidism (Rapoport, McLachlan 
2007). Abs against TSHR have also been reported to exist in HT patients (Weetman, 
McGregor 1994). 
 
1.4. Animal models of autoimmune thyroiditis  
To advance the understanding of HT pathogenesis, animal models of the disease have 
been developed to examine the therapeutic potential of various treatments and to facilitate 
the study of individual parameters contributing to the disease. In the field of thyroiditis, 
there are two animal models: the model of experimental autoimmune thyroiditis (EAT) in 
which the disease is induced in animals; and the model of spontaneous autoimmune 
thyroiditis (SAT) in which the disease develops spontaneously. In this thesis, both models 
have been used to examine mechanisms involved in the immunoregulation of the disease. 
 
1.5. Experimental autoimmune thyroiditis  
1.5.1. Methods of induction 
In 1956, Rose et. al. reported for the first time that rabbits immunized with whole thyroid 
extract in Freund’s complete adjuvant (CFA) produced thyroid-specific Abs in their sera 
and mononuclear cell infiltration was observed in their thyroid glands (Rose, Witebsky 
1956). Using the similar approach, EAT was also induced in a variety of species; in mice 
(Rose et al. 1971), monkeys (Rose et al. 1966), dogs (Terplan et al. 1960), guinea pigs 
(Terplan et al. 1960), rats (Jones, Roitt 1961) and chickens (Jankovic, Mitrovic 1963). 
Most attention however has been given to mouse models because of: a) the availability of 
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immunological reagents; b) the well known genetics and availability of inbred mouse 
strains; and c) the relative ease and cost-effectiveness of mouse breeding and 
maintenance. In the following paragraphs, I will focus on the parameters involved in 
induction of EAT in mice. 
 
EAT is induced in genetically susceptible mice either after direct immunization with 
thyroid autoantigens in adjuvant or after adoptive transfer of activated thyroid 
autoantigen-specific T cells into naïve recipients. The most commonly used protocol for 
direct induction of EAT uses Tg or Tg peptides as thyroid autoantigen. Mice are 
immunized with Tg in the presence of an adjuvant; CFA (Rose et al. 1971) and 
lipopolysaccharide (LPS) (Esquivel et al. 1977) are the most commonly used but 
muramyl dipeptide (Kong et al. 1985) and poly(A:U) (Esquivel et al. 1978) have also 
been shown to have adjuvant properties. EAT has also been induced in C3H/Anf mice in 
the absence of adjuvant by repeated immunizations with mouse Tg (mTg) (Eirehewy et 
al. 1981). Furthermore, immunization with mTg conjugated to anti-IAk monoclonal Ab 
(mAb) in the absence of adjuvant elicited Tg-specific IgG, but no thyroid lesions in 
CBA/J mice (Balasa, Carayanniotis 1993).  
 
Other autoantigens have also been used to directly induce EAT in susceptible mice. 
Porcine TPO in CFA induced EAT in C57BL/6 and C57BL/10 mice, whereas the strains 
A/J, BALB/c, DBA, CBA, C3H and SJL were poor responders (Kotani et al. 1990). 
Various TPO peptides were also found to be thyroiditogenic (Kotani et al. 1992, Ng, 
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Kung 2006, Hoshioka et al. 1993). Lastly, EAT has been reported in BALB/c mice after 
immunization with the extracellular domain of human TSHR expressed as a fusion 
protein with maltose-binding protein in E.coli (Costagliola et al. 1994). 
 
For induction of EAT by the adoptive transfer protocol, splenocytes or lymph node cells 
(LNC) from mTg-primed mice, after in vitro activation with mTg for a 72 hour period, 
transfer thyroiditis to naïve recipient animals (Braley-Mullen et al. 1985). The recipient 
mice developed equivalent or higher levels of EAT compared to mice directly immunized 
with mTg in CFA or LPS (Braley-Mullen et al. 1985). Adoptive transfer of EAT was 
mediated by T cells because T lymphoblasts activated in vitro by monolayers of 
thyrocytes (Charreire, Michel-Bechet 1982), mTg-specific T cell clones (Romball, 
Weigle 1987) or T cell lines  (Maron et al. 1983) were able to cause EAT in naïve mice. 
The adoptive transfer protocol has also been used successfully with Tg peptide-primed 
cells that were further activated in vitro with the immunizing peptide (Carayanniotis, Rao 
1997). 
 
A different type of EAT, called granulomatous EAT, was elicited by splenocytes from 
mTg-primed mice, further activated in vitro with mTg and an anti-interleukin-2 (IL-2) 
receptor Ab (Braley-Mullen et al. 1991). In this case, EAT was more severe than that 
adoptively transferred by lymphocytes cultured only with mTg. Granulomatous EAT was 
characterized by extensive follicular destruction, presence of multinucleated giant cells 
and proliferation of thyrocytes. Mice with granulomatous EAT also had higher mTg 
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specific-IgG responses compared to the group developing lymphocytic EAT (Braley-
Mullen et al. 1991).  
 
1.5.2. The role of MHC genes in murine models of EAT 
To examine possible effects of H-2 haplotypes on susceptibility to EAT, Vladutiu et. al., 
challenged thirty three mouse strains, expressing 11 different H-2 haplotypes, with 
thyroid extract in CFA and monitored EAT development 4 weeks after the first   
immunization (Vladutiu, Rose 1971). Murine strains expressing the H-2k and H-2s 
haplotypes were characterized as excellent responders since they developed the highest 
pathology index and thyroid-specific Ab titers. Mice of the H-2q and H-2a type were 
reported to be good and fairly good responders respectively whereas mice with the H-2b, 
H-2d and H-2v haplotypes were characterized as poor responders (Vladutiu, Rose 1971). 
This study showed that gene(s) within the H-2 locus influence the induction of EAT. 
Further work by Tomazic et al. mapped the major susceptibility gene(s) for thyroiditis 
between the K and A loci of the H-2 locus since intra-H-2 recombinant mice expressing 
the Kk and Ak alleles consistently developed thyroiditis at moderate to high levels 
compared to other recombinant mice (Tomazic et al. 1974). Finally, the generation of 
new suitable intra-H-2 recombinant strains of mice allowed identification of the H-2A 
gene as the principal gene controlling susceptibility to thyroiditis induction (Beisel et al. 
1982). This finding was further supported by the fact that anti-H-2A mAb completely 
prevented EAT when administered around the time of immunization with Tg in CFA 
(Vladutiu, Steinman 1987). The crucial involvement of the H-2A locus in EAT induction 
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was also shown by introduction of the Aαk and Aβk genes, expressed in good responder 
mice, to resistant (B10.M) or intermediate (B10.Q) responder mice, which led to a 
significant increase in the incidence and severity of thyroiditis compared to wild type 
(WT) control mice (Kong et al. 1997). 
 
Other loci within the H-2 have been reported to affect the incidence and/or severity of 
thyroiditis. For example, B10.A and B10.AQR mice, differing at the K locus, developed 
thyroiditis at 52% vs. 70 % incidence, respectively. These data suggested that the 
presence of the Kk allele in B10.A mice vs. the presence of the Kq allele in B10.AQR 
mice lowered the incidence of the disease via an unknown mechanism (Beisel et al. 
1982). In addition, point mutations in the K locus of the C57BL/6 mice were found to 
increase the incidence of thyroiditis from 20% in WT mice to 79%, after challenge with 
thyroid extract (Maron, Cohen 1979). However, these data were not confirmed by similar 
work performed in the same murine background by another group (Beisel et al. 1982). 
 
In an analogous manner, the presence of certain D alleles - Dd, Db and Dq – significantly 
reduced the levels of thyroid infiltration, as compared to the levels of disease in good 
responder mice (Kong et al. 1979). Also, the presence of the Dd and Db alleles in strains 
expressing H2Kk genes was associated with lower anti-Tg Ab responses than those 
observed in the H-2k progenitor strain (Tomazic et al. 1974). Later studies related the 
involvement of major histocompatibility complex (MHC) class I genes in EAT induction 
to production of cytotoxic T cells (Rose 2011), since anti-Kk and anti-Dk mAb completely 
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blocked the cytotoxic effects of mTg primed T cells on thyroid epithelial cells in vitro 
(Creemers et al. 1983).  
 
The role of the E locus on EAT induction remains unclear since it has not been studied 
extensively. Previous work with intra-H-2 recombinant mice in the B10 background 
showed that the Ek molecule was necessary for EAT induction in mice of the H-2k type 
after challenge with the Tg peptide (p2495-2511) in CFA (Chronopoulou, Carayanniotis 
1993). However, the presence of the Ek molecule alone was not permissive for EAT 
induction, because mice expressing the resistant Kb, Ab, Dd alleles and the Ek molecule 
did not develop EAT. Findings from another study showed that introduction and 
expression of the EαkEβs molecule in B10.S mice led to a decrease in the severity of EAT 
compared to WT B10.S mice, which are E-, after challenge with mTg in CFA or LPS 
(Kong et al. 1997). In the same study it was shown that the expression of a different E 
molecule, EαkEβd in B10.RQB3 mice did not affect EAT susceptibility, suggesting that 
different E alleles can have differential effects on EAT induction. 
 
In humans, HT has been associated with the presence of certain human leukocyte antigen 
(HLA) proteins like HLA-DR4 (Jenkins et al. 1992, Thompson, Farid 1985), HLA-DR5 
(Farid et al. 1981, Thomsen et al. 1983, Weissel et al. 1980) and HLA-DR3 (Golden et al. 
2005, Tandon et al. 1990). Since conflicting data were reported regarding the association 
of HT and HLA-DR3 (Hasham, Tomer 2012), more studies have focused on this MHC 
class II molecule. To study its permissiveness to thyroiditis induction, DR3 transgenic 
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mice were generated in resistant B10.M mice in the absence of endogenous H-2A 
molecules (Kong et al. 1996).  DR3+ transgenic mice immunized with mTg or human Tg 
(hTg) developed significantly higher levels of mononuclear cell infiltration compared to 
DR3- mice that remained resistant to disease development (Kong et al. 1996). These data 
suggested that the DR3 molecule confers susceptibility to thyroiditis induction. The 
development of such HLA class II transgenic mice has allowed the examination of the 
role of HLA-DR and –DQ polymorphisms in susceptibility to EAT (Kong et al. 2007). 
 
1.5.3. Pathogenic thyroglobulin epitopes in murine models of EAT 
Immunologically, Tg has been reported to be the largest known autoantigen (van de 
Graaf et al. 2001). So far, 25 pathogenic T cell epitopes within Tg have been uncovered 
by different experimental approaches (Figure 1.1) (Carayanniotis 2007). The majority of 
the thyroidogenic peptides were identified by computer-based algorithms predicting 
putative MHC-binding Tg peptides (Caturegli et al. 1997, Chronopoulou, Carayanniotis 
1992, Li, Carayanniotis 2006, Verginis et al. 2002, Flynn et al. 2004). Other approaches 
searched for the presence of common T cell epitopes between Tg and TPO (Hoshioka A 
1993) or used T cell hybridomas to identify the minimal epitopes recognized by the T cell 
receptor (TCR) (Texier et al. 1992, Champion et al. 1991). More recently, studies using 
mass spectrometry identified Tg peptides eluted from HLA-DR-expressing cells from 
patients with Graves’disease (Muixi et al. 2008a, Muixi et al. 2008b). None of the known 
Tg peptides has been characterized as immunodominant according to criteria set by 
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Sercarz et al (Sercarz et al. 1993). The known pathogenic Tg peptides can be categorized 
into three groups based on their iodide content. 
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      Figure 1.1 
Relative positions of pathogenic Tg peptides prior to the initiation of the thesis work. Red: 
pathogenic peptides containing no iodotyrosyls; dark blue: peptides that are pathogenic only 
in their iodinated form; light blue: peptides in which the presence of iodine has variable 
effects on their pathogenicity; purple: pathogenic hTg-derived peptides; green: hTg-derived 
peptides found to be pathogenic in HLA-DR3 transgenic mice; gold: peptides containing 
hormonogenic sites. Numbers show a.a. coordinates without the leader sequence. 
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A) Pathogenic peptides containing hormonogenic sites. 
The first pathogenic Tg peptide was identified in 1991 by Roitt’s group (Champion et al. 
1991). In that study, the Ak-binding peptide (a.a. p2551-59) containing T4 at position 
2553 was reported to be recognized by two clonotypically distinct Tg autoreactive T cell 
hybridomas, CH9 and ADA2. The presence of T4 in the sequence was found to be 
critical since replacement of T4 by any other a.a. blocked the activation of both T cell 
hybridomas. Subsequent studies showed that the 12-mer peptide 2549-60 was able to 
induce proliferative (Hutchings et al. 1992) and cytolytic responses (Wan et al. 1998) in 
Tg-primed LNC and was able to cause lymphocytic (Hutchings et al. 1992) and 
granulomatous EAT (Braley-Mullen, Sharp 1997). The peptide p2549-60 was found to be 
pathogenic in the H-2k CBA/J (Hutchings et al. 1992, Braley-Mullen, Sharp 1997, Kong 
et al. 1995), C57BR (Wan et al. 1997) as well as H-2s A.SW and SJL (Wan et al. 1997) 
strains of mice. Interestingly, p2549-60 is the only Tg epitope so far that has been 
characterized as subdominant, since LNC from hTg- or mTg-primed mice proliferate in 
its presence in vitro (Hutchings et al. 1992, Kong et al. 1995, Wan et al. 1997). A second 
Tg peptide, p1-12, containing T4 at position 5, has also been reported to induce cytolytic 
responses (Wan et al. 1998) and cause mild lymphocytic thyroiditis (Kong et al. 1995). 
Not all epitopes containing T4 have a pathogenic potential, however. Peptides p2559-70 
and p2737-48 with T4 at positions 2567 and 2746, respectively, were not immunogenic 
in the CBA/J background (Kong et al. 1995). 
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The finding that autoreactive T cells are activated by T4-containing peptides raised 
questions regarding the mode of interaction between the TCR and the peptide-MHC 
complex. To address whether the four iodine atoms within T4 are involved in T cell 
recognition, Kong’s group generated an analog peptide of p2549-60 containing thyronine 
(T0) instead of T4 at position 2553. T0 retains the two-phenyl ring side chain of T4 
without the four iodine atoms (Kong et al. 1995). Interestingly, the T0 containing peptide 
was also found to be immunopathogenic in CBA/J mice indicating that the presence of 
the four iodine atoms within T4 is not necessary for T cell activation at the polyclonal 
level. In contrast, in the same study it was shown that LNC from T4p2553-primed mice 
were unable to proliferate in vitro in the presence of the T0 analog peptide whereas they 
showed a strong proliferative capacity against the T4 analog. These data indicated the 
presence of distinct T cell clones responding only to the iodinated peptide. Similar 
findings at the clonal level have been reported by other groups showing that T4p2553-
specific T cell hybridomas were activated in vitro only in the presence of the T4 
containing peptide whereas the T0 analog was non stimulatory (Dawe et al. 1996, Dai et 
al. 2005). Data from these two studies also demonstrated that T4 was a critical residue for 
contact with the TCR, since the presence of a T4-specific Ab abrogated activation of the 
hybridoma. 
B) Pathogenic peptides containing iodotyrosyl residues.   
Previous work in our laboratory has shown that the three peptides I-p117 (a.a. 117-32), I-
p304 (a.a. 304-18) and I-p1931 (a.a. 1931-45) were imunopathogenic in CBA/J mice 
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whereas the non-iodinated analogs p117, p304 and p1931 were not even immunogenic in 
the CBA/J background (Li, Carayanniotis 2006). The data from this study indicated that 
the presence of iodine in these peptides increased their pathogenic potential either by 
favoring their binding to the MHC or by activating T cell clones specific only for the 
iodinated epitopes. More studies, however, showed that the presence of an iodotyrosyl on 
a Tg peptide can affect its immunogenicity in multiple ways, i.e. it can either increase 
(p179, a.a. 179-94), decrease (p2540, a.a. 2540-54) or not affect (p2529, a.a. 2529-45) 
recognition by T cells at the polyclonal level (Li et al. 2007). Similarly, at the clonal 
level, a number of T cell hybridomas specific for the iodinated Tg peptide p179 or its 
non-iodinated analog required the iodine atom on the peptide for their activation. Other 
clones required the absence of the iodine atom, whereas activation of a third group of 
clones was independent of the iodine atom (Jiang et al. 2007).  
C) Pathogenic non-iodinated peptides. 
Several studies have reported the pathogenicity of non-iodinated Tg peptides 
(Carayanniotis 2007). The first identified peptide of this category was the 17-mer p2495 
(a.a. 2495-2511), which was described to be thyroidogenic in the high responder murine 
strains SLJ, C3H and B10.BR (Chronopoulou, Carayanniotis 1992). Further work 
revealed that this epitope contained two overlapping determinants, the Ek and As-
restricted 2496-2504 and the Ak-restricted 2499-2507 (Rao et al. 1994). The epitope 
2496-2504 directly induced thyroiditis in C3H and SJL mice, whereas 2499-2507 caused 
weak EAT in both strains (Rao et al. 1994). In 1992, another group identified the 40 a.a. 
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peptide (F40D), (a.a.1671-1710), as the porcine Tg (pTg) fragment that could be 
recognized by a cytotoxic Tg-specific T cell hybridoma (Texier et al. 1992). In the same 
study it was shown that this peptide, located at the end of the second third of Tg, was able 
to cause EAT in CBA/J mice. In 1993, the epitope 2730-2743 was shown to be identical 
between hTg and human TPO (hTPO) and its pathogenicity was shown by adoptive 
transfers of Tg-primed splenocytes previously in vitro activated with this peptide to naïve 
mice. Recipients developed EAT whereas the control groups receiving phosphate 
buffered saline (PBS) or ovalbumin (OVA) had no thyroid infiltration (Hoshioka et al. 
1993). In 1994, the peptide 2694-2711 was identified by algorithms as a putative T cell 
epitope and it was shown to be pathogenic in SJL mice (Carayanniotis et al. 1994). 
Further work showed that the major T cell determinant was spanning a.a. residues 2694-
2705 (Rao, Carayanniotis 1997). 
Searching for putative Ak binding peptides by Altuvia’s algorithm (Altuvia et al. 1994) 
allowed identification of the following pathogenic peptides in CBA/J mice: 306-320, 
1579-1591, 1826-1835, 2102-2116, 2596-2608 (Verginis et al. 2002) as well as 2529-
2545 and 2540-2554 (Li et al. 2007). Following a similar algorithm-based approach, 
three HLA-DR3 binding peptides from hTg were found to be thyroidogenic in DR3 
transgenic non-obese diabetic (NOD) mice; 2079-93 causes EAT consistently, whereas 
the peptides 1518-32, 181-195 cause only weak EAT (Flynn et al. 2004). A different 
methodology allowed identification of the peptide 2340-2359 from hTg as pathogenic in 
AKR/J (Karras et al. 2003) and DR3 transgenic C57LB/10 (Karras et al. 2005) mice by 
direct challenge. Initially, this epitope was found to be a target of Tg-specific B cells in 
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patients with Graves’ disease. Recently, the peptide 409-423 from mTg was reported to 
be pathogenic in A-E+ C57BL/10 mice (Brown et al. 2008a) and the peptide 1677-1692 
from mTg in A-E+ and A+E+ C57BL/10 mice (Brown et al. 2008b). 
 
1.6. Antigen presentation in EAT 
1.6.1. Dendritic cells 
Most of the studies in autoimmune thyroiditis have focused on the role of dendritic cells 
(DC) and thyrocytes as antigen presenting cells (APC). DC reside intrathyroidally (Kabel 
et al. 1988, Klein, Wang 2004, Voorby et al. 1990), outside of the follicles and in close 
proximity to small capillaries (KAbel et al. 1988, Voorby et al. 1990). Little is known 
about the phenotype and function of resident DC, since their low frequency within the 
gland has hindered more extensive studies (Simons et al. 2000). So far, only one group 
has reported that the majority of intrathyroidal resident DC are characterized as 
CD11clowCD11b+CD8α- cells, at a density of two cells per thyroid follicle (Klein, Wang 
2004). Intrathyroidal DC were described to have an immature phenotype since there was 
no expression of the CD40 and CD80 proteins (Klein, Wang 2004), supporting findings 
from  previous work that resident DC are in an immature state (Simons et al. 2000, 
Croizet et al. 2000). Regarding the function of intrathyroidal resident DC, it has been 
proposed that DC can inhibit the growth of thyrocytes via secretion of interleukin-1β (IL-
1β) and interleukin-6 (IL-6) (Simons PJ 1998), while thyrocytes can promote the 
immature state of DC via secretion of soluble factors (Croizet et al. 2001). 
Immunologically, it has been suggested that intrathyroidal DC constitutively express Tg 
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cryptic peptides on their MHC class II molecules, generated either after processing of Tg 
fragments or from processed Tg that had been transcytosed (Carayanniotis 2003). This is 
supported by the fact that activated Tg peptide specific CD4+ T cells selectively home to 
the thyroid after direct challenge of mice with peptide in CFA or after adoptive transfer 
of activated cells to naïve mice. Under steady state conditions, presentation of these Tg 
peptides to naïve T cells should lead to peripheral tolerance either due to the absence of 
co-stimulatory signals on DC and/or low expression levels of peptides prohibiting T cell 
activation (Carayanniotis 2003). 
 
Under inflammatory conditions, however, the presence of danger signals can induce the 
maturation and migration of intrathyroidal DC to the draining LN via the lymph. These 
mature DC subsets can initiate immune responses in the LN (Canning et al. 2003). This 
concept has been supported by the finding that necrotic thyrocytes were able to stimulate 
the maturation of bone marrow (BM) - derived DC in vitro as reported by the 
upregulation of MHC class II, CD80, CD86 and CD40 molecules (Li et al. 2006). Similar 
stimulatory effects on DC were not detected in the presence of healthy thyrocytes. In the 
same study, they also elicited Tg-specific Th1 and B cell responses as well as EAT (Li et 
al. 2006). Findings from spontaneous models of thyroiditis indicate that during the early 
stages of the disease there is a small increase in the number of DC intrathyroidally in the 
BB-DP rat (Voorby et al. 1990), the NOD mouse (Many et al. 1995) as well as in patients 
with HT, compared to those in the normal gland (Vasu et al. 2003). 
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The crucial role of DC in initiation of thyroiditis has also been shown in other studies. 
CBA/J mice, that do not develop spontaneously thyroiditis, developed the disease after 
injections of mTg-pulsed DC. The control groups receiving either PBS or DC-depleted 
splenocytes did not show any sign of infiltration or Tg specific-Ab in their serum (Knight 
et al. 1988). Similarly, DC pulsed with pTg stimulated proliferative Th1 responses of 
pTg-primed CD4+ T cells from B10BR mice. Also, these animals injected 
subcutaneously (s.c.) with DC pulsed with pTg in the absence of adjuvant developed 
severe thyroiditis and anti-pTg IgG2a Abs, compared to animals receiving unpulsed DC 
(Watanabe et al. 1999). 
 
Besides initiation of the disease, DC are also able to suppress the development of 
thyroiditis via activation of Tg-specific regulatory T cells (Treg). After treatment with 
TNF-α in vitro, BM-derived DC become semimature i.e. express high levels of MHC 
class II and co-stimulatory molecules, but they do not secrete proinflammatory cytokines 
(Menges et al. 2002). TNF-α treated DC were shown in vivo to activate interleukin-10 
(IL-10)-producing Tg-specific cells that had a regulatory phenotype and suppressive 
function in vitro. Interestingly, repetitive injections of TNF-α treated DC pulsed with Tg 
were able to suppress development of thyroiditis in mice challenged with Tg in CFA. 
Similarly, CD4+CD25+ T cells isolated from mice injected with TNF-α treated DC pulsed 
with Tg, suppressed the incidence and severity of EAT (Verginis et al. 2005). In a similar 
manner, it was shown that in granulocyte-macrophage colony stimulating factor (GM-
CSF) treated mice, only the CD8α- DC subset acquired a tolerogenic phenotype and 
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function (Ganesh et al. 2009). Ex vivo analysis showed that this subset was able to 
increase the frequency of Foxp3+ cells as well as IL-10-producing cells in mTg-primed T 
cells in the presence of mTg in vitro. CD8α+ DC from GM-CSF treated mice did not have 
such a capacity. Interestingly, adoptive transfers of CD8α- DC from GM-CSF treated 
mice prevented EAT development in Tg-challenged mice (Ganesh et al. 2009). More 
studies revealed that the OX40L and Jagged1 signaling pathways have a crucial role in 
Treg expansion by GM-CSF BM-derived DC (Gopisetty et al. 2013). 
 
1.6.2. Thyrocytes 
Thyrocytes have also been reported to have an antigen presenting capacity within the 
thyroid gland. It has been shown that IFN-γ treated murine thyrocytes were able to 
generate and express the T4p2553 peptide on their surface as well as activate a T4p2553-
specific hybridoma in vitro (Champion et al. 1991). Also, thyrocytes from patients with 
Graves’ disease, which were MHC class II positive, were able to induce proliferative 
responses of the HA1.7 T cell clone in the presence of its ligand; the influenza strain A 
haemagglutinin peptide p20 (Londei et al. 1984). Under normal conditions, thyroid 
epithelial cells do not express MHC class II molecules (Voorby et al. 1990, Simons et al. 
2000, Verma et al. 2000, Bonita et al. 2003), however, they become MHC class II 
positive under pathological conditions in humans, mice and rats (Voorby et al. 1990, 
Verma et al. 2000, Bonita et al. 2003, Hanafusa et al. 1983). This observation indicates 
that they do not have a primary role as APC in the initial events triggering thyroiditis. 
Also, work with transgenic mice expressing the MHC class II, I-Ak gene constitutively on 
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thyrocytes showed that no SAT was detected in these animals, whereas there was only an 
8% higher severity of the disease in transgenic vs. WT mice after immunization with Tg 
in CFA (Kimura et al. 2005, Li et al. 2004). These data clearly indicated that epithelial 
cells expressing MHC class II molecules alone are not sufficient to initiate autoimmunity. 
However, the fact that they can present Tg peptides to T cells indicates that thyrocytes 
may participate in amplification of the autoimmune response. 
 
1.7. Spontaneous autoimmune thyroiditis  
SAT has been reported to occur in chickens - the Cornell C Strain (CS) of White Leghorn 
(Cole et al. 1968) and the Obese Strain (OS) (Wick et al. 1974); rats – the Buffalo 
(Hajdu, Rona 1969) and the BB/W strain (Sternthal et al. 1981); dogs, monkeys and mice 
(Bigazzi, Rose 1975). In the following paragraphs, the murine models of SAT will be 
discussed in detail. 
 
The NOD mouse is an animal model for insulin dependent diabetes mellitus. NOD mice, 
expressing the H-2g7 haplotype, (Kd, Ag7, E0, Db), usually develop diabetes at 60-80% 
incidence in female and 20-30% in male animals (Anderson, Bluestone 2005). Besides 
diabetes, NOD mice are prone to develop sialitis, prostatitis and SAT (Anderson, 
Bluestone 2005). Lymphocytic infiltration in the thyroid gland in NOD mice was initially 
reported to occur with 18.5% incidence (Asamoto et al. 1986). Later studies showed that 
the incidence of SAT in NOD mice varies among different colonies but mostly ranges 
from 5-25% (Many et al. 1995, Wicker et al. 1995, Damotte et al. 1997, Hutchings et al. 
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1999). Only one study has described very high incidence of SAT, reporting that 90% of 
10 day-old NOD mice develop the disease in their colony (Bernard et al. 1992). 
 
In regards to the presence of anti-Tg Abs in NOD mice developing SAT, one group has 
not detected them (Bernard 1992), whereas two other groups have reported a sporadic 
presence of anti-Tg Abs in older NOD mice (Damotte et al. 1997, Hutchings et al. 1999). 
The incidence and severity of SAT in NOD mice is comparable for female and male mice 
(Asamoto et al. 1986, Damotte et al. 1997, Bernard et al. 1992). Also, thyroiditis 
incidence was not reported to be significantly different in diabetic and non-diabetic NOD 
mice (Damotte et al. 1997, Bernard et al. 1992) supporting the concept that these two 
diseases are precipitated by dinstict mechanisms. 
 
The NOD.H2h4 strain is one of several NOD MHC congenic strains that were generated 
by Dr. Linda Wicker’s group investigating the role of the I-E MHC class II molecule in 
insulitis and diabetes development in the NOD background (Podolin et al. 1993). 
NOD.H2h4 mice, expressing the H-2h4 haplotype, Kk, Ak, E0, Db, do not become diabetic 
spontaneously or after treatment with cyclophosphamide (Podolin et al. 1993), but 
interestingly, they develop insulitis (Podolin et al. 1993), sialitis (Cihakova et al. 2009) 
and thyroiditis (Wicker et al. 1995, Kolypetri et al. 2010, Braley-Mullen et al. 1999, 
Burek et al. 2003, Weatherall et al. 1992). One group has reported a 50% incidence of 
thyroiditis in their colony (Wicker et al. 1995, Burek et al. 2003, Weatherall et al. 1992). 
A detailed kinetic analysis of SAT in our colony has shown disease onset around 15 
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weeks of age with SAT incidence increasing to 50% in 20-33-week old mice and 
reaching 100% in one year old animals. The severity of the disease increases over time 
but it can range from interstitial infiltration - infiltration index (I.I.)=1 - to extensive 
infiltration (I.I.=4) even in one year old animals (our unpublished data). Interestingly, 
similar findings have been reported by another group (Burek, Talor 2009). 
 
1.7.1. The role of MHC genes in murine models of SAT 
The role of individual MHC genes in the development of SAT has not been examined. 
However, the importance of the H-2 locus on the onset of SAT arises from the fact that 
NOD mice, H-2g7 haplotype, develop thyroiditis at a low incidence, ranging from 5-25% 
in different colonies (Many et al. 1995, Wicker et al. 1995, Damotte et al. 1997, 
Hutchings et al. 1999), whereas congenic NOD.H2h4 mice, H-2h4 haplotype, develop 
thyroiditis at 100% incidence by the age of one year old (Burek, Talor 2009). The high 
incidence of SAT in the NOD.H2h4 strain has been related to the combined presence of 
the Ak molecule with NOD non-MHC genes that are known to predispose to 
autoimmunity development (Wicker 1997). However, the NOD.H2k strain, carrying the 
H-2k haplotype, has been reported to develop SAT at 30.3% incidence by the age of 
almost 2 year old (Damotte et al. 1997). This indicates that additional genes within the H-
2 locus, other than the Ak molecule, contribute to thyroiditis development. Such a gene 
could be Ceat1, which is tightly linked to the H-2 complex and has been reported to 
control thyroiditis induction in NOD mice (Boulard et al. 2002). 
 
29 
 
1.8. Links between iodine and thyroiditis development 
Iodine is a trace element that has a central role in thyroid physiology since it acts as a 
substrate for the formation of the thyroid hormones, T3 and T4 and has a regulatory role 
in thyroid function (Saller et al. 1998). Iodine enters the human body through the dietary 
intake of milk and dairy products, fish, salt, seaweed, kelp, eggs and bread, drinking 
water or iodine-containing drugs, food preservatives and vitamin preparations (Roti, 
Uberti 2001). 
 
After iodine enters the gastrointestinal tract, it is first converted to inorganic iodide and 
then it is completely absorbed. Following absorption, iodide circulates between the 
plasma, red blood cells, intraluminal fluids of the gastrointestinal tract and other 
extracellular compartments (Saller et al. 1998). The majority of inorganic iodide is stored 
within the thyroid gland (Saller et al. 1998). Besides the thyroid, iodide can also be found 
in the salivary glands, mammary glands, colon and placenta. Eventually, more than 90% 
of the iodide is excreted from the body through the kidneys (Cavalieri 1997). In the 
thyroid, epithelial cells actively take up inorganic iodide via NIS present on their basal 
membrane (Dai et al. 1996). Then, iodide is transferred to the apical surface of the cell 
due to its electrochemical gradient where iodide is oxidized by the enzyme TPO. 
Subsequently, TPO catalyzes the iodination of Tg and the thyroid hormones are 
generated (paragraph 1.5.1). Once T4 and T3 are released into the bloodstream, iodide is 
removed from MIT and DIT and either is reused or it enters the circulation (Dunn J.T., 
Dunn A.D. 2000, Cavalieri 1997). 
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The human thyroid gland requires 52 µg of iodine on a daily basis to remain in balance 
(Burgi 2010). According to the World Health Organization, an adult should receive up to 
150 µg of iodine per day, i.e. 3x the daily required dose (WHO 2004), while the tolerable 
upper level of iodine intake has been set to 600 µg per day in the European Union and 
1100 µg per day in the United States (Burgi 2010). The amount of iodine intake per day 
varies among countries with different dietary characteristics as well as among individuals 
within the same country (Rasmussen et al. 2009). For example, in populations consuming 
seaweed and fish, like the Japanese, the average dietary iodide can reach up to 2-3 
mg/day whereas in the United States, Canada and parts of Europe, the intake is around 
500 µg/day (WHO 2004). At an individual level, increased iodine supply has been related 
to chronic treatment with iodine-rich drugs like amiodarone, a medication used to treat 
cardiac arryhtmia, which releases 9 mg of iodine per day during its metabolism (Roti, 
Uberti 2001). Despite several studies (Roti, Uberti 2001, Burgi 2010) it still remains 
unclear whether high iodine ingestion is well tolerated over long time periods but reports 
have described a relation between increased incidence of autoimmune thyroiditis and 
high iodine intake in different countries like Brazil (Camargo et al. 2007), China (Teng et 
al. 2008), Japan (Konno et al. 1994), Argentina (Harach et al. 1985), United States 
(Weaver et al. 1966) and Switzerland (Hedinger 1981). 
 
Similar observations have been described in animal models of autoimmune thyroiditis. 
An iodide-rich diet was reported to increase the incidence and severity of thyroidits in CS 
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chickens (Bagchi et al. 1985), Buffalo rats (Cohen, Weetman 1988), BB/W rats (Allen et 
al. 1986),  NOD mice (Verma et al. 2000, Hutchings et al. 1999, Vecchiatti et al. 2013) 
and NOD.H2h4 mice (Hutchings et al. 1999, Kolypetri et al. 2010, Braley-Mullen et al. 
1999, Burek, Talor 2009, Rasooly et al. 1996, Teng et al. 2009). Similar observations 
have been reported in iodide-deficient goitrous mice (Many et al. 1995, Mahmoud et al. 
1986) and hamsters with hyperplastic goiters (Follis 1959). In contrast, high iodide intake 
did not induce SAT in SJL (Li, Carayanniotis 2007), CBA/J (Hutchings et al. 1999, 
Braley-Mullen et al. 1999, Li, Carayanniotis 2007) and Biozzi (Hutchings et al. 1999) 
mice. So far, the mechanism whereby iodide affects thyroiditis development remains 
unknown. 
 
1.9. Iodide-accelerated SAT in NOD.H2h4 mice 
In 1996, a study from Dr. Rose’s laboratory showed that addition of 0.05% NaI in the 
drinking water of six to eight week old NOD.H2h4 mice for 8 weeks accelerated the 
incidence and severity of SAT (ISAT) compared to age-matched mice drinking normal 
water (Rasooly et al. 1996). The main charactestics of ISAT were: 1) mononuclear cell 
infiltration in the thyroid glands of fifteen out of 25 mice and 2) increased levels of anti-
Tg-specific Abs in their sera. In the control group, the thyroid gland of only one out of 20 
mice had a pathology index of 4, whereas none of the animals developed Tg-specific 
Abs. Interestingly, serum levels of the thyroid hormone T4 were similar in iodide treated 
and control mice, indicating that the iodide rich diet did not induce hypothyroidism in 
this strain as previously shown in SJL mice (Li, Carayanniotis 2007). This observation in 
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combination with the fact that the incidence of the disease in female and male mice was 
comparable, represent the two main differences between the human disease and this 
animal model of thyroiditis.  
Notably, many groups have confirmed the findings described by Rasooly et. al. 
(Hutchings et al. 1999, Kolypetri et al. 2010, Braley-Mullen et al. 1999, Burek, Talor 
2009, Teng et al. 2009, Oppenheim et al. 2003, Nagayama et al. 2007) and have tried to 
shed more light into the pathway leading to ISAT onset. A kinetic analysis of the disease 
in NOD.H2h4 mice has shown that the first signs of thyroid infiltration become evident 
after 2 weeks of NaI administration and become more prominent after prolonged iodide 
intake (Bonita et al. 2003, Kolypetri et al. 2010, Braley-Mullen et al. 1999). 
Immunohistochemical data have shown that CD4+ and α+ T cells are the first immune 
cells infiltrating the gland (Verma et al. 2000, Bonita et al. 2003, Yu et al. 2001). During 
this time point, few or no macrophages and no DC or natural killer (NK) cells have been 
detected in the thyroid lobes (Yu et al. 2001), whereas the presence of B cells has been 
reported by one group (Yu et al. 2001) but not confirmed by others (Bonita et al. 2003). 
After prolonged iodide administration, 4 to 8 weeks, an increased number of CD4+, CD8+ 
T and B cells has been detected in the gland with CD4+ T cells being the predominant 
type of infiltrating cell (Bonita et al. 2003, Yu et al. 2001). At these stages of the disease 
macrophages, DC and NK cells are also present in the thyroid (Yu et al. 2001). 
Interestingly, the presence of such an inflammatory environment in the thyroid glands of 
iodide-fed mice is chronic and remains unchanged even after 23-24 weeks of treatment 
(Braley-Mullen et al. 1999, Teng et al. 2009). After 24 weeks of iodide administration, 
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when extensive infiltration is present in the thyroid, electron microscopy analysis has 
shown that thyrocytes have been described to have a high number of lysosomes 
containing lipofuscin granules, peroxisomes as well as mitochondrial swelling and 
dilatation of the rough endoplasmic reticulum compared to cells from control mice (Teng 
et al. 2009). Also, signs of apoptosis and necrosis have been reported in thyroid epithelial 
cells from iodide-fed animals at this stage (Teng et al. 2009). 
In the serum, Tg-specific IgG Abs become detectable after 2-3 weeks of high iodide 
administration, reaching their maximum level 10-16 weeks later (Kolypetri et al. 2010, 
Braley-Mullen et al. 1999). The main subclasses of Tg-specific Abs have been identified 
as IgG2a, IgG2b and IgG1 (Hutchings et al. 1999, Braley-Mullen et al. 1999, Rasooly et 
al. 1996). Tg-specific IgM have also been detected in the sera of iodine-fed and control 
mice (Rasooly et al. 1996), but IgM binding to Tg appeared to be non-specific (Braley-
Mullen et al. 1999). In older animals, 7 to 12 months old, IgG responses against mouse 
but not hTPO have been reported in iodide-treated and control mice by one group (Chen 
et al. 2010), whereas other studies were unable to detect them (Verma et al. 2000, 
Rasooly et al. 1996). The fact that TPO-specific Abs are detected at late stages of ISAT 
implies that TPO may not be the autoantigen triggering initiation of the autoimmune 
cascade in NOD.H2h4 mice.  
1.9.1. The role of T cells in ISAT development  
The involvement of T cells in ISAT development has been examined mostly by depletion 
studies (Verma et al. 2000, Hutchings et al. 1999, Braley-Mullen et al. 1999, Nagayama 
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et al. 2007, Yu et al. 2006). MAb-mediated depletion of CD4+ cells during or at the end 
of the iodine administration period led to minimal or no thyroiditis development in 
NOD.H2h4 mice compared to control mice receiving a rat IgG isotype control Ab. This 
supports the view that CD4+ T cells are necessary for the development and progression of 
ISAT (Braley-Mullen et al. 1999). Depletion of CD8+ T cells during the first weeks of 
iodine supplementation also decreased ISAT development, but when CD8+ cells were 
depleted at the end of iodine supplementation period the treatment was ineffective. This 
suggests that CD8+ T cells have an important role only in the initiation of ISAT (Verma 
et al. 2000, Braley-Mullen et al. 1999). 
 
The involvement of another T cell subset, CD4+CD25+ Treg cells, in ISAT development 
remains unclear as shown by studies following different approaches (Nagayama et al. 
2007, Yu et al. 2006, Ellis et al. 2013). Administration of anti-CD25 mAb to NOD.H2h4 
mice 4 days before initiation of iodide-rich diet led to increased severity of ISAT and 
higher production of anti-Tg Ab titers compared to untreated age-matched mice 
(Nagayama et al. 2007). These data indicated that CD4+CD25+ Treg cells can suppress 
ISAT development. In contrast, Yu’s group reported that administration of anti-CD25 Ab 
to NOD.H2h4 mice 10, 17 and 24 days after birth led to less severe ISAT after 8 weeks of 
NaI supplementation compared to mice receiving normal rat Ig (Yu et al. 2006). Also, 
elimination of Treg by thymectomy at 3 days of age did not affect ISAT incidence in 
iodine-fed mice compared to nonthymectomized control mice indicating that Treg cannot 
inhibit ISAT in NOD.H2h4 mice (Yu et al. 2006). In another study, the same group 
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reported that CD28-/- NOD.H2h4 mice which have reduced numbers of CD4+Foxp3+ cells 
in the spleen and cervical LN (CLN) compared to WT NOD.H2h4 mice, developed 
significantly higher levels of ISAT compared to WT mice (Ellis et al. 2013). Also, 
adoptive transfer of CD4+Foxp3+ cells to CD28-/- NOD.H2h4 mice reduced the severity of 
thyroiditis after 7 weeks of high iodide diet. Similar observations were not reported in 
CD28-/- mice receiving the same number of CD4+Foxp3- cells or CD28-/- mice that did 
not receive any cells (Ellis et al. 2013). These data supported the view that Treg cells are 
involved and have the capacity to suppress ISAT in contrast to the opposite conclusions 
reached earlier by the same group. The involvement of Treg cells in ISAT progression 
was indicated by studies showing that splenocytes from iodide-fed animals for 8, 12 and 
16 weeks had significantly lower percentages of CD4+CD25+Foxp3+ cells and Foxp3 
mRNA expression compared to mice receiving normal water (Xue et al. 2011). 
 
NKT cells have also been implicated playing an effector role in ISAT development in 
NOD.H2h4 mice. NOD.H2h4 mice have been reported to contain unusually high numbers 
of NKT cells in their spleens, compared to age-matched BALB/c mice (Burek et al. 
2003), and Tg-specific T cell lines generated from splenocytes of iodine-fed NOD.H2h4 
mice possess characteristics of NKT cells i.e. the presence of DX5 marker on their 
surface as well as the expression of Vα14Jα281 (Sharma et al. 2011). Stimulation of these 
cell lines with Tg was shown to be CD1d-restricted and led to production of interleukin- 
12 (IL-12), interleukin-4 (IL-4), IFN-γ, TNF-α and IL-10. Adoptive transfer of these T 
cell lines to iodide-pretreated NOD.H2h4 recipients increased the production of Tg-
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specific Abs and cellular infiltration in the thyroid glands, compared to the control group, 
indicating that NKT cells may have a pathogenic role in ISAT. However, transfer of the 
same T cell lines to NOD.H2h4 mice drinking normal water did not lead to thyroiditis 
development, suggesting that NKT cells cannot initiate ISAT in this strain. Their role is 
most likely exerted by cytokine release in the periphery, since transferred NKT cells did 
not migrate to the thyroid glands of NOD.H2h4 recipient mice (Sharma et al. 2011). 
 
Another T cell subset that may be involved in ISAT development is Th17 cells (Horie et 
al. 2009). It has been shown that intrathyroidal expression of IL-17 as well as IFN-γ at 
the mRNA level was significantly higher in NOD.H2h4 mice after 4 and 8 weeks of 
iodide administration compared to control mice. Also, splenocytes from iodine-fed mice 
were reported to have an increased number of Th17 and Th1 cells compared to 
splenocytes from the control group, suggesting that iodine administration is related to an 
increased generation of both Th17 and Th1 cells. Interestingly, IL-17 knockout 
NOD.H2h4 mice were characterized by a significantly lower incidence and severity of 
infiltration as well as lower titers of Tg-specific IgG Ab compared to WT NOD.H2h4 
mice after 8 weeks of iodine administration (Horie et al. 2009). However, another study 
by the same group, suggested that Th1 cells alone are able to induce thyroiditis (Horie et 
al. 2011). In this paper, they depleted the Treg cells from IL17-/- and IFNγR-/- NOD.H2h4 
mice, which are known to be resistant to ISAT, and examined ISAT symptoms after 8 
weeks on 0.15% NaI water. In NaI treated/Treg-depleted IL17 knock out mice, where 
only Th1 cells were present, ISAT symptoms were comparable to symptoms in WT mice 
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whereas, NaI treated/Treg-depleted IFNγR knock out mice had minimal ISAT. These data 
implied that Th1 cells alone are able to induce thyroiditis in this strain.  
 
1.9.2. Antigens targeted by T cells in ISAT  
NOD.H2h4 mice produce high titers of anti-Tg-specific Abs during early stages of ISAT 
suggesting that Tg-specific helper T cells have been previously activated. So far, 
however, studies have reported lack of or low detectable spontaneous T cell reactivity to 
mTg or to the Ak-binding Tg peptides I-p117, I-p179, I-p1931, I-p2529, I-p2540, p226, 
p1579, p1826 and p2026 using splenocytes after 21, 28, 42  and 56 days of iodide 
administration (Verma et al. 2000, Kolypetri et al. 2010, Braley-Mullen et al. 1999). 
Also, proliferative responses against Tg were not detected using thyroid draining CLN 
cells (CLNC) before ISAT onset - after 7 days of iodide administration (Kolypetri et al. 
2010). Only one group so far has reported, but not shown, significant T cell responses to 
Tg in iodine-treated and untreated NOD.H2h4 mice (Rose et al. 1999, Rose et al. 1997). 
These observations outline a paradox between the abundance of Tg-specific IgG Abs and 
the low spontaneous T cell reactivity to Tg in NOD.H2h4 mice, in a similar manner to 
insulin in NOD mice (Kaufman et al. 2001). 
 
To provide an explanation for this paradox, it was suggested that T cell responses are 
directed against a “modified form” of Tg. According to this premise, excess iodine intake 
may lead to formation of highly iodinated Tg (I-Tg) which is more immunopathogenic 
than Tg with normal iodine content (Verma et al. 2000, Burek, Rose 2008, Rose et al. 
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2002) as previously shown in the EAT model (Champion et al. 1987, Dai et al. 2002, 
Sundick et al. 1987). However, work from our laboratory showed that Tg preparations 
from NOD.H2h4 B cell deficient mice, designated as NOD.Kµ, drinking water with or 
without NaI, had comparable iodide content, suggesting that the NOD.H2h4 background 
does not favor generation of I-Tg in vivo after high iodide intake (Kolypetri et al. 2010). 
Furthermore, in the same study it was shown that in vitro, mildly iodinated Tg (24 iodine 
atoms/monomer) was not preferentially recognized by T or B cells compared to normal 
Tg (14 iodine atoms/monomer). This demonstrates that the high iodine content of Tg 
does not enhance its antigenicity in NOD.H2h4 mice and contrasts with previous results in 
the NOD.H2h4 model indicating that iodine can affect the antigenicity of Tg at the B and 
T cell level (Barin et al. 2005).  
 
Significant proliferative T cell responses against hTPO were observed using splenocytes 
from iodide-fed mice as well as splenocytes from control 11 to 12 month old mice that 
had already developed spontaneous thyroid lesions (Verma et al. 2000). These data have 
not been confirmed by other groups so far. A concern about these findings is that the 
murine T cells may be cross-reactive to epitopes found only in hTPO and not present in 
murine TPO (mTPO). To exclude this possibility, the proliferation assays should be 
performed using mTPO. 
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1.9.3. The role of B cells in ISAT development 
B cells have a crucial role during the onset and progression of ISAT in NOD.H2h4 mice. 
B cell-deficient NOD.H2h4 mice, designated as NOD.Kµ-, develop minimal thyroid 
infiltration after 8 weeks of iodide supplementation, compared to WT NOD.H2h4 mice 
(Braley-Mullen, Yu 2000). In the same study, the presence of B cells was necessary 
during the first 4 weeks after birth for optimal ISAT development. B cell depletion using 
either an anti-IgM mAb during the first 3 weeks after birth (Braley-Mullen, Yu 2000) or 
an anti-CD20 – present on all mature B cells - mAb in 2-3 week old mice (Yu et al. 2012) 
resulted in minimal ISAT development compared to mice receiving an isotype control 
mAb. 
 
A key role has also been attributed to B cells during the progression of ISAT in 
NOD.H2h4 mice (Yu et al. 2008). Seven to 10 week old mice receiving three injections of 
an anti-CD20 IgG2a mAb during an 8-week period of iodide-rich diet developed reduced 
ISAT symptoms compared to mice receiving an isotype control Ab (Yu et al. 2008). 
Interestingly, anti-CD20 IgG2a mAb was able to reduce ISAT symptoms even when its 
administration started 5 weeks after NaI treatment – i.e., in mice that had already 
developed ISAT symptoms at that time point (Yu et al. 2008). In this experiment, anti-
CD20 treatment decreased the infiltration of B and T cells as well as the formation of T-B 
cell clusters in the thyroid gland compared to glands from mice receiving the isotype 
control mAb.  
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B cells may also have a pathogenic role after their infiltration into the thyroid gland since 
they have been reported to interact with CD4+ T cells to form structures resembling 
germinal centers in the thyroid (Yu et al. 2001). A recent study focused on the 
intrathyroidal B cells in iodide-fed WT NOD.H2h4 mice (Hong, Braley-Mullen 2014). 
This group reported that the majority of infiltrating B cells are follicular B cells 
expressing high levels of the costimulatory molecule CD80 and reduced levels of CD24, 
compared to splenic follicular B cells. The authors of this paper concluded that 
infiltrating B cells are more mature than splenic B cells.  They also reported that thyroidal 
B cells were able to produce proinflammatory cytokines, TNF-a and IL-6, whereas they 
did not express the marker CD138 suggesting that they were not plasma cells. 
 
Even though the B cell requirement for thyroiditis development has been well 
documented, the function of B cells during the different stages of the disease remains 
poorly understood. Data from studies so far support the idea that B cells may be required 
during early stages of life for optimal ISAT development, because they act as APC 
during the maturation of T cells (Braley-Mullen, Yu 2000). This concept was supported 
by the fact that when lethally irradiated mice were reconstituted with BM precursors from 
B cell deficient mice, minimal ISAT developed (Braley-Mullen, Yu 2000). However, 
transfer of BM precursors from B cell deficient mice and B cells in recipient mice 
resulted in ISAT development at comparable levels to iodide-fed WT mice. These data 
implied that B cells may be necessary as APC for the activation or maturation of 
autoreactive T cells early in life (Braley-Mullen, Yu 2000). 
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The production of IgG Abs by B cells seems to have a secondary role in ISAT 
pathogenesis. This premise was supported by the finding that passive transfer of 
NOD.H2h4 derived Tg-specific IgG to B cell-depleted NOD.H2h4 mice having an iodide- 
rich diet did not elicit disease, indicating that Tg-specific IgG production alone cannot 
lead to ISAT development. Similarly, irradiated adult NOD.Kµnull mice, after 
reconstitution with B cells, were able to produce anti-Tg IgG but did not develop ISAT 
(Braley-Mullen, Yu 2000). The secondary role of antibodies in ISAT development was 
described in experiments with nitrophenyl (NPL) - receptor transgenic NOD.H2h4 mice 
(Yu et al. 2006). These transgenic mice, expressing only NPL-specific B cells that cannot 
secrete IgG, develop mild thyroiditis after NaI administration and anti-CD25 treatment 
was shown to exacerbate ISAT symptoms (Yu et al. 2006). Thyroids of anti-CD25 
treated NPL transgenic mice were characterized by the presence of NPL-specific B cells, 
CD4+ and CD8+ T cells. These data suggested that: 1) transport of B cells to the thyroid 
is independent of their specificity and the production of IgG and 2) lymphocytic 
infiltration is independent of the production of Tg-specific IgG Abs. Thyroid-infiltrating 
B cells participate in the formation of germinal centers within the gland but their function 
still remains unknown (Hong, Braley-Mullen 2014).  
 
1.10. Effects of iodide on thyroid epithelial cells 
One of the mechanisms whereby iodide may initiate an autoimmune cascade in animals 
or humans is through thyrocyte death, i.e., the generation of an inflammatory 
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environment. Indeed high doses of iodide cause thyroid epithelial cell death in several 
animal species (Many et al. 1995, Teng et al. 2009, Bagchi et al. 1995, Li, Boyages 1994) 
or human thyroid follicles (Many et al. 1992) by ex vivo and in vitro studies. Ex vivo 
work examining the structure of the BB/W rat thyroid gland after 12 weeks on moderate 
(3 x 10-6 M) or high (3 x 10-3 M) iodide intake showed that thyrocytes had undergone 
ultrastructural changes compared to cells from control mice (Li, Boyages 1994). In 
thyrocytes from iodide-treated rats, swollen mitochondria as well as dilatation of rough 
ER were evident under electron microscopy. Also, accumulation of lipid droplets, 
condensation of chromatin, nuclear disintegration (karyolysis) and nuclear fragmentation 
(karyorrhexis) were observed in the iodide-treated group, whereas in the control group, 
thyrocytes were intact and only a few showed dilatation of the ER and mitochondrial 
swelling (Li, Boyages 1994). Similar observations have been reported in NOD.H2h4 mice 
after 8 to 24 weeks of iodide administration (1 x 10-5 – 2 x 10-3 M) (Teng et al. 2009), in 
the OS chickens 12 hours after an intraperitoneal injection of 250 µg of iodide (Bagchi et 
al. 1995) and NOD mice after 96 days of high iodide intake (10 mg/day) (Many et al. 
1995). The interpretation of these findings has been that iodide may have a direct toxic 
effect on the thyrocytes of these animals.  
 
In vitro work has further supported the concept that iodide can directly induce thyrocyte 
death. In several studies, primary thyroid cells or thyroid cell lines were cultured in the 
presence of different concentrations of iodide to estimate the rate of cell death. The range 
of iodide concentrations is wide, starting from 10-6 M (Lehmann et al. 2006, Langer et al. 
43 
 
2003), since the physiological iodine plasma levels are estimated to be 10-7 M for mice 
(Bernstein 2007, Taurog A. 1946) and humans (Many et al. 1992), to 10-2 M being the 
highest concentration (Yao et al. 2012, Golstein, Dumont 1996). Studies using relatively 
low iodide concentrations (10-6-10-5 M) have been performed with porcine (Langer et al. 
2003) and human (Lehmann et al. 2006) thyroid follicles. Specifically, intact porcine 
follicles were cultured with 2 x 10-6 M or 2 x 10-5 M potassium iodide for 8, 24 and 72 
hours. The percentage of apoptotic cells was estimated as 4.18% ± 1.8% and 4.27 ± 
2.68% for both doses after 8 hours of potassium iodide treatment whereas the incidence 
of apoptosis in untreated follicles was 1.14 ± 0.65%. After 24 and 72 hours, the number 
of apoptotic cells in the treated group remained unchanged. Interestingly, levels of 
necrosis in the culture were not affected by the presence of potassium iodide (1.13 ± 
0.59). These data indicated that iodide was able to cause apoptosis and not necrosis in 
porcine thyroid follicles (Langer et al. 2003). Similar observations have been reported 
using human thyroid follicular cells (Lehmann et al. 2006). Incubation with 5 x 10-6 M 
and 1 x 10-5 M potassium iodide increased the rate of apoptosis to 4.3% and 5.8%, 
respectively, compared to the untreated group with an apoptotic rate of 3.38%. Despite 
the fact that the above studies were performed using low iodide concentrations, in an 
effort to model the in vivo conditions, the conclusions were weakened by the small 
differences detected in the apoptotic rate between the iodide-treated and untreated groups. 
 
Studies using high iodide concentrations (10-4-10-2 M) have been performed with a rat 
thyroid cell line, the FRTL-5 (Yao et al. 2012, Golstein, Dumont 1996), a human cell line 
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derived from fetal thyroid cells after infection by Simian virus 40, the TAD-2 (Vitale et 
al. 2000), as well as human thyroid follicles (Many et al. 1992) and primary dog 
thyrocytes (Golstein, Dumont 1996). Studies showed that TAD-2 cells cultured with 5 x 
10-2 M KI for 24 or 48 hours underwent morphological changes, as observed under the 
light and fluorescence microscope and exposed the phospholipid phosphatidylserine on 
their cell surface, as detected by Annexin-V staining. DNA fragmentation had also 
occurred as demonstrated by gel electrophoresis (Vitale et al. 2000). All the above 
observations were signs of apoptotic cell death. Furthermore, KI treated TAD-2 cells 
were reported to produce high intracellular levels of reactive oxygen species (ROS) 
compared to KCl treated cells as well as lipid peroxides. Since the apoptotic pathway 
triggered by iodide in this cell line was not known, it was also examined whether iodide 
treatment affected the expression levels of p53, Bcl-2, Bcl-XL and Bax proteins – known 
to be involved in the mitochondrial apoptotic pathway. Interestingly, no change in the 
expression levels of these proteins was shown by Western blot analysis, suggesting that 
iodide-mediated apoptosis in TAD-2 cells does note require upregulation of these 
proteins (Vitale et al. 2000). 
 
The iodide doses reportedly required to affect viability of FRLT-5 cells have been 
controversial. One study reported that their relative viability was significantly decreased 
when KI was added to the culture at 10-5-10-2 M for 24 hours, as compared to that of 
untreated cells (Yao et al. 2012). As early as 2 hours after exposure to 10-4 or 10-2 M KI, 
there was a significant increase in the production of mitochondrial superoxide, but no 
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damage to the cell membrane. After 4 hours, a significant release of mitochondrial 
cytochrome c to the cytosol was reported in the iodide-treated group and damage of the 
cell membrane was indicated by increased lactate dehydrogenase activity in the 
supernatant. DNA fragmentation became evident after 24 hours of treatment with 10-4 or 
10-2 M (Yao et al. 2012). Another study reported that FRTL-5 cells were susceptible to 
iodide-induced cell death only when 10-2 M of KI was used (Golstein, Dumont 1996), but 
specific pathways were not examined. 
 
Effects of high iodide concentrations on the viability of cultured primary thyroid cells 
have been also examined. Human thyroid follicles incubated with 10-3 M NaI for 24 
hours were reported to undergo approximately 10% necrosis whereas cells treated with 
10-7 M NaI contained only 4% necrotic cells (Many et al. 1992). These data suggested 
that high iodide doses have a toxic effect on human thyroid cells. In contrast, primary dog 
thyrocytes incubated with 10-2 M NaI for 24 or 48 hours did not exhibit any signs of cell 
death compared to cells cultured only with medium (Golstein, Dumont 1996).  
 
The majority of the studies described above have reported apoptosis as the most prevalent 
mode of iodide-induced cell death. The molecular pathway of iodide-induced apoptosis in 
thyrocytes has not yet been identified and it may be different between primary thyroid 
cells and cell lines. So far, however, a crucial step for the induction of iodide-induced 
apoptosis has been reported to be the organification of iodide by TPO since two inhibitors 
of TPO, methimazole and propylthiouracil, can abolish iodide-induced apoptosis in TAD-
46 
 
2 cells and human thyroid follicles (Many et al. 1992, Vitale et al. 2000). Organified 
iodide can then be incorporated into lipids and proteins to form iodocompounds. Many 
studies have focused on the role of a certain iodolipid, 6-iodo-5-hydroxy-8, 11, 14-
eicosatrienoic acid δ-lactone (δ-lactone) in apoptosis of thyrocytes (Gartner 2009). ∆-
lactone has been isolated from porcine thyroid follicles (Dugrillon et al. 1990) as well as 
human thyroid tissue from patients with Grave’s disease treated with high doses of iodide 
(Dugrillon et al. 1994). It has been shown that both iodine and δ-lactone induce apoptosis 
in porcine (Langer et al. 2003) as well as human thyroid follicles (Lehmann et al. 2006) 
and the thyroid carcinoma cell line B-CPAP (Gartner et al. 2010) through the 
mitochondrial pathway. Unfortunately, no more details about this signaling cascade in 
thyrocytes is known. 
 
1.11. Other environmental factors affecting thyroiditis  
Autoimmune thyroiditis is influenced by the interplay between genetics and environment 
and many exogenous factors contribute to the development of the disease (Saranac et al. 
2011). For example, high iodine intake has been related to increased incidence and/or 
severity of thyroiditis in humans and in animal models (Ruwhof, Drexhage 2001) as 
discussed in detail in paragraph 1.8. Selenium deficiency has also been reported to 
contribute to the pathogenesis of thyroiditis via the generation of oxidative stress in 
thyrocytes (Kohrle et al. 2005). Environmental pollutants like polybrominated or 
polychlorinated biphenyls have also been related to oxidative stress generation in the 
thyroid gland and disease development (Saranac et al. 2011). Also, the presence of 
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infections agents like Yersinia enterocolitica, a Gram-negative coccobacillus (Strieder et 
al. 2003), hepatitis C virus (Testa et al. 2006) as well as drugs like amiodarone (Roti, 
Uberti 2001), interferon-α, interferon-β (Schuppert et al. 1997) and stress (Tsatsoulis 
2006) have been linked to thyroiditis induction. 
 
Recently, high salt diet (HSD) has been reported to be an environmental factor 
contributing to the development of autoimmunity (Wu et al. 2013, Kleinewietfeld et al. 
2013). Specifically, it was shown that NaCl promotes the differentiation of Th17 cells in 
vitro and in vivo via the induction of the serum glucocorticoid kinase 1 (SGK1) followed 
by expression of the interleukin-23 receptor (IL-23R) (Wu et al. 2013, Kleinewietfeld et 
al. 2013). Also, these two studies reported that HSD can exacerbate experimental 
autoimmune encephalomyelitis (EAE) since C57BL/6 mice, challenged with the myelin 
oligodendrocyte glycoprotein (MOG) peptide 35-55 in CFA, developed higher scores of 
the disease when they received a sodium-rich diet compared to the control group on 
normal diet. The increased severity of the disease was related to increased frequency of 
Th17 cells infiltrating the CNS. These studies raised the question of whether this 
mechanism would apply to other autoimmune diseases. In Chapter 6, we examined 
whether HS diet can exarcebate autoimmune thyroiditis using 3 animal models of the 
disease. 
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CHAPTER 2  
 
MATERIALS AND METHODS 
 
 
2.1. Animals 
 
NOD.H2h4 mice, originally derived by Dr. L.Wicker (Merck Laboratories, Rahway, NJ), 
were kindly provided to us by Dr. H. Braley-Mullen (University of Missouri, Columbia, 
MO). The mice were bred and maintained under specific pathogen-free conditions in the 
animal facility of the Faculty of Medicine, Memorial University of Newfoundland. Both 
male and female mice were used and they were age- and sex-matched in each 
experiment. Female CBA/J and C57BL/6J mice were purchased from the Jackson 
Laboratory (Bar Harbor, ME) and were used at 6-8 weeks of age. All experimental 
procedures were reviewed and approved by the Animal Care Committee at Memorial 
University of Newfoundland. 
 
2.1.1. Generation of NOD.H2h4.Foxp3gfp mice. 
NOD.H2h4.Foxp3gfp mice were generated in our colony by crossing male NOD.Foxp3gfp 
mice, kindly provided by Dr. C.A. Piccirillo (McGill University, Montreal, Quebec) with 
female NOD.H2h4 mice. Female mice from the F1 progeny were backcrossed to male 
NOD.H2h4 mice. Offsprings of these matings (BC1 mice) were genotyped for the 
presence of Foxp3gfp allele by PCR using the following set of primers: forward: 5’-
A.A.GTTCATCTGCACCACCG-3’, reverse: 5’-TCCTTGAAGAAGATGGTGCG-3’. 
Also, in the same reaction tube, amplification of an internal control gene was performed 
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with the following set of primers: forward: 5’-CTAGGCCAC AGAATTGAAAGATCT-
3’, reverse: 5’-GTAGGTGGAAATTCTAGCATCATCC-3’. PCR was performed for 35 
cycles under the following conditions: 94° C for 30 seconds, 60° C for 1 minute and 72° 
C for 1 minute. PCR products were analyzed on a 1.8% agarose gel and had a size of 173 
bp for the gfp product and 324 bp for the internal control product. BC1 mice were also 
genotyped for expression of the H-2h4 or H-2g7 haplotype by staining peripheral blood 
cells with Phycoerythrin (PE)-conjugated Kk, Kd and isotype control mAb (BD 
Pharmingen, Mississauga, ON, Canada) and analyzing by flow cytometry. To exclude the 
possibility of intra-MHC recombination, peripheral blood cells from Kk homozygous 
mice were stained with a Fluorescein isothiocyanate (FITC)-conjugated I-Ad mAb (BD 
Pharmingen), cross-reactive to I-Ag7 but not I-Ak molecule and were found to be negative 
for the I-Ag7 expression. BC1 mice, homozygous for the Kk allele and expressing the 
Foxp3gfp allele were intercrossed. Female mice homozygous for the Foxp3gfp allele were 
identified by PCR analysis using the primers: forward 5’-
GCCTCTGACAAGAACCCAATG-3’ and reverse 5’-
CTGGTCCCTAGAAGTTCTGAG-3’. Amplification was performed at 94° C for 30 
seconds, 65° C for 1 minute and 72° C for 1 minute for 35 cycles. The PCR products had 
a size of 133 bp for the WT Foxp3 allele and 852 bp for the Foxp3gfp allele.  
 
2.1.2. Special diet 
NOD.H2h4 and NOD.H2h4.Foxp3gfp mice received 0.05% NaI water starting at 6-8 weeks 
of age for the indicated time period. CBA/J and C57BL/6J mice were on a special diet as 
51 
 
described by Kleinewietfeld et al. (Kleinewietfeld et al. 2013). The high salt diet groups 
received a combination of salt-enriched chow (4% NaCl Teklad TD.92034) and water 
supplemented with 1% NaCl. Control mice received a regular sodium diet (0.49% NaCl, 
Teklad TD.96208) and deionized distilled water (autoclaved before distribution) ad 
libitum. The commercial rodent chow had a natural ingredient base containing wheat, 
corn, soy and alfalfa; (w/w) 19% protein; 48% carbohydrates; 5.2% fat; 0.9% Ca; 0.8% 
K. Water intake was monitored weekly and is expressed as grams consumed per mouse 
per day. 
 
2.2. Antigens and peptides 
 
Tg was purified from frozen thyroid glands of ICR mice (Bioproducts for Science, 
Indianapolis, IN) or CD1 mice (Charles River, Quebec, Canada) by gel filtration. Briefly, 
thyroid glands were homogenized in PBS buffer, pH=7, containing 10-6 M leupeptin, 10-6 
M pepstatin and 10-3 M phenylmethanesulfonylfluoride (Sigma Aldrich, St. Louis, MO). 
Extracts were centrifuged 3x at 16,000 g for 10 minutes and supernatant was loaded to a 
Sepharose CL-4B (Amersham Biosciences AB, Uppsala, Sweden) column. Fractions 
were collected and their optical density was determined at λ=280 nm by 
spectrophotometry (Life Science UV/Vis spectrophotometer, Beckman Coulter, Du® 
730). Based on the elution profile of the supernatant, the fractions forming the second 
peak of the chromatogram (Figure 2.1) were pooled, dialyzed 3x in distilled water 
concentrated to 1-2 mg/ml (Amicon, Millipore Corporation, Bedford, USA), lyophilized 
in Speedvac and stored at -20° C. OVA was purchased from Sigma. The Tg peptides, 
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(557-568), FLVFLQRAVSVP, p557; (771-781), QNGDGQELTPA, p771; (1822-1832), 
SDFPGDMATEL, p1822; (2369-2380), DVASIHLLISRP, p2369; (2439-2450), 
NILNDAQTKLLA, p2439; were synthesized by Biosynthesis Inc. (Lewisville, Texas) 
and were used at >85% purity. F-moc L-T4 was produced as previously described (Kong 
et al. 1995, Adamczyk et al. 1994). The 12 mer Tg peptide T4p2553 (a.a. 2549-2560), 
STDD(T4)ASFSRAL was synthesized at the University of Patras, Greece, and at 
Biosynthesis, Inc (Lewisville, Texas, USA) at >90% purity. The 19mer OVA peptide 
(322-340), CISQAVHAAHAEINEAGRY, was synthesized at the Alberta Institute 
(Edmonton, Alberta, Canada) and the purity was 70%. All peptides were blocked with an 
acetyl group at the N-terminus and with an amide group at the C-terminus.  
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Figure 2.1 
Thyroid glands from 20 ICR mice were homogenized in PBS buffer, pH=7, as described 
in Materials and Methods. The thyroid extract was passed through a Sepharose CL-4B 
column and its elution profile is shown above. The box indicates the elution volume of 
free Tg. The fractions within the box were pooled, dialyzed in distilled water, 
concentrated to 1-2 mg/ml and lyophilized. Samples were kept at -20 oC until use. 
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2.3. Cell lines and tissue culture  
 
The TA3 cell line, kindly gifted by Dr. L. Glimcher (Harvard University, Cambridge, 
MA) and provided by Dr. T. Watts (University of Toronto, Ontario, Canada), was 
produced by fusion of B cells from CAF1 mice with the M12.4.1 BALB/c B lymphoma 
(Allen et al. 1985). The IL-2 dependent CTLL-2 cell line, purchased from the American 
Type Culture collection, was cultured in medium supplemented with 10% supernatant 
from Concanavalin A-activated rat spleen cells. All cell lines were cultured in Dulbecco’s 
modified Eagle’s medium (DMEM) (Life Technologies, Invitrogen, Grand Island, NY), 
supplemented with 10% Fetal Calf serum (FCS) (PAA Laboratories, Ontario, Canada), 
20 mM HEPES buffer, 2 mM L-glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin 
(all from Life Technologies) and 5 x 10-5 M 2-mercaptoethanol (Sigma). The NOD.H2h4-
derived T4p2553-specific T cell hybridoma KC1 was generated following a modified 
procedure (Perkins et al. 1991). Briefly, NOD.H2h4 mice were immunized with 100 nmol 
T4p2553 peptide in CFA emulsion. Nine days later, draining LN were collected and 
single cell suspensions were prepared in DMEM supplemented with 10% FCS. Cells 
were cultured in the presence of 20 µΜ T4p2553 for 4 days and subsequently were fused 
with BW5147α-β- cells, kindly provided by P. Marrack (National Jewish Medical and 
Research Center, Denver, CO) in a 1:1 ratio in the presence of polyethylene glycol 1500 
(Roche Diagnostics GmbH, Mannheim, Germany). After this fusion step, cells were 
cultured in the presence of hypoxanthine-aminopterin-thymidine containing DMEM 
supplemented with 20% FCS for 7-21 days followed by a 10-day culture in 
hypoxanthine-thymidine containing DMEM supplemented with 20% FCS. Cells that 
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survived the selection procedure were cultured in DMEM supplemented with 10% FCS 
and their specificity was tested as described below. T4p2553-specific T cell hybridomas 
were cloned by limiting dilution at 0.3 cells/well using red blood cells (RBC) as feeder 
cells.  
 
2.3.1. Primary thyrocyte culture 
 
Thyroid cells were isolated and cultured according to a modified method (Jeker et al. 
1999). Thyroid lobes from mice were aseptically removed from the trachea, cut into 
small fragments, teased apart and material from three glands was placed in 1 ml DMEM 
digestion medium (Gibco, Life Technologies, Grand Island, NY, USA) containing 1 unit 
/ml of collagenase type I (Sigma-Aldrich, St. Louis, MO) and 1.2 units/ml of dispase I 
(Sigma). Enzymatic digestion was performed at 37° C for 45 minutes followed by 
vigorous pipetting. The cells were then washed twice and were re-suspended in F-12 
Nutrient Mixture (HAM) culture medium (Invitrogen) supplemented with BDTM Nu-
Serum IV Replacements (BD Biosciences, Bedford, MA, USA) (diluted 2.5 x), glycyl-L-
histidyl-L-lysine acetate salt (2 ng/ml final), somatostatin (10 ng/ml), TSH (10 mU/ml) 
and NaI (1 µM) (all from Sigma). 
 
To ascertain purity, thyrocytes were cultured as described above in 8-well chamber slides 
(Nalge Nunc International, Rochester, NY, USA) using material from three NOD.H2h4 
thyroid glands per well.  On day 10, cells were fixed with acetone for 10 min at -20° C, 
washed, and subsequently were placed in PBS containing 10% FCS for 20 min at room 
temperature (blocking step). Then, cells were incubated with Tg-specific antisera 
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from iodide-fed NOD.H2h4 mice or antisera from control CBA/J mice (1:20 dilution) for 
1 hour. The cells were then washed 3x and incubated with a secondary FITC-labeled goat 
anti-mouse IgG (Jackson Immunoresearch LAboratories, West Grove, PA, USA) for 30 
min. Cells were again washed 3x and one drop of VECTASHIELD Hard-Set Mounting 
Medium with DAPI (Vector Laboratories, Burlingame, CA, USA) was added to each 
well.  Fluorescent cells were viewed using a Carl Zeiss AxioImager Z.1 microscope. 
 
2.4. T cell hybridoma activation / inhibition assay 
Specificity of T cell hybridoma KC1 was examined by an activation assay in which 105 
TA3 cells and 105 T cell hybridomas were cultured in wells of a 96-well plate in the 
presence of titrated amounts of T4p2553 and Tg (starting concentration 100 nM). After 
24 hours, supernatant from wells was removed and its IL-2 content was assessed upon 
incubation with the IL-2 dependent CTLL cells. CTLL proliferation was measured by 
[3H] thymidine incorporation. MHC restriction of KC1 was examined by an inhibition 
assay. 105 TA3 cells and 105 T cell hybridomas were cultured in the presence of 25 nM 
T4p2553 and 10 µg/ml of anti-Ak or anti-influenza A nucleoprotein (NP) mAb, purified 
as previously described (Verginis et al. 2002), as inhibitors. Percent of inhibition was 
calculated as follows: [1-(cpm in the presence of mAb)/(cpm in the absence of mAb)] x 
100.  
 
2.5. Immunizations and T cell proliferation assays  
 
CBA/J and NOD.H2h4 mice were challenged s.c. at the base of the tail and the dorsal side 
of the neck with 100 nmol of peptide or 100 µg of Tg in 100 µl CFA emulsion (with 
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Mycobacterium butyricum; Difco LAboratories). After nine days, the inguinal, branchial 
and axillary LN were isolated and single cell suspensions were prepared in DMEM 
supplemented with 10% FCS, 20 mM HEPES buffer, 2 mM L-glutamine, 100 U/ml 
penicillin, 100 µg/ml streptomycin and 5 x 10-5 M 2-ME (Sigma-Aldrich, St. Louis, MO). 
After centrifugation and washing, 4 x 105 cells/well were cultured with or without titrated 
amounts of peptide (0.5-25 µΜ), Τg or OVA (1 µΜ)  in flat-bottom 96-well plates and 
were incubated for 4 days at 37° C in a 10% CO2, 90% air-humified incubator. Eighteen 
hours prior to harvesting, 1 µCi of [3H] - thymidine (6.7 mCi/mmol; Perkin Elmer, 
Boston, USA) was added to each well. The cells were harvested using a Classic Cell 
Harvester (Skatron Instruments) and radioactivity was measured using the LS6500 Multi-
Purpose Scintillation Counter. Stimulation index (S.I.) was defined as: cpm in the 
presence of Ag/cpm in the absence of Ag.  
 
2.6. Spontaneous T cell proliferation assays 
For assessment of spontaneous T cell proliferation, CLN and spleens were removed from 
NOD.H2h4 mice after 7, 11 and 15 days of iodide treatment. Single cell suspensions were 
prepared in HL-1 medium (Lonza, Walkersville, MD, USA) supplemented with 100 U/ml 
penicillin/streptomycin, 2 mM glutamine and 5 x 10-5 M 2-ME and were cultured at 4 x 
105 cells/well in the presence of 10 µg/ml T4p2553, 20 µg/ml Tg, 20 µg/ml OVA for 3 
days at 37° C, in a 5% CO2 incubator. During the last eighteen hours, 1 µCi [3H] 
thymidine (Perkin Elmer, Boston, MA) was added to each well. Then, cells were 
harvested and radioactivity was measured as described above. 
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2.7. Detection of IgG responses by enzyme-linked immunosorbent assay (ELISA)  
Serum IgG antibodies specific for Tg or Tg peptides were detected by a two-step ELISA, 
as previously described (Kolypetri et al. 2010). Briefly, wells of polyvinylchloride plates 
were coated overnight with 10 µg/ml Tg or 4 µg/ml Tg peptide in carbonate buffer, pH= 
9.6 and blocked with 0.1% bovine serum albumin in PBS for 1 hour. Serum samples, 
diluted in PBS/Tween 20 containing 0.1% bovine serum albumin, were added to wells for 
1 hour and specific ab binding was assessed with an alkaline phosphatase-conjugated 
goat anti-mouse IgG Ab (Jackson Immunoresearch LAboratories, Inc., West Grove, 
Pennsylvania). After 20 minutes, conversion of the p-nitrophenyl phosphate substrate 
(Sigma) into the p-nitrophenol product was determined by light absorption at 405 nm 
using a Vmax plate reader (Molecular Devices, Sunnyvale, CA). 
 
2.7.1. Detection of cytokines in the culture supernatant 
 
The presence of IL-2, IFN-γ and IL-4 in the culture supernatant of LNC after 48 hours 
was assessed by sandwich ELISA via extrapolation from standard curves generated using 
known amounts of murine recombinant IL-2, IFN-γ and IL-4 (BD Biosciences, San 
Diego, CA), according to the manufacturer’s instructions. Light absorbance was 
measured using a Vmax plate reader at 450 nm. The detection limits were 4 pg/ml for IL-
2, 40 pg/ml for IFN-γ and 8 pg/ml for IL-4.  
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2.7.2. Detection of aldosterone in mouse serum. 
Serum aldosterone was assessed by RIA (Coat-a-count Aldosterone kit TKAL1, 
Siemens) according to the manufacturer’s instructions. 
 
2.8. EAT induction and histological assessment 
 
EAT was induced in mice either directly or upon adoptive transfers of in vitro activated 
cells. CBA/J and NOD.H2h4 mice were immunized s.c. with 100 nmol of peptide 
emulsified in CFA and three weeks later were challenged with 50 nmol of the same 
peptide in incomplete Freund’s adjuvant (IFA). C57BL/6J mice were immunized s.c. 
with 100 µg of Tg in 100 µl of CFA and three weeks later were boosted with 50 µg of Tg 
in IFA. EAT was assessed two weeks after the last challenge. Induction of EAT by 
adoptive transfer was conducted as previously described (Rao et al. 1999). Briefly, LNC 
isolated from donor CBA/J mice, previously challenged s.c. with 100 nmol of peptide in 
CFA, were incubated for 72 hours in the presence of 25 µM of the appropriate peptide. 
After harvesting and washing, 2 x 107 cells in 200 µl of PBS were administered i.p. into 
syngeneic recipients and EAT was evaluated 14 days later. Fixation, embedding in 
methacrylate and sectioning of thyroids were performed as previously described (Rao et 
al. 1999). The sections were stained with hematoxylin and eosin and were scored for 
thyroid pathology as follows: 0, no infiltration; 1, small interstitial infiltration; 2, one or 
two foci of inflammatory cells; 3, diffuse infiltration of 10-40% of total area; 4, extensive 
infiltration, 40-80% of total area and 5, extensive infiltration over 80% of total area.  
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2.9. Microscopic detection of apoptosis  
Cells from 10 thyroid glands were added into 18 wells of black 96-well plates (Costar 
#3603, Corning Incorporated, NY, USA) and were cultured for 10 days at 37° C, 5% 
CO2. Medium was changed one day later and then every third day. On day 9, the plates 
were centrifuged and cells were washed 2x to remove non-adherent, floating cells. Then, 
various concentrations of NaI (Sigma) or 6 µΜ camptothecin (Sigma) were added to the 
cells for 24 hours. Apoptosis was assessed by the  FAM-FLICATM in vitro Poly Caspases 
kit (Immunochemistry Technologies, Bloomington, MN, USA), which utilizes a 3-
aminoacid sequence (VAD) sandwiched between carboxyfluorescein (FAM) and 
fluoromethylketone (FMK). The FAM-VAD-FMK reagent penetrates the cell membrane 
and binds irreversibly to activated caspases 1, 3, 4, 5, 6, 7, 8 and 9.   During the last five 
minutes, propidium iodide and Hoechst 33342 were also added to the wells. After 
extensive washing (10x), live cells were observed under an inverted Carl Zeiss 
AxioObserver A.1 microscope. Images were captured using a Zeiss AxioCam MRM3 
camera with Zeiss Axiovision 4.8 Software. At least 300 cells per group were counted 
and analyzed by the ImageJ 1.41 Software (NIH, USA).  
 
2.10. Expression analysis of apoptosis and oxidative-stress related genes by Real-
Time PCR 
The expression of 168 genes involved in apoptotic and oxidative stress-related pathways 
was measured by the mouse Apoptosis and Oxidative stress PCR arrays (Qiagen 
Sciences, Maryland, USA). Thyroid glands from 80 NOD.H2h4 and 80 CBA/J mice were 
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isolated and cultured as described above. On day 9, thyrocytes were incubated with or 
without iodide (4 x 10-6 M final concentration) for 24 hours. Then, the supernatant of 
cultured thyrocytes was removed and the cells were lysed by the addition of Trizol 
(InVitrogen). The aqueous phase was mixed with an equal volume of 70% ethanol and 
subsequently the sample was transferred to an RNeasy spin column (Qiagen). The RNA 
was purified following on-column DNase treatment (RNase-free DNase set, Qiagen) 
according to the manufacturer’s instructions. RNA purity was quantified by 
spectrophotometry at 260/230 nm and 260/280 nm ratios. The cDNA was transcribed 
from 1 µg total RNA per group using the RT2 First Strand Kit (Qiagen,) in a total volume 
of 222 µl. Next, 102 µl of cDNA (equivalent to 0.5 µg RNA) were mixed with 1350 µl 
RT2 SYBR Green Mastermix and RNase-free water in a total volume of 2700 µl. 
Twenty-five µl of this PCR components mix were added to each well of the RT2 Profiler 
PCR Array and quantitative PCR was performed using a StepOnePlus Applied 
Biosystems cycler. The cycling conditions were 950 C for 10 min for activation of 
HotStart DNA Taq Polymerase followed by 40 cycles of denaturation at 950 C for 15 s 
and annealing at 600 C for 60 s. A dissociation (melting) curve analysis was performed to 
verify PCR specificity. Each 96-well plate contained primers for 84 pathway-related 
genes and 5 housekeeping genes whereas 7 wells contained reverse-transcription 
controls, positive PCR controls and genomic DNA contamination control. For each gene 
of interest, the difference (∆CT) between its CT value and the average CT value of the 5 
housekeeping control genes was calculated. For each pair-wise set of samples to be 
compared, the difference in ∆CT values was calculated as: ∆∆CT = ∆CT (exp) - ∆CT 
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(control) and the fold-change of target gene expression was calculated as 2(-∆∆CT). Fold 
change values of <1 are expressed as negative inverse of fold change.  
 
2.11. Purification of DC from spleen and CLN 
To obtain DC, spleens and/or CLN were digested with Liberase TM research grade (1.67 
Wünsch units/ml RPMI) (Roche Applied Science, Quebec, Canada) for 30 minutes at 37° 
C. After a gentle pipetting, cell suspensions were passed through a nylon mesh to remove 
undigested material, washed, and then incubated with PBS supplemented with 5% FCS 
and 5 mM EDTA, pH 7.2, for 5 minutes to disrupt DC/T cell complexes. After an 
additional wash, splenic cells were treated with RBC lysing buffer (Sigma) while CLNC 
suspensions were passed through Lympholyte M (Cedarlane, Burlington, ON, Canada) to 
remove RBC and debris. The cells were resuspended in PBS containing 0.5% BSA and 2 
mM EDTA and DC were positively selected using anti-mouse CD11c-coated magnetic 
beads and MACS columns according to the manufacturer’s instructions (Miltenyi Biotec, 
Auburn, CA, USA).  The purity of the CD11c+ population was >93%, as confirmed by 
flow cytometry.   
 
2.12. Purification of thyroid infiltrating lymphocytes. 
Intrathyroidal lymphocytes (IL) were obtained from 15 NOD.H2h4 mice drinking 0.05% 
NaI water for 35 days. Thyroids were treated with 0.28 U/ml Liberase TM research grade 
(Roche Applied Science) in serum-free RPMI -1640 medium for 45 minutes at 37° C. 
Undigested material was mechanically disrupted by pipetting and passing through a 35-
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µm diameter nylon cell strainer (BD Discovery LAbware, Mississauga, ON, Canada). 
Lymphocytes were separated using Lympholyte M. 
 
2.13. Flow cytometry and intracellular cytokine staining. 
CD4+ cells were purified from CLNC and/or spleens using a mouse CD4+ T cell 
enrichment kit (StemCell Technologies, Vancouver, Canada). Subsequently, they were 
cultured at 2 x105 cells/well in HL-1 medium with splenic DC (4 x 104 cells/ well) and 
antigen in 96 flat-bottom well plates for 4 days. During the last 6 hours, 5 µg/ml of 
Brefeldin A (Sigma) were added to the wells. All staining steps were performed at 4o C.  
FcR were blocked with anti-mouse CD16/32, (clone 93; eBiosciences, San Diego, CA) 
for 15 min and subsequently incubated with an FITC-conjugated anti-CD4 mAb or 
isotype control (BD Biosciences, Mississauga, Ontario, Canada) for 30 min. After three 
washing steps, cells were fixed in 2% paraformaldehyde and permeabilized with 0.5% 
saponin in PBS + 2% FCS. Then, staining using a PE-conjugated anti-mouse IFN-γ and 
the isotype control mAb was performed (BD Biosciences) for 30 minutes at 4° C. 
 
2.14. Statistical analysis 
Statistical significance was assessed by the non-parametric Mann-Whitney test or by a 
one-tailed unpaired Student’s t-test using the GraphPad Prism 4 Software. 
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3.1. Abstract 
 
 
EAT, induced in mice after challenge with Tg, is known to be under the genetic control 
of the H2Ak locus. Because cathepsins are known to influence proteolytic processing of 
Tg in vivo, we examined in this study whether putative H2Ak-binding Tg epitopes, 
located near cathepsin cleavage sites within mTg, have immunopathogenic properties. 
Cathepsin L, B, and D cleavage sites in mTg were predicted based on homology with 
known cathepsin cleavage sites in rabbit Tg. We used an algorithm-based approach to 
identify H2Ak - binding motifs within 20-a.a. residue segments adjacent to cathepsin 
cleavage sites, and five 12-mer peptides encompassing these sequences were synthesized. 
Two of them, p2369 (a.a. 2369-2380) and p2439 (a.a. 2439-2450) were immunogenic, 
eliciting significant proliferative T cell responses using LNC from peptide-primed mice 
and production of IL-2 and IFN-γ in recall assays in vitro. Both peptides induced EAT 
upon direct challenge of CBA/J mice with peptide in CFA and by adoptive transfer of 
peptide-primed LNC into naïve recipient hosts, but neither peptide was characterized as 
dominant.  
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3.2. Introduction 
 
EAT, a model of HT in humans, is induced in mice after challenge with Tg in adjuvant 
(Rose et al. 1971, Esquivel et al. 1977). Successful induction of EAT is characterized by 
infiltration of mononuclear cells in the thyroid gland, follicular cell destruction and 
production of Tg–specific Abs (Weetman, McGregor 1994). Early studies have 
delineated the importance of the MHC region in EAT induction (Vladutiu, Rose 1971) 
attributing the genetic control of the disease to the H2Ak locus in H2k mice (Beisel et al. 
1982, Kong et al. 1997). EAT is considered to be a T-cell mediated disease (Braley-
Mullen et al. 1985, Romball, Weigle 1987, Maron et al. 1983, Vladutiu, Rose 1975) and 
CD4+ T cells play a pivotal role in the initiation and development of the disease (Flynn et 
al. 1989). 
 
Tg, the most abundant thyroid protein, is produced by thyrocytes and then is exported and 
stored in the follicular lumen (Dunn J.T., Dunn A.D. 2000). Since its discovery as an 
autoantigen in 1956 (Roitt I.M. et al. 1956), 25 Tg pathogenic epitopes have been 
identified using a variety of approaches (Carayanniotis 2007). A common strategy 
involved the use of computer algorithms to delineate putative MHC-binding Tg peptides 
(Caturegli et al. 1997, Chronopoulou, Carayanniotis 1992, Li, Carayanniotis 2006, 
Verginis et al. 2002, Flynn et al. 2004) whereas other methods employed cloned T-cell 
hybridomas as screening tools (Texier et al. 1992, Champion et al. 1991), elution of 
human MHC-bound peptides (Muixi et al. 2008a, Muixi et al. 2008b) or focused on 
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searching for T-cell epitopes shared between Tg and TPO (Hoshioka et al. 1993). All 
known Tg pathogenic peptides have fallen under three categories: a) iodinated peptides 
containing iodotyrosyls; b) peptides encompassing hormonogenic sites; and c) non- 
iodinated peptides scattered throughout the Tg molecule (Carayanniotis 2007). 
Interestingly, none of them has been characterized as dominant according to criteria 
established by Sercarz et al. (Sercarz et al. 1993). The large molecular size of Tg (660 
kDa in its dimeric form) and the lack of posttranslational modifications on candidate 
synthetic peptides have been mentioned as two possible reasons to account for this rather 
paradoxical finding (Carayanniotis 2003, Carayanniotis 2007). 
 
The large size of the Tg molecule affords it two main functions: 1) Tg acts as a scaffold 
to allow the formation of T3 and T4 by intramolecular coupling of iodotyrosines, and 2) 
Tg provides a substrate for selective endoproteolytic cleavages that may facilitate the 
release of these hormones (Dunn et al. 1991, Gentile et al. 1992, Rousset et al. 1989). The 
cleavage sites most likely represent conserved, solvent-exposed regions of the primary 
structure and occur within sequences that disrupt the Cys-rich, tandem repeats of Tg 
(Gentile, Salvatore 1993). Limited digestion of rabbit Tg by human cathepsins B, D and 
L has identified major cleavage sites (Dunn et al. 1991) that are near those observed after 
digestion with different enzymes, supporting the view that the lysosomal degradation of 
Tg is governed by the intrinsic susceptibility of some of its regions to various proteases 
(Gentile, Salvatore 1993). With the rationale that the presence of an enzymatic cleavage 
site near an epitope is a factor enhancing its immunodominance (Sercarz et al. 1993), we 
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have searched in this report for pathogenic T cell epitopes localized in the proximity of 
mTg sequences homologous to those encompassing the cathepsin cleavage sites in rabbit 
Tg. We have looked for Ak-binding motifs within 20-a.a. residue segments adjacent to the 
homologous murine cathepsin cleavage sites. The immunopathogenicity and 
immunodominance of 12-mer peptides encompassing these motifs were examined in this 
study. 
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3.3. Results 
3.3.1. Prediction of H2Ak-binding peptides in mTg. 
Because cathepsin L, B, and D cleavage sites in rabbit Tg have been previously described 
(Dunn et al. 1991), we identified the homologous sites in the mTg sequence. Four 
cathepsin L cleavage sites in mTg were identified with the P’1 residue at a.a. positions 
2388, 2451, 2490 and 2657 (Table 3.1). In a similar manner, a.a. 531, 795 and 2486 were 
defined as P’1 residues for cathepsin B, and a.a. 550, 1833, 2467, and 2642 as P’1 
residues for cathepsin D. We then searched for the presence of Ak-binding motifs within 
20 a.a. residues from the above sites by scanning the mTg sequence (Kim et al. 1998) 
with an algorithm described by Altuvia et al. (Altuvia et al. 1994). This approach allowed 
us to delineate five peptides (Table 3.2) encompassing such motifs: 2 peptides (a.a. 557-
568 and a.a. 1822-1832) were found near 2 putative cathepsin D cleavage sites, 2 
peptides (a.a. 2369-2380 and a.a. 2439-2450) near a cathepsin L cleavage site, and 1 
peptide (a.a. 771-781) near a cathepsin B cleavage site. The relative position of these 
mTg peptides vis a vis the location of the putative cathepsin cleavage sites is shown 
schematically in Figure 3.1. 
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Table 3.1. Possible cathepsin L, B and D cleavage sites in mTg 
Endopeptidase P4-P1 sequencea P'1-P'n+1 sequenceb P'1 residue no.a 
Cathepsin L QLFR KALLMGGSALS 2388 
 KLLA VSGPFHYWGPVVDGQ 2451 
 LIGG SQDDGLINRA 2490 
 FSRK A.A.EFATPWP 2657 
Cathepsin B RVVG NFGFKVNLQENQDAL 531 
 REVA SRNFSLFLQ 795 
 KVDL LIGGSQDDGLINRA 2486 
Cathepsin D FLVS SLLELPEFLVFLQR 550 
 ATEL FSPVDITQVI 1833 
 DGQY LRELPSRRLKRPL 2467 
 FSNF IRSGNPNYPHEFS 2642 
 
a A.a. coordinates are based on the cDNA- derived sequence of mTg by Kim et al. (Kim et al. 
1998) 
b
 Homologous rabbit Tg residues identified by Dunn et al. (Dunn et al. 1991) are underlined. 
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Table 3.2. Amino acid co-ordinates and sequences of mTg peptides used in the study. 
 
a
 A.a. coordinates are extrapolated from the mTg sequence according to Kim et al. (Kim 
et al. 1998) and do not include the leader sequence. Three additional peptides were 
identified by this methodology but were not used in the study for technical reasons: 
p1838-1849 had a solubility problem; p2467-2477 carried a proline within a motif 
sequence; and p2490-2504 was overlapping significantly with the previously identified 
pathogenic T-cell epitope 2495-2504 (Rao et al. 1994). 
b
 The underlined sequences represent Ak-binding motif A: [DEHNQ]-{NQ}-X-[ILTV]-
X-{FHWY}-[ACFILMTVWY]; and the sequences in bold represent Ak-binding motif B: 
[CDEHNQY]-{DE}-X-[ILTV]-[DEHQN]  where [ ] represents inclusion and 
{}represents exclusion of the indicated amino acids at this position; X denotes any amino 
acid (Altuvia et al. 1994). 
 
 
Amino acid 
coordinatesa 
Motif-containing sequence Peptide  denotation 
557-568               FLVFLQRAVSVP                 p557               552 (cathepsin D)      
771-781               QNGDGQELTPA                 p771    795 (cathepsin B) 
1822-1832            SDFPGDMATEL                  p1822            1833 (cathepsin D) 
 2369-2380           DVASIHLLISRP                   p2369             2388 (cathepsin L) 
 2439-2450           NILNDAQTKLLA                 p2439             2451 (cathepsin L)  
 
 
 
Putative 
cleavage site P’ 
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Figure 3.1 
Relative position of Tg peptides (shown in blue) used in this study vis a vis the location 
of putative cathepsin L, B and D cleavage sites (arrows)  in mTg based on homology to 
known cleavage sites in rabbit Tg (Dunn et al. 1991). Peptides were identified by the 
presence of Ak-binding motifs within 20 a.a. from the cleavage sites, after scanning the 
mTg sequence with the computerized algorithm described by Altuvia et al. (Altuvia et al. 
1994).  
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3.3.2. Assessment of Tg peptide immunogenicity and immunodominance. 
To examine the immunogenicity of the Tg peptides, we challenged CBA/J mice s.c. with 
100 nmol of each peptide. Inguinal, axillary and branchial LNCs were collected 9 days 
later and cultured in the presence of the immunizing peptide. Peptides p2369 and p2439, 
induced significant specific LNC proliferation compared to undetectable responses to 
control peptide p1579 (Figure 3.2A), indicating that these Tg peptides contain epitopes 
that elicit T cell responses in CBA/J mice. To examine the immunodominance of T cell 
determinants contained in these peptides, we challenged CBA/J mice with 100 µg of Tg 
in CFA and 9 days later, LNCs were collected and cultured in the presence of Tg or free 
p2369 or p2439. As shown in Figure 3.2B, LNCs from Tg-primed mice responded to Tg 
but failed to respond to equimolar (0.2 - 0.9 µΜ range) concentrations of free peptide, 
with responses remaining undetectable at peptide concentrations as high as 75 µΜ. 
Conversely, LNCs from peptide-primed mice responded in vitro to the immunizing 
peptide but did not respond to Tg (Figure 3.2C), indicating that p2369 and p2439 do not 
contain dominant T cell epitopes. The cytokine production profile of peptide-reactive 
LNCs from p2369- and p2439-primed CBA/J mice showed secretion of IL-2 and IFN-γ 
(Figure 3.3), but no IL-4 detection (data not shown), suggesting the activation of Th1 
cells. No cytokine secretion was detected upon culturing the above peptide-primed LNCs 
with the unrelated p1579 peptide control (not shown). 
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Figure 3.2 
Secondary proliferative responses in vitro of LNC from: A) peptide-primed CBA/J mice 
in the presence of 5 µΜ of the immunizing peptide or p1579 control. Data were obtained 
from full peptide titration curves (0.5 – 25 µΜ) and are representative of four 
independent experiments; B) Tg-primed CBA/J mice against Tg or equimolar 
concentration (1 µM) of the peptide antigen shown; C) Peptide-primed CBA/J mice in the 
presence of 1 µM of the immunizing peptide or Tg. Data show the mean S.I. of triplicate 
wells ± S.D. 
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Figure 3.3 
Cytokine profile of Tg peptide-reactive LNC as determined by sandwich ELISA after 48 
hour culture in the presence of 25 µM of the respective peptide shown. IL-2 (A) and IFN-
γ (B) concentrations were extrapolated from standard curves. Cytokine production in 
response to p1579 peptide control was at background levels (17-22 pg/ml for IL-2 and < 
40 pg/ml for IFN-γ).  Results represent the mean values of triplicate wells ± S.D.  
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3.3.3. Assessment of Tg peptide pathogenicity. 
CBA/J mice were subsequently challenged with p2369 (n=8) or p2439 (n=7) in CFA and 
3 weeks later were boosted with the same peptide in IFA. Two weeks after the last 
immunization, thyroid glands were histologically examined for EAT development. Both 
peptides were pathogenic inducing EAT with low incidence (4/8 mice with EAT after 
challenge with p2369 and 2/7 mice with EAT after challenge with p2439) and severity 
(mean I.I.) ranging from 0.4-0.6; Table 3.3). Thyroiditogenicity was confirmed when 
adoptive transfer of p2369-specific effector cells into naïve hosts induced EAT in 3/5 
mice with mean I.I. = 0.6, and that of p2349-specific cells elicited EAT in 6/6 mice with 
mean I.I. = 1.5 (Table 3.3). In contrast, neither peptide induced peptide-specific IgG 
responses (data not shown).  
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Table 3.3. EAT induction by Tg peptides in CBA/J mice. 
 
Direct induction of EATa Adoptive transfer of EATb 
                        I.I.                          I.I. 
 
Peptide 
 
0 1 2 No of mice 
with EAT 
Mean 
I.I. Peptide 0 1 2 
No of mice 
with EAT Mean I.I. 
 
p2369 
 
4 3 1 4/8 0.6  p2369 2 3 
 
3/5 0.6  
 
p2439 
 
5 1 1 2/7 0.4  p2439 0 3 3 6/6 1.5 
 
a CBA/J mice were challenged s.c. with 100 nmol of the indicated peptide and 3 weeks later 
boosted with 50 nmol of the peptide in IFA. Thyroids were removed 2 weeks after the last 
immunization as described in Materials and Methods. 
b Twelve CBA/J mice were challenged s.c. with 100 nmol of the indicated peptide. Nine days 
later LNC were collected and cultured in vitro with 25 µΜ peptide for 72 hours. Next, cells 
were transferred i.p. into syngeneic recipients (6 mice per group) and thyroids were collected 14 
days later. 
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3.4. Discussion 
In this study, we have used sequence homology comparisons to correspond known 
cathepsin L, B and D cleavage sites in rabbit Tg (Dunn et al. 1991) with their 
counterparts in the mTg sequence, and we examined whether putative Ak-binding 
peptides located near these cleavage sites would have immunodominant and 
immunopathogenic properties in CBA/J mice. Our data describe two new thyroiditogenic 
Tg epitopes, p2369-2380 and p2439-2450, located near the cathepsin L cleavage sites 
2388 and 2451, respectively. Interestingly, these epitopes are clustered close to known 
immunopathogenic Tg epitopes p2494-510 (Chronopoulou, Carayanniotis 1992), p2495-
503 and p2498-506 (Rao et al. 1994) in mTg and p2340-59 in hTg (Karras et al. 2003, 
Karras et al. 2005) at the C-terminal region of the large Tg molecule. Recent work by 
Tomer’s group (Jacobson et al. 2009) examining hTg digests by individual human 
cathepsins L, B and D identified cleavage sites near the ones described by earlier work of 
Dunn et al. with rabbit Tg in 7 out of 11 cases shown in Table 1. Also, it is interesting 
that work with mTg digests by Dedieu et al. (Dedieu et al. 2011) has confirmed that the 
a.a. sites 2368-71 (ADVA motif) and a.a. 2410-11 (a.a. co-ordinates do not include the 20 
a.a. leader sequence), located at the start or near our identified peptides, are very sensitive 
to proteolytic attack. That study revealed that six out of the 11 cleavage sites shown in 
Table 1 were near to or overlapping with the N-termini of peptide fragments solubilized 
from mouse thyroid lobe extracts. These, as well as earlier (Gentile et al. 1992, Gentile, 
Salvatore 1993) findings give support to the notion that the Tg substrate(s) recognized by 
proteolytic enzymes within thyrocytes may be conserved among species. 
79 
 
 
The rationale that immunodominant epitopes are likely to be found near proteolytic sites 
was based on earlier work with antigens such as hen egg lysozyme (Schneider et al. 
2000) and myelin basic protein (Manoury et al. 2002, Anderton et al. 2002). However, 
the immunodominant peptide(s) in mTg remain elusive as neither of p2369/p2439 
appeared to be generated by the processing of intact mTg in vivo or in vitro. The 
paradoxical finding that no one of the 27 (including this study) known pathogenic Tg 
peptides exhibits clear immunodominant behavior stems from using an arbitrary 
definition since, by convention, we expect such a peptide to be generated following 
processing of intact Ag in peripheral APC. Parameters involved in this process can be 
categorized at two levels: 1) The level of the substrate; and 2) the level of the APC 
involved.  
 
At the level of the substrate, it has been suggested that the large size of Tg (consisting of 
two identical subunits of 330 kDa) may prohibit the quantitative yield of any given 
average (2 kDa) candidate peptide following Tg processing in peripheral APC 
(Carayanniotis 2003, Carayanniotis 2007). Also, requirements for post-translational 
modifications of epitopes such as glycosylation, phosphorylation or iodination are not 
usually been taken into account by the screening assays (Carayanniotis 2007). A third 
view argues that the relevant peptidic substrate for APC (intrathyroidal or peripheral) is 
not intact Tg per se, but rather Tg fragments released from thyrocytes. In this case, the 
epitopes under consideration could be dominantly expressed due to an alteration of the 
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immunodominance hierarchy in the shorter Tg fragments. This is a plausible explanation, 
given that only very small amounts of intact Tg are secreted from the basolateral 
membrane of thyrocytes during transepithelial transport (transcytosis) – a process 
mediated by megalin which protects Tg from lysosomal degradation (Marino et al. 2001). 
This process competes with the main proteolytic pathway of Tg in lysosomes which is 
orchestrated to maximize hormone recovery under a regimen of limited proteolysis. In 
this regard, working with SDS-PAGE bands of mouse thyroid extracts comprising 
proteins with molecular masses lower than 250 kDa, Dedieu et al. identified 174 different 
peptides corresponding to Tg fragments (Dedieu et al. 2011). Thus, although the relative 
amounts of intact Tg vs Tg fragments in the secreted peptidic repertoire are not known, it 
is conceivable that Tg fragments may be the main substrate of relevance in the 
aetiopathogenesis of disease. Unfortunately, a “model Tg peptidic repertoire” that could 
be used in studies of immunodominance of given Tg epitopes remains obscure. Tg 
degradation is a complex process, starting with the solubilization of stored Tg from 
covalently cross-linked globules by cathepsins B and L, limited digestion by cathepsins K 
and L for extracellular T4 liberation (in the lumen) and final re-entry into endo-
lysosomes for complete proteolysis by several lysosomal enzymes (Friedrichs et al. 
2003). In addition, several proteases may act in concert, and their activities may be 
influenced by their subcellular location (Jordans et al. 2009) or by protease-resistant 
segments (type 1 repeats) of Tg itself (Molina et al. 1996, Mihelic, Turk 2007, Gentile et 
al. 2004). 
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At the level of APC, DC - intrathyroidal or within thyroid-draining LN - are likely to be 
the primary cells involved in the MHC-class II presentation of Tg peptides derived from a 
Tg fragment substrate. Proteolytic action within BM-derived APC would be distinct from 
that occurring within thyrocytes as cathepsin L and S mediate the late stages of invariant 
chain degradation (Nakagawa et al. 1998, Nakagawa et al. 1999, Riese et al. 1998, Shi et 
al. 1999). A developing immune response would further complicate the regulation of this 
process, since IFN−γ is known to enhance the role of cathepsin S and inhibit cathepsin L 
activity in APC (Beers et al. 2003, Guncar et al. 1999). As a consequence of an 
inflammatory response, thyroid epithelial cells could also become APC – once they 
acquire antigen-presenting capability through IFN-γ-induced MHC class II upregulation 
(Londei et al. 1984, Bottazzo et al. 1983) – and new sets of Tg peptides, endogenously 
processed in thyrocytes may be recognized by autoreactive T cells. In this regard, work 
with human T cell clones, derived from thyroid infiltrates and specific for TPO epitopes, 
has supported the notion that thyrocytes as APC present a different TPO peptide 
repertoire from that obtained by the processing of the exogenous antigen in blood 
mononuclear cells (Quaratino et al. 1996).  
 
 In this and earlier work, the recognition of a plethora of Tg peptides by pre-activated 
specific effector T cells that home to the thyroid, after adoptive transfer in the mouse 
EAT model, formulates two important corollaries: First, it clearly argues that these 
epitopes must be intrathyroidally expressed under steady-state conditions, perhaps on 
resident DC (Voorby et al. 1990). This view is supported by data published by Unanue’s 
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group in autoimmune diabetes which show that DC in islets of Langerhans constitutively 
present β cell-derived peptides bound to class II MHC molecules (Calderon et al. 2008, 
Calderon, Unanue 2012). Constitutive presentation of a “constellation” of Tg peptides to 
the immune system may contribute to the maintenance of peripheral tolerance which 
could be abrogated by conditions that favor the generation of effector cells in the 
periphery. Second, for unknown reasons, the proximity of peptides such as 2369-2380 
and 2439-2450 to proteolytic cleavage sites may facilitate their processing and 
presentation on MHC class II antigens without necessarily promoting their destruction by 
exopeptidase activity.   
 
In view of the above, it is remarkable that traditional methods of epitope mapping applied 
to the large mTg molecule in the field of mouse EAT have identified peptides that may 
have biological relevance to the pathogenesis of human autoimmune thyroid disease. For 
example, a large homologous segment of the mTg pathogenic peptide p2495-2511, 
initially identified by an algorithm searching for the presence of mouse MHC-binding 
motifs (Chronopoulou, Carayanniotis 1992) was eluted from DR molecules in thyroid 
samples from patients with Graves’ disease (Muixi et al. 2008a), and  overlapped 
significantly with a hTg peptide obtained after digestion with human cathepsin B 
(Jacobson et al. 2009). Also, diverse screening methodologies have independently 
resulted in the delineation of identical pathogenic peptides. For example, the pathogenic 
mTg peptide 179-194 that was initially identified for encompassing an Ak-binding motif 
flanked by a Tyr residue (Li et al. 2007), was subsequently found to be a major 
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thyroiditogenic peptide in the A-E+ transgenic model of EAT (Brown et al. 2008a). 
These examples strongly suggest that, currently, there is no single best methodology for 
the continuing discovery of pathogenic Tg peptides and that any clinical implications 
stemming from the EAT data will slowly emerge as human studies progress in the future. 
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CHAPTER 4 
 
 
 
Apoptosis of NOD.H2h4 thyrocytes by low concentrations of iodide is 
associated with impaired control of oxidative stress 
 
Kolypetri P., Carayanniotis G. 
 
The main body of this work was accepted for publication in Thyroid, on March 24, 2014 
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4.1. Abstract  
Enhanced iodide intake in NOD.H2h4 mice accelerates the incidence and severity of SAT 
(ISAT) via an unknown mechanism. A plausible hypothesis is that iodide-induced 
apoptosis of thyrocytes can create imbalances in antigenic load and/or disruption of 
immunoregulatory mechanisms that facilitate activation of autoreactive T cells in CLN 
draining the thyroid. We have examined whether NOD.H2h4 thyrocytes, exposed to low 
NaI concentrations in vitro, are more susceptible to apoptosis compared to thyrocytes 
from CBA/J mice which are resistant to ISAT. We have also looked, at the transcriptional 
level, for differential activation of genes involved in apoptosis or oxidative stress 
pathways that may account for potential differences in iodide-mediated apoptosis 
between NOD.H2h4 and CBA/J thyrocytes. We report that NOD.H2h4 thyrocytes, cultured 
for 24 hr at very low (4-8 µM) concentrations of NaI, exhibit high levels (40-55%) of 
apoptosis, as assessed microscopically following staining with fluorescent caspase 
inhibitors. Similar treatment of thyrocytes from CBA/J mice which are resistant to ISAT 
yielded significantly lower (10-20%) apoptotic rates. Expression analysis by real-time 
PCR using arrays of apoptosis- and oxidative stress-related genes showed that NaI intake 
upregulates the expression of 22 genes involved in ROS metabolism and/or anti-oxidant 
function in CBA/J thyrocytes whereas only two of these genes were upregulated in 
NOD.H2h4 thyrocytes.  Among the set of overexpressed genes were those encoding TPO 
(Tpo) (5.77 fold), glutathione peroxidases (Gpx2, Gpx4, Gpx7), (2.03 – 3.14 fold), 
peroxiredoxins (Prdx1, Prdx2, Prdx5) (2.27 - 2.97 fold), superoxide dismutase 1 (Sod1) 
(3.57 fold), thioredoxin 1 (Txn1) (2.13 fold) and the uncoupling proteins 2 and 3 (Ucp2, 
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Ucp3) (2.01-2.15 fold). The results demonstrate that an impaired control of oxidative 
stress mechanisms is associated with the observed high susceptibility of 
NOD.H2h4 thyrocytes to NaI-mediated apoptosis and suggest a contributing factor for the 
development of ISAT in this strain. 
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4.2. Introduction 
 
The NOD.H2h4 mouse strain has been well established as an animal model for the study 
of SAT. This strain was originally made in 1993 to investigate potential effects of H-2 
region genes on diabetes but it was serendipitously found to develop only insulitis and 
not diabetes (Podolin et al. 1993) and a much higher incidence (50%) of SAT vs. 5% in 
NOD mice (Wicker et al. 1995, Burek, Rose 2008). The high incidence of SAT in this 
strain, carrying the Kk, Ak, E0, Db haplotype, has been attributed in part to the combined 
presence of the Ak molecule which is permissive for thyroiditis development (Kong et al. 
1997) and NOD non-MHC genes that are known to predispose to autoimmunity (Wicker 
1997). SAT appears after 15 weeks of age and its incidence and severity increase 
progressively with time. However, when 6-8 wk old NOD.H2h4 mice are placed on 
drinking water containing 0.05% NaI, SAT becomes detectable as early as 2 weeks after 
the initiation of the dietary regimen and plateaus within 4-8 weeks. The discovery of 
ISAT in NOD.H2h4 mice complements similar earlier observations of thyroiditis 
induction by iodide in NOD mice (Hutchings et al. 1999, Vecchiatti et al. 2013), BB/W 
rats (Allen et al. 1986) and OS chickens (Bagchi et al. 1985). These animal models 
strongly suggest the interplay between dietary (environmental) and genetic factors in the 
activation of an autoimmune response and are likely to involve processes similar to those 
that precipitate development of autoimmune thyroiditis and hypothyroidism in humans 
following excessive iodine intake (Konno et al. 1994, Markou et al. 2001, Bournaud, 
Orgiazzi 2003). 
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Intrathyroidal infiltration by mononuclear cells and production of Tg-specific IgG Abs 
have been well established as the cardinal symptoms of ISAT in NOD.H2h4 mice 
(Hutchings et al. 1999, Braley-Mullen et al. 1999, Rasooly et al. 1996) but the early 
events whereby iodide triggers the autoimmune cascade remain unknown. Thyrocytes 
actively take up iodide through the function of the NaI symporter (Provenzano et al. 
2009) and is well known that their exposure to high concentrations of iodide can induce 
their apoptosis or necrosis in vivo (Bagchi et al. 1985, Teng et al. 2009, Li, Boyages 
1994, Chen et al. 2011), or in vitro (Many et al. 1992, Lehmann et al. 2006, Yao et al. 
2012, Vitale et al. 2000). A plausible hypothesis is that iodide-induced apoptosis of 
thyrocytes can create imbalances in antigenic load and/or disruption of immunoregulatory 
mechanisms that facilitate activation of autoreactive T cells in CLN draining the thyroid. 
In this report, we have examined whether NOD.H2h4 thyrocytes, exposed to low NaI 
concentrations in vitro, are more susceptible to apoptosis compared to thyrocytes from 
CBA/J mice which are resistant to ISAT (Li, Carayanniotis 2007). We have also looked, 
at the transcriptional level, for differential activation of genes involved in apoptosis or 
oxidative stress pathways that may account for potential differences in iodide-mediated 
apoptosis between NOD.H2h4 and CBA/J thyrocytes. 
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4.3. Results 
 
4.3.1. Establishment of primary thyroid epithelial cell culture and assessment of 
apoptosis 
 
Single cell suspensions from NOD.H2h4 thyroid glands were prepared and cultured for 10 
days in complete Ham F-12 medium promoting epithelial cell growth, as described in 
Materials and Methods. Using a two-step immunofluorescence assay with FITC-labeled 
goat anti-mouse IgG, it was shown that over 98% of the grown cells were thyrocytes 
since their cytoplasm was positively stained by thyroglobulin-specific IgG antibodies 
(Figure 4.1A) but remained unstained by normal serum IgG (Figure 4.1B). In 
preliminary experiments, apoptosis of thyrocytes, cultured in the presence of various NaI 
concentrations, was assessed with the FAM-FLICATM in vitro Poly Caspase kit which 
uses a reagent that penetrates the cell membrane and binds irreversibly to activated 
caspases. With this method, we could readily enumerate healthy (Figure 4.1C) vs. early 
or late apoptotic thyrocytes (Figure 4.1D, E). Necrotic thyrocytes were identified by 
staining with propidium iodide (Figure 4.1F). 
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Figure 4.1 
 
Establishment of primary mouse thyrocyte cultures and assessment of NaI-induced apoptosis.  
NOD.H2h4 thyrocytes were expanded in culture for 10 days and their purity was assessed by 
a two-step immunofluorescence assay using FITC-labeled goat anti-mouse IgG, as described 
in Materials and Methods.  (A) Thyrocytes incubated with NOD.H2h4 serum containing high 
titers of Tg-specific IgG; (B) thyrocytes incubated with control serum from healthy CBA/J 
mice. Appearance of NOD.H2h4 thyrocytes following exposure to apoptotic/necrotic stimuli. 
(C) Healthy thyrocytes (blue staining of nucleus with Hoechst 33342); (D) Early apoptotic 
thyrocyte cultured in 10-5 M NaI (green fluorescent staining of cytoplasm with FAM-FLICA 
poly caspase reagent); (E) late apoptotic thyrocyte cultured in 10-5 M NaI (cytoplasmic stain 
with FAM-FLICA and propidium iodide); (F) necrotic thyrocyte following exposure to 90% 
ethanol for 30 sec (cytoplasmic stain with propidium iodide). 
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4.3.2. Low concentrations of iodide induce differential apoptosis in NOD.H2h4 vs CBA/J 
thyrocytes. 
 
The effect of iodide on NOD.H2h4 thyrocyte viability in vitro was initially tested within a 
large range of final NaI concentrations (10-5 – 10-3 M). NaI was added to 9-day cell 
cultures for 24 hours and subsequently apoptosis was microscopically assessed with the 
FAM-FLICA assay by counting 300 cells from cultures at each NaI concentration in five 
independent experiments (Figure 4.2). It was found that the background apoptosis of 
thyrocytes grown in the absence of NaI was relatively high (27.12 ± 3.1) (percentage 
mean +/- SEM) and that exposure to 10-5 M NaI significantly increased the percentage of 
total apoptotic cells to 58.34 ± 6.3, (p= 0.021). This level of apoptosis remained relatively 
constant over the 10-5 -10-3 M NaI range and was comparable to that observed following 
a 12 hour treatment of thyrocytes with 6 µΜ camptothecin (59 ± 3.6). The number of 
necrotic cells in all cultures was negligible. On the basis of these initial data we selected 
the 1 x 10-6 – 1.6 x 10-5 M NaI range to compare NOD.H2h4 vs CBA/J thyrocytes in terms 
of their susceptibility to iodide-induced apoptosis since CBA/J mice do not develop ISAT 
following high NaI intake. As shown in Figure 4.3, in the absence of NaI, NOD.H2h4 
thyrocytes showed a background apoptotic rate of 21.59 ± 4.00 which was not 
significantly higher than that  observed in the corresponding CBA/J cell culture, (11.5 ± 
0.5,  p = 0.128). However, increasing NaI concentrations induced higher apoptotic rates 
in NOD.H2h4 thyrocytes, peaking at 54.45 ± 5.45 at 8 x 10-6 M NaI. In contrast, over the 
same molar range of NaI, CBA/J thyrocytes exhibited total apoptotic cell levels which 
were not significantly higher than those of the control (no NaI) cultures. The percentage 
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of necrotic cells in all cultures was negligible (not shown) and never exceeded 3.4%. 
Possible osmotic effects were excluded because after exposure to equimolar NaCl 
concentrations, apoptotic cell rates did not rise above background values (not shown). 
These data demonstrated that, at low NaI concentrations in vitro, NOD.H2h4 thyrocytes 
are more sensitive to iodide-mediated apoptosis than CBA/J thyrocytes which appeared 
to be unaffected by the NaI treatment. 
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Figure 4.2 
 
Death of cultured NOD.H2h4 thyrocytes following 24 hour treatment with the indicated 
concentrations of NaI or camptothecin control (12 hr, 6 µΜ). Apoptosis or necrosis was 
microscopically assessed by examination of at least 300 cells per group after staining as 
described. The data indicate mean ± SEM of 5 experiments. The statistical significance 
between the untreated controls and the NaI-treated groups assessed by a paired t-test was 
as follows: NaI 10-3 M, p=0.019; NaI 10-4 M, p=0.001; NaI 10-5 M, p=0.021.  
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Figure 4.3 
 
NOD.H2h4 thyrocytes are highly sensitive to iodide-induced apoptosis. Day 9 NOD.H2h4 
and CBA/J thyrocyte cultures were exposed to the indicated final NaI concentrations for 
24 hours. Total (early and late) apoptotic cells were microscopically viewed and counted 
as described in Figure 1, using the FAM-FLICA assay. Three hundred cells were 
examined per group and data represent percent apoptosis mean ± SEM of two 
independent experiments. The percentage of necrotic cells in all cultures never exceeded 
3.4%. Statistical significance was determined by a two-tailed unpaired t-test. * p = 0.051; 
** p = 0.025.  
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4.3.3. Analysis using apoptosis PCR arrays 
 
To further investigate the iodide-mediated apoptosis pathway, we looked at the 
expression of 84 apoptosis-related genes (Appendix 1) by real time PCR using a mouse 
Apoptosis PCR array. We first examined whether the number or the relative constitutive 
expression of pro-apoptotic genes was higher in NOD.H2h4 vs. CBA/J thyrocytes. Within 
a set of 35 apoptosis-promoting genes, significant expression differences were observed 
at eight genes, with two genes (Tnf and TnfSF10) showing higher expression and six 
genes (Traf 2, Trp73, Card 10, Casp 9, Dffb, and Casp6) showing lower expression in 
NOD.H2h4 vs. CBA/J/ thyrocytes (Table 4.1). Conversely, within a set of 26 apoptosis-
inhibiting genes, significant expression differences were observed at four genes, with one 
gene (Naip2) showing higher expression (3.29-fold) and three genes (Nme5, Cidea, 
BCl2l10) showing lower expression in NOD.H2h4 vs. CBA/J/ thyrocytes (Table 4.1). 
These data did not support the view that NOD.H2h4 thyrocytes intrinsically express a 
clear apoptosis-promoting profile at the gene transcription level, as compared to CBA/J 
thyrocytes. 
 
Next, we examined the effects of NaI on gene transcription rates in thyrocytes from each 
strain. After nine days of culture, cells were treated with 4 x 10-6 M NaI and RNA from 
these - and from untreated thyrocyte controls - was extracted 24 hours later. Surprisingly, 
in NOD.H2h4 thyrocytes only the pro-apoptotic gene bok (BCL-2 related ovarian killer 
protein), showed significant alteration in its expression as it was completely suppressed 
(> - 500-fold) (Appendix 1). Interestingly, expression of several genes that belong in the 
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Bcl-2 family, and various caspases and their activators, was not significantly affected by 
the iodide treatment. In NaI-treated CBA/J thyrocytes, there was mild downregulation of 
five pro-apoptotic genes (Abl1, Dffb, RipK1, Casp9, Card 10) and three anti-apoptotic 
genes (Bcl2l0, Atf5, Il10) vs. the untreated controls (Appendix 1).  Only 1 pro-apoptotic 
gene (Tnfsf10) was upregulated (2.36-fold). Taken together, these data suggested that the 
apoptosis-enhancing effect of NaI, differentially observed in NOD.H2h4 vs. CBA/J 
thyrocytes in Figure 3, could not be clearly attributed to factors operating at the 
transcriptional level of the genes tested. 
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Table 4.1.  Differential expression of apoptosis-related genes in NOD.H2h4 and CBA/J thyrocytes 
 
a A fold change ≥ 2.00 (upregulation) and  ≤ -2.00 (downregulation) was considered significant.
RefSeq Symbol Description Fold change 
 (NOD.H2h4/CBA/J) a 
Apoptosis promoting genes 
NM_013693 Tnf Tumor necrosis factor 3.04 
NM_009425 Tnfsf10 Tumor necrosis factor (ligand) superfamily, member 10 2.95 
NM_009422 Traf2 Tnf receptor-associated factor 2 -2.01 
NM_130859 Card10 Caspase recruitment domain family, member 10 -2.89 
NM_015733 Casp9 Caspase 9 -3.03 
NM_007859 Dffb DNA fragmentation factor, beta subunit -4.01 
NM_009811 Casp6 Caspase 6 -23.85 
Apoptosis inhibiting genes 
NM_010872 Naip2 NLR family, apoptosis inhibitory protein 2 3.29 
NM_080637 Nme5 Non-metastatic cells 5, protein expressed in (nucleoside-diphosphate kinase) -2.00 
NM_007702 Cidea Cell death-inducing DNA fragmentation factor, alpha subunit-like effector A -2.57 
NM_013479 Bcl2l10 Bcl-2-like 10 -2.66 
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4.3.4. Analysis using oxidative stress PCR arrays 
 
Enhanced iodide-induced apoptosis in NOD.H2h4 thyrocytes could be triggered by high 
levels of ROS that has been reported to be detected in thyrocytes of this strain in the 
absence of NaI (Sharma et al. 2008). To examine whether NaI-treated or control 
NOD.H2h4 thyrocytes have a defect in the expression of genes participating in ROS 
metabolism or anti-oxidant defense mechanisms leading to overproduction of ROS, we 
performed analysis using an oxidative stress PCR array. The constitutive expression 
levels of 84 oxidative stress-related genes, (Appendix 2), was initially compared between 
control thyrocytes from the two strains. Significant expression differences were observed 
at only four genes involved in ROS metabolism, with three genes (Ncf1, Ncf2 and Ccl5) 
showing higher and one gene (Duox1) showing lower expression in the NOD.H2h4 group 
(Table 4.2). On the other hand, NOD.H2h4 thyrocytes significantly overexpressed three 
genes (Gpx2, Cygb, and Mpo) and underexpressed one gene (Fancc) associated with anti-
oxidant function (Table 4.2).  
 
When the effects of NaI on oxidative stress-related gene transcription rates were 
examined in thyrocytes from each strain, the results were striking. In CBA/J thyrocytes, 
NaI upregulated the expression of 22 genes involved in anti-oxidant defense mechanisms 
and ROS metabolism whereas the same treatment increased expression of only two of 
these genes (Gpx2, glutathionine peroxidase 2, and Nqo1, NADPH dehydrogenase, 
quinone 1) in NOD.H2h4 thyrocytes (Figure 4.4). This gene set comprised several 
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peroxidases, with the main effect observed with Tpo, (5.77-fold change). In contrast, NaI 
mildly upregulated the expression of only one gene (Noxo1, NADPH oxidase organizer 
1) (2.09-fold change) and downregulated the expression of two genes Cygb, (cytoglobin) 
(-2.17-fold) and Krt1, (keratin 1), (-3.7-fold) in NOD.H2h4 cells. These results strongly 
suggested that an impaired capacity to mobilize molecules with anti-oxidant function 
might explain in part the observed susceptibility of NOD.H2h4 thyrocytes to apoptosis 
induced by low concentrations of NaI. 
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Table 4.2. Differential expression levels of oxidative stress- related genes in NOD.H2h4 and CBA/J 
thyrocytes 
 
 
 
 
a A fold change ≥2.00 (upregulation) and ≤ -2.00 (downregulation) was considered significant. 
 
 
 
 
 
 
 
 
 
 
RefSeq Symbol Description 
Fold change  
(NOD.H2h4 / 
CBA/J)a 
Genes encoding proteins involved in ROS metAbolism 
NM_010876 Ncf1 Neutrophil cytosolic factor 1 4.52 
NM_010877 Ncf2 Neutrophil cytosolic factor 2 2.89 
NM_013653 Ccl5 Chemokine (C-C motif) ligand 5 2.40 
NM_001099297 Duox1 Dual oxidase 1 -2.74 
Genes encoding proteins with anti-oxidant function 
NM_030677 Gpx2 Glutathione peroxidase 2 2.88 
NM_030206 Cygb Cytoglobin 2.51 
NM_010824 Mpo Myeloperoxidase 2.00 
NM_007985 Fancc Fanconi anemia, complementation group C -4.78 
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Figure 4.4 
Differential expression of oxidative stress-related genes in iodide-treated NOD.H2h4 and 
CBA/J thyrocytes. Thyroid cell suspensions from 80 NOD.H2h4 and 80 CBA/J thyroid 
glands were cultured in vitro for 9 days. On day 9, 4 x 10-6 M NaI was added to wells and 
RNA was isolated 24 hours later. cDNA was used in an Oxidative Stress PCR array and 
analyzed by real time PCR. Fold change ≥ 2.00 or ≤ - 2.00 was considered significant 
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4.4. Discussion 
 
The goal of this study was to examine whether NOD.H2h4 thyrocytes exhibit high 
sensitivity to NaI-induced apoptosis with the view that this might provide an early trigger 
in ISAT development in this mouse strain. Work with thyrocytes from euthyroid mice 
and relatively low doses of NaI could model in vivo processes of protracted increased 
dietary iodine intake in healthy people and in this regard, this approach differs from 
numerous previous studies which have described iodide-induced cell death in thyrocytes 
from goitrous animals (Ruwhof, Drexhage 2001). Our data showed that NOD.H2h4 
thyrocytes, cultured for 24 hours in the presence of 4-8 x 10-6 M NaI, underwent 
apoptosis at very high rates (40 – 55 %) whereas similar treatment of thyrocytes from 
CBA/J mice – which are resistant to ISAT (Li, Carayanniotis 2007) – did not raise 
apoptosis above  background levels. To our knowledge, such high levels of apoptosis 
induced by very low concentrations of iodide in vitro have not been previously reported. 
Previous studies with porcine (Langer et al. 2003) or human (Lehmann et al. 2006) 
thyroid follicles have shown pro-apoptotic effects of iodide in the 2-5 x10-6 M range but 
the observed apoptotic rates were low (4-5%). Usually, very high levels (10-4 - 10-2 M) of 
iodide have been used to induce significant cell death in thyroid cell lines such as FRTL-
5 cells (Yao et al. 2012, Golstein, Dumont 1996), TAD-2 cells (Vitale et al. 2000) or 
human thyroid follicles (Many et al. 1992). To a certain extent, variances in apoptotic 
rates reported by various studies may be due to the use of different assays of apoptosis 
measurement or even the animal species examined (Golstein, Dumont 1996). 
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In this study, the enhanced NaI-induced cell death of NOD.H2h4 thyrocytes cannot be 
attributed to necrosis since the levels of necrotic cells in all groups did not exceed 3.4%. 
The irreversible binding of the fluorescent inhibitor FAM-VAD-FMK to activated 
caspases 1,3,4,5,6,7,8 and 9 precludes speculation about the possible apoptotic pathways 
involved, e.g. the participation of inflammasome via activation of caspase-1 or the 
apoptosome followed by activation of caspase-9 (Latz et al. 2013). Given the extent of 
apoptosis observed microscopically, it was surprising that the NaI treatment was found 
not to up- or down-regulate any genes in the apoptotic gene array involved in the intrinsic 
and extrinsic apoptotic pathways as well as in caspase and DNA damage response 
cascades, strongly suggesting that this process is independent of regulation at the 
transcription level and it is executed by proteins already present in the cell. This finding 
is in agreement with data from a previous study showing that increasing concentrations of 
cycloheximide, a protein synthesis inhibitor, did not block the apoptosis of the iodide-
treated thyroid cell line, TAD-2 (Vitale et al. 2000). Expression of p53, Bcl-2, Bax and 
Bcl-XL genes has also been reported to remain unchanged at the protein level after 12, 24 
and 48 hours of KI treatment of TAD-2 cells (Vitale et al. 2000) while gene array 
analysis in NIS/TPO modified lung cancer cells has shown that iodide-induced apoptosis 
did not alter significantly the expression levels of all apoptosis-related genes except p21 
and survivin (Zhang et al. 2003). In our study, the apoptotic gene array data derived from 
NOD.H2h4  and CBA/J thyrocytes at the basal (non NaI-treated) state (Table 4.1) did not 
provide clear evidence that NOD.H2h4  thyrocytes exhibit an intrinsic defect favoring 
induction of apoptosis since simultaneous mild over- or under- expression of apoptosis-
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promoting or inhibiting genes was detected in the thyrocytes from both strains. It remains 
open whether the iodolipid δ-lactone which has been isolated from porcine thyroid 
follicles (Dugrillon et al. 1990) as well as human thyroid tissue from patients with 
Graves’ disease treated with high doses of iodide (Dugrillon et al. 1994) has an active 
role in the apoptosis mechanism operating in our system. Both iodine and δ-lactone have 
been reported to induce apoptosis in porcine (Langer et al. 2003) as well as human 
thyroid follicles (Lehmann et al. 2006) and in the thyroid carcinoma cell line B-CPAP 
(Gartner et al. 2010) through the mitochondrial pathway. 
 
Thyroid epithelial cells are constantly exposed to ROS because they produce large 
amounts of H202 required for iodination of Tg. Since high levels of ROS can lead to 
oxidative damage, thyrocytes have protective mechanisms to control the intracellular 
levels of ROS (Schweizer et al. 2008, Smyth 2003). Defects in these regulatory networks 
have been proposed to underlie the spontaneous thyroiditis onset in OS chickens (Bagchi 
et al. 1990). NOD.H2h4 thyrocytes, either in the basal state or after exposure to 10-4 M 
NaI in vitro, have previously been reported to overexpress ROS as compared to control 
BALB/c and B10.A thyrocytes (Sharma et al. 2008). Our data suggest that the high 
sensitivity of NOD.H2h4 thyrocytes to apoptosis, induced by low levels of NaI in vitro, 
may be, in part, due to an impairment in the up-regulation of anti-oxidant activity. 22 out 
of 84 oxidative stress-related genes in the array showed mild (2.01 – 3.57-fold) but 
significant overexpression in CBA/J thyrocytes which were resistant to apoptosis. 
Highest overexpression (5.77-fold) was observed with the Tpo gene. This contrasts with 
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findings from previous studies reporting either no effect of iodide treatment on Tpo 
expression (Li, Carayanniotis 2007, Leoni et al. 2008, Kawashima et al. 2013) or even 
downregulation of this expression (Morand et al. 2003, Muller et al. 2011) in thyroid 
cells or lines. The reasons for this discrepancy are unclear but may be due to the different 
protocols used.  
 
Among the set of overexpressed genes encoding proteins with anti-oxidant function were 
several glutathione peroxidases (Gpx2, Gpx4, Gpx7) and peroxiredoxins (Prdx1, Prdx2, 
Prdx5) as well as Sod1 (superoxide dismutase 1) and Txn1 (thioredoxin 1) (Schweizer et 
al. 2008). Interestingly, increased expression of Gpx2, Txn1 but not Gpx4 has been 
previously reported in the rat PCCL3 thyroid cells after iodide treatment in vitro (Leoni et 
al. 2008, Leoni et al. 2011). Other identified genes were: a) the Ucp2, Ucp3, encoding the 
uncoupling proteins 2 and 3, located in the inner mitochondrial membrane. Ucp2 mainly 
functions to attenuate mitochondrial production of ROS (Pi et al. 2010) whereas Ucp3 
seems to protect mitochondria against lipid-induced oxidative stress (Liu et al. 2013);  b) 
Nqo1, (NAD(P)H dehydrogenase, quinone 1, encoding a detoxification enzyme that 
catalyzes reduction in quinines (Nioi et al. 2003);  c) Park7 (Parkinson’s disease 
associated protein) encoding a protein that stabilizes Nrf2, the master regulator of 
antioxidant genes (Clements et al. 2006) and protects mitochondria from oxidative stress 
(Ma 2013); d) Fth1 encoding the iron-storing protein ferritin that minimizes oxidative 
stress (Hintze, Theil 2005); e) Serpinb1b encoding an inhibitor of neutrophil serine 
proteases, with a strong anti-inflammatory activity (Polytarchou et al. 2008); f) the ROS 
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responsive genes Ccl5, encoding the chemokine (C-C motif) ligand 5 and Psmb5, 
encoding the proteasome subunit, beta type 5; g) Mb, encoding a protein involved in 
oxygen transportation with a described antioxidant function in cardiac muscle (Flogel et 
al. 2004); h) Fmo2, encoding a NADPH-dependent enzyme involved in the oxidation of 
various xenobiotics (Gornicka et al. 2011); i) Txnip, encoding a protein inhibiting the 
function of Txn1 and promoting induction of ROS generation (Spindel et al. 2012). Of 
particular interest was the upregulation of the gene Ncf2 (p67phox) (neutrophil cytosolic 
factor) expression  in CBA/J thyrocytes, encoding a subunit of the ROS-generating 
NADPH oxidase since it has been similarly reported to increase in iodide-treated BALB/c 
thyrocytes but not in iodide-treated NOD.H2h4 thyrocytes (Sharma et al. 2008). In the 
iodide-treated NOD.H2h4 group, the expression of two genes, Gpx2 and Nqo1, with 
antioxidant function was upregulated as well as Noxo1, encoding for a cytosolic subunit 
of NADPH oxidase. Significant downregulation was observed in the expression of Krt1, 
a ROS responsive gene and Cygb, encoding an oxygen transporter with an antioxidant 
function in neuronal cells (Li et al. 2007). Since the apoptotic fate of a thyrocyte lies on 
the balance between ROS production and catabolism, these data imply that activation of 
several genes encoding proteins with anti-oxidant function plays a main role in the 
differential apoptosis observed in our study.   
 
The high sensitivity of NOD.H2h4 thyrocytes to apoptosis induced by low concentrations 
of NaI in vitro may have important implications for the mechanisms operating in ISAT 
development. Apoptotic cascades in thyrocytes could be triggered by iodide and not 
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result simply by mononuclear cell infiltration of the gland, as described in other studies 
(Teng et al. 2009). The physiological iodine plasma levels in mice (Bernstein 2007, 
Taurog A. 1946), as well as in humans (Many et al. 1992) are estimated to be in the 10-7 
M range and it has been reported that when the iodine intake is very high, e.g. 20 mg/day 
in some Japanese populations, the plasma iodine can increase 100-fold (Many et al. 1992, 
Nagataki 1974, Suzuki 1980). It is thus conceivable that the pro-apoptotic in vitro effects 
of NaI on NOD.H2h4 thyrocytes shown in the present study might reflect similar 
processes in ISAT when mice are placed on 0.05% NaI in water (3 x 10-3 M) for several 
weeks. The increased apoptotic death of NOD.H2h4 thyrocytes in combination with the 
defective clearance of apoptotic cells by macrophages that has been described in NOD 
mice (Maree et al. 2008, O'Brien et al. 2006) - and possibly present in NOD.H2h4 mice - 
could lead to an antigenic overload in thyroid draining LN and activation of thyroid 
antigen specific T cells as shown in the NOD system (Hoglund et al. 1999, Turley et al. 
2003). 
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CHAPTER 5 
 
 
 
The thyroxine-containing thyroglobulin peptide (a.a. 2549-2560) is a target 
epitope in iodide-accelerated spontaneous autoimmune thyroiditis 
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5.1. Abstract 
 
Enhanced iodide ingestion is known to accelerate the incidence and severity of disease of 
SAT (ISAT) in NOD.H2h4 mice. CD4+ cells are required for the development and 
maintenance of ISAT but their target epitopes remain unknown. In this study, we show 
that the previously identified Tg T-cell epitope (a.a. 2549-2560), containing T4 at a.a. 
position 2553 (T4p2553), induces thyroiditis as well as strong specific T and B cell 
responses in NOD.H2h4 mice.  In ISAT, activated CD4+ T cells specific for T4p2553 are 
detected before the disease onset in thyroid-draining CLNC only in mice placed on 
iodide-rich diet and not in age-matched controls. In addition, selective enrichment of 
CD4+ IFN-γ+ T4p2553-specific cells is observed among CLNC and IL. T4p2553 was 
equally detectable on DC obtained ex vivo from CLNC of NaI-fed or control mice 
suggesting that the iodide-rich diet contributes to the activation of autoreactive cells 
rather than the generation of the autoantigenic epitope. Furthermore, spontaneous 
T4p2553-specific IgG are not detectable within the strong Tg-specific autoantibody 
response. These data identify for the first time a Tg T-cell epitope as a spontaneous target 
in ISAT. 
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5.2. Introduction 
 
 
NOD.H2h4 mice are well known to develop SAT at a much higher incidence than the H-2 
congenic NOD strain (Wicker et al. 1995, Hutchings et al. 1999, Braley-Mullen et al. 
1999, Burek et al. 2003, Wicker 1997), while they remain free of diabetes (Podolin et al. 
1993). In this model, addition of 0.05% NaI in the drinking water has been found to 
accelerate both the incidence and the severity of SAT (Wicker et al. 1995, Hutchings et 
al. 1999, Kolypetri et al. 2010, Braley-Mullen et al. 1999, Burek, Talor 2009, Wicker 
1997, Rasooly et al. 1996, Teng et al. 2009), providing opportunities to study the 
interplay of genetics and environment in the progression of autoimmune disease. ISAT is 
characterized by mononuclear cell infiltration of the thyroid and strong serum IgM and 
IgG responses to Tg (Braley-Mullen et al. 1999, Hutchings et al. 1999, Kolypetri et al. 
2010, Rasooly et al. 1996, Burek, Talor 2009, Teng et al. 2009). Immunohistochemical 
staining studies have suggested that the thyroid is initially infiltrated by CD4+ and CD8+ 
T cells (Verma et al. 2000, Bonita et al. 2003, Yu et al. 2001) and depletion experiments 
have shown that CD4+ cells are required for the development and maintenance of ISAT 
(Hutchings et al. 1999, Braley-Mullen et al. 1999). Weak proliferative responses of 
thyroid-draining CLNC to Tg have been observed at various time points after the 
initiation of the NaI diet regimen (Kolypetri et al. 2010) but the target epitopes 
recognized by CD4+ T cells, during the initial stages of the autoreactive cascade in ISAT, 
remain unknown. Since in NOD.H2h4 mice (Kk, Ak, E0, Db) functional MHC class II 
antigens are limited only to Ak molecules, such epitopes are expected to be recognized by 
Ak-restricted CD4+ T cells. 
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Tg is the most abundant protein in the thyroid gland and encompasses many Ak-restricted 
T cell epitopes which can elicit EAT when administered into mice with adjuvant 
(Carayanniotis 2011). In NOD.H2h4 mice developing ISAT, we have not been previously 
able to detect proliferative splenic cell responses to several Ak-restricted pathogenic T 
cell epitopes, 56 days following the initiation of iodide supplementation (Kolypetri et al. 
2010). To address the concern that thyroid antigen-specific T cells may not be detected in 
the periphery during later stages of the disease because they might have already migrated 
into the thyroid, we have in this study examined antigen-specific responses of CLNC in 
the initial stages of ISAT, and of IL during the course of disease. Our attention was 
focused on the Ak-restricted Tg peptide p2549-2560 containing T4 at position 2553 
(T4p2553) because it can induce lymphocytic (Hutchings et al. 1992) as well as 
granulomatous EAT (Braley-Mullen, Sharp 1997) and can be seen as a target by class I-
restricted cytotoxic T cells in vitro (Wan et al. 1998). Furthermore, T4p2553-specific T 
cell clones can be activated in vivo following mouse challenge with intact Tg (Hutchings 
et al. 1992). The results show that T4p2553 can be immunopathogenic in NOD.H2h4 mice 
and comprises a target epitope in ISAT recognized by spontaneously emerging CD4+ T 
cells. 
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5.3. Results 
5.3.1. T4p2553 is an immunopathogenic epitope in the NOD.H2h4 strain 
To examine the immunogenicity of T4p2553 in NOD.H2h4, 6-8 week old mice were s.c. 
challenged with 100 nmol of peptide in CFA. Nine days later inguinal, branchial and 
axillary LNC were pooled and tested for recall responses against various antigens in 
vitro. Strong proliferative LNC responses were detected in the presence of 1 µΜ (S.I. = 
9) and 10 µΜ of T4p2553 (S.I. = 15) whereas background responses were obtained 
against Tg or OVA (Figure 5.1A). When NOD.H2h4 mice were challenged with 100 µg 
of Tg in CFA for 9 days, weak (S.I. = 2-3) but significant proliferative LNC responses 
were observed against T4p2553 but the response to Tg itself or OVA remained at 
background levels (Figure 5.1B). To assess the pathogenicity of T4p2553, eight week-
old NOD.H2h4 mice (n=10) were primed with 100 nmol T4p2553 in CFA for 3 weeks 
and further boosted with 50 nmol of the same peptide in IFA for 2 weeks. Control mice 
(n=8) were similarly sensitized with 50 µg and boosted with 25 µg OVA. Histological 
examination of the thyroids showed mononuclear cell infiltration in 10/10 mice of the 
experimental group (mean I.I. = 2.1) which was significantly higher than that observed in 
only 2/8 OVA-challenged controls (mean I.I. = 0.38) (Figure 5.1C, D). The collective 
data demonstrated the immunopathogenic properties of the T4p2553 T-cell epitope in 
NOD.H2h4 mice during a time interval (8-13 weeks) in which SAT is minimally present.  
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Figure 5.1 
T4p2553 is an immunopathogenic epitope in NOD.H2h4 mice.  Recall in vitro  
proliferative assays of LNC from mice s.c. challenged for 9 days with A) 100 nmol of 
T4p2553 in CFA (n=4), or B) 100 µg of Tg (n=4), followed by a 4 day LNC culture in 
the presence of the indicated antigens. Data show mean stimulation index ± SEM of 
triplicate wells and they are representative of two experiments; C) EAT development in 
NOD.H2h4 mice after challenge with 100 nmol T4p2553 (n=10) or 50 µg OVA (n=8), as 
described in Materials and Methods. Statistical significance was calculated by the Mann-
Whitney test; D) Representative mononuclear cell infiltration of the thyroid (I.I. = 3) in 
NOD.H2h4 mice challenged with 100 nmol T4p2553 (Magnification, x100) 
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5.3.2. Accumulation of T4p2553-specific T cells in thyroid-draining CLNC and in the 
thyroid. 
Next, we proceeded to determine whether T4p2553-specific T cells could be detected 
within thyroid-draining CLNC before the ISAT onset. NOD.H2h4 mice were placed on 
NaI/H20 diet for 7, 11 and 15 days and recall in vitro assays against T4p2553 were 
performed at each time point using CLNC or splenic cells. As shown in Figure 5.2A, 
strong CLNC responses (S.I. = 8) against T4p2553, but not against Tg or OVA, were 
detected after 11 days of NaI intake whereas the CLNC response from control mice 
placed on a regular diet remained at background levels.  Day 7 or day 15 responses to any 
of the antigens tested were undetectable (data not shown). Furthermore, day 11 T4p2553-
specific responses of splenocytes were weak and not significantly different between the 
experimental and control groups (Figure 5.2B), indicating selective enrichment of 
antigen-specific T cells in the thyroid-draining LN and not in the periphery.  
The presence of activated T4p2553-specific T cells in CLNC of iodide-fed mice was 
further examined by intracellular cytokine staining 12 days after the diet initiation. CD4+ 
T cells were purified from CLNC and cultured with splenic DC as a source of APC, in 
the presence of antigen. Culture with T4p2553 activated a significantly higher number of 
IFN-γ-producing cells from CLNC of iodide-fed mice vs the controls (13.21% vs 6.22%) 
(Figure 5.2C). This difference was not evident in cultures containing the OVA peptide 
(322-340), as an antigen control (Figure 5.2C). In contrast to CLNC-derived cells, the 
percentage of splenic CD4+ IFN-γ+ cells responding to either peptide did not differ 
significantly between iodide-fed and control mice (Figure 5.2D). Lastly, 35 days after 
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the initiation of the dietary regimen, intracellular cytokine staining of thyroid-IL showed 
a small but significant difference in the percentage of CD4+ IFN-γ+ IL responding to 
T4p2553 vs OVA peptide (10.22% vs 7%) (Figure 5.2E). Overall, these data strongly 
suggested that an iodide-rich diet led to an early enrichment of activated T4p2553-
specific cells in CLNC as well as in lymphocytic infiltrates of the thyroid during ISAT 
development. 
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Figure 5.2 
T4p2553 is a natural T-cell target in ISAT. Recall assays of A) CLNC and B) splenocytes 
from NaI-fed or control NOD.H2h4 mice (n=4) against the antigens shown, 11 days after 
the initiation of the dietary regimen. Antigen concentrations were: 20 µg/ml Tg, 20 µg/ml 
OVA or 10 µg/ml T4p2553. Cell proliferation was measured by 3H-thymidine 
incorporation at 72 hours of culture. Data represent the mean ± SEM of quadruplicate 
wells from six out of 10 independent experiments in which response was detected. 
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Intracellular cytokine staining of CD4+ cells, purified from C) CLNC and D) spleen, 
previously cultured (2 x 105 /well) with splenic CD11c+ cells (4 x 104/well) in the 
presence of 20 µg/ml T4p2553 or OVA peptide for 4 days. In the last 6 hours, 5 µg/ml 
Brefeldin A was added to wells and the intracellular production of IFN-γ by was assessed 
by flow cytometry. Data are representative of three experiments. (p value= 0.0012). E) 
Percentages of IFN-γ+ CD4+ cells (mean ± SEM) within thyroid- IL after 35 days of 
enhanced NaI intake. Lymphocytes were cultured in the presence of 10 µg/ml T4p2553 
or OVA peptide and 5 µg/ml Brefeldin A for 5 hours prior to staining. Data are 
representative of two experiments. (p value= 0.03). Flow cytometric analysis was 
performed on gated lymphocytes and samples were run in duplicates. 
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5.3.3. T4p2553 is detected on DC isolated from thyroid-draining CLNC  
To test whether enhanced iodide intake would promote generation of T4p2553 on DC in 
lymphoid tissue, we generated KC1, a T4p2553-specific, IL-2-secreting T cell hybridoma 
clone, as a detection tool. The KC1 clone was selected for its sensitivity as it responded 
to as little as 12 nM T4p2553 in culture, but interestingly, remained unresponsive to 
intact Tg in the 100-200 nM range (Figure 5.3A). KC1 activation was strongly inhibited 
by an Ak-specific mAb but not by a control mAb specific for influenza NP, confirming 
presentation of T4p2553 in the context of the Ak molecule (Figure 5.3B). A low but 
significant activation of KC1 was equally detectable following its co-culture with ex vivo 
obtained DC from NaI-fed or control mice 12 days after the initiation of the dietary 
regimen (Figure 5.3C). These data suggested a constitutive presence of T4p2553 on DC 
in thyroid-draining CLNC. 
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Figure 5.3 
 T4p2553 is constitutively present on DC from CLNC.  A) T4p2553-specific reactivity of 
the KC1 hybridoma clone cultured (105/well) with the antigens shown and TA3 cells 
(105/well) as APC. Activation was measured by IL-2 secretion and the use of the IL-2 
dependent line CTLL; B) Inhibition of KC1 activation by blocking mAbs specific for Ak 
or influenza A NP (at 10 µg/ml) in the presence of 25 nM of T4p2553 and TA3 cells as 
APC. Data show the mean ± SEM of triplicate wells and are representative of two 
experiments; C) Detection of T4p2553 on CD11c+ cells purified from CLNC of iodide-
fed or control mice, 12 days after the initiation of the iodide-rich diet. Ex vivo obtained 
CD11c+ cells (1 x 104/well) were cultured with KC1 (5 x 104/well) for 24 hours and 
activation was assessed by a CTLL proliferation assay. Addition of exogenous T4p2553 
yielded ~ 45,000 cpm. Data represent the mean ± SEM from 4-6 wells/group and are 
representative of four experiments. P values (* < 0.001, ** = 0.0003). 
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5.3.4. In ISAT, T4p2553-specific B cells do not contribute significantly to the Tg 
autoantibody repertoire 
Following challenge with T4p2553, 6-8 week old NOD.H2h4 mice mounted strong 
peptide-specific as well as Tg-specific serum IgG responses, as assayed by ELISA 
(Figure 5.4A) suggesting localization of the T4p2553 epitope on the surface of the Tg 
molecule. The response was not due to spontaneous production of anti-Tg IgG since anti-
Tg or anti-T4p2553 IgG responses were not detected in OVA-challenged age-matched 
mice (data not shown). In contrast, in mice developing ISAT, T4p2553-specific 
serological IgG responses were not detected after 30, 40, or 60 days on the NaI/water diet 
despite the presence of anti-Tg IgG Abs at those time intervals (Figure 5.4B, C, D). 
These results indicated that, in NOD.H2h4 mice developing ISAT, T4p2553-specific IgG 
does not comprise a detectable portion of the Tg autoantibody repertoire.  
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Figure 5.4 
Screening for IgG responses against T4p2553 in EAT and ISAT by ELISA. Pooled sera 
from T4p2553-primed NOD.H2h4 mice (n=10) (A), or NOD.H2h4 mice on an iodide-rich 
diet for B) 30, C) 40 and D) 60 days, (n=6 per group) were tested for the presence of Tg-
specific or T4p2553-specific IgG. Results are expressed as mean O.D. values of triplicate 
wells ± SEM after subtraction of background values from wells with no serum added. 
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5.4. Discussion 
Our findings show that direct challenge of NOD.H2h4 mice with the Tg peptide T4p2553 
generates EAT with 100% incidence and significant severity (mean I.I. = 2.1). Previous 
studies described either weak EAT induction after direct challenge with T4p2553 (Kong 
et al. 1995) or disease induction only after adoptive transfer of T4p2553-specific T cells 
(Hutchings et al. 1992, Braley-Mullen, Sharp 1997, Kong et al. 1995), perhaps reflecting 
differences in the protocols and the mouse strain (CBA/J vs NOD.H2h4) used. In vivo 
priming with intact Tg or Tg peptide allowed for detection of subsequent T4p2553-
specific, proliferative LNC responses in vitro, confirming earlier findings by other groups 
(Hutchings et al. 1992, Braley-Mullen, Sharp 1997, Kong et al. 1995). In that regard, it is 
surprising that deliberate challenge of NOD.Hh4 mice with intact Tg in CFA does not 
yield detectable recall responses to Tg itself. This has also been observed with 52-week 
old NOD.H2h4 mice, i.e. at a time that SAT is fully developed (unpublished 
observations), while weak splenic Tg-specific T cell responses are obtained in ISAT (day 
28 and 42 of the dietary regimen) at a time when a strong spontaneous Tg-specific IgG 
response is clearly evident (Kolypetri et al. 2010). These results are reminiscent of 
observations in diabetes where insulin-specific T cell responses are difficult to detect in 
NOD mice, either spontaneously or after immunization (Kaufman et al. 2001, Mohan et 
al. 2010, Hurtenbach, Maurer 1989) despite the presence of anti-insulin autoantibodies 
(Yu et al. 2000). Unresponsiveness to the intact autoantigen in this system has been 
attributed to possible generation of suppressor cells mediating dominant tolerance 
(Jaeckel et al. 2004). It is noteworthy that T4p2553-specific T cells are unlikely to 
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undergo negative selection pressure in the thymus because thymic cells do not synthesize 
T4, although they express truncated mRNA isoforms of Tg that encode this peptide 
sequence (Li, Carayanniotis 2005). The T4 moiety with the four bulky iodine atoms 
forms an integral part of the Ak-T4p2553 complex because anti-T4 Abs are known to 
block T-cell recognition of this peptide (Dai et al. 2005). 
 
In this study, we report for the first time that a defined Tg epitope is a natural target of the 
spontaneous T-cell response in ISAT. Our previous inability to detect spontaneous 
splenic T cell responses to known pathogenic Tg peptides in later stages of ISAT 
(Kolypetri et al. 2010) prompted us to search for autoreactive T cells in thyroid-draining 
LN in early stages of the disease, i.e. before day 15 of the NaI/water dietary regimen, 
when the first signs of ISAT appear in our colony. We observed selective enrichment of 
T4p2553-specific, proliferative or CD4+ IFN-γ+ T cells in CLNC - but not in the spleen – 
only in mice receiving NaI for 11-12 days. Proliferative CLNC responses were 
undetectable at earlier time points (day 7) probably due to the low frequency of the 
peptide-specific T cells, and later time points (day 15) perhaps due to their exiting from 
CLNC and homing to the thyroid. Early detection of activated autoreactive T cells in 
CLNC, i.e. the thyroid-draining LN, is analogous to that seen in diabetes where CD4+ and 
CD8+ T cell priming in pancreatic LN occurs before the onset of insulitis in NOD mice 
(Hoglund et al. 1999, Zhang et al. 2002, Gagnerault et al. 2002). The presence of 
T4p2553-specific T cells within thyroidal infiltrates, also suggests recognition of this 
peptide ligand on thyrocytes – which are known to upregulate MHC class II expression 
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after IFN-γ treatment (Champion et al. 1991) or peptide recognition on intrathyroidal 
resident DC (Voorby et al. 1990). 
 
The detection of T4p2553 on DC obtained ex vivo from CLNC of either iodide-fed or 
control mice suggests their constitutive presence on APC that is independent of iodide 
intake. We have previously hypothesized that T4p2553 and several other defined Tg 
peptides with pathogenic potential comprise part of a “cryptic self” that must be 
intrathyroidally expressed on resident DC under steady-state conditions since they are 
recognized in naïve animals by pre-activated specific effector T cells that home to the 
thyroid and initiate tissue damage (Carayanniotis 2003). Detection of T4p2553 on DC 
from CLNC suggests that either intrathyroidal DC carrying this peptide migrate to CLNC 
or the peptide is transferred to CLNC through the lymphatic drainage. This process may 
contribute to peripheral tolerance mechanisms that inactivate autoreactive T cells through 
anergy or active suppression (Carayanniotis 2003). Analogous findings have been 
reported in diabetes by Unanue’s group in which CD11c+ cells from pancreas or 
pancreatic LN were shown to constitutively present hen-egg lysozyme (HEL) peptides in 
mice expressing the HEL gene under the insulin promoter (Calderon et al. 2008). 
Constitutive expression of tissue-specific antigens such as the H+/K+-ATPase protein 
(Scheinecker et al. 2002) or foreign antigens such as the simian virus 40 T antigen 
(Forster, Lieberam 1996), the influenza virus hemagglutinin (Morgan et al. 1999), or 
OVA (Kurts et al. 1997) by DC in draining LN has been proposed to promote peripheral 
tolerance (Steinman et al. 2000).  
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Our findings indicate that high iodide intake does not promote T-cell autoreactivity to 
T4p2553 through enhanced generation of this peptide on DC. Analogous data have been 
reported with a HEL peptide-specific T cell hybridoma that was equally activated by DC 
from normal or streptozotoxin-treated IP-HEL mice (Calderon et al. 2008, Calderon, 
Unanue 2012). Furthermore, in the NOD system it has been previously shown that beta 
cell death, either induced by streptozotoxin or transferred by injections of dead cells in 
the pancreas,  promotes the activation of the transgenic BDC2.5 CD4+ and 8.3 CD8+ T 
cells in pancreatic LN (Turley et al. 2003, Zhang et al. 2002). Since NOD.H2h4 
thyrocytes are highly sensitive to iodide-mediated apoptosis (Kolypetri et al. submitted 
for publication), it can be argued that apoptosis could trigger autoreactivity by inducing 
tolerogenic DC to adopt an immunogenic phenotype as has been shown in other systems 
(Rovere et al. 1998). 
 
At the B cell level, T4p2553 priming induced strong peptide-specific IgG responses in 
NOD.H2h4 mice, as previously seen in the CBA/J strain (Kong et al. 1995). Other groups 
have reported low or undetectable immunogenicity of T4p2553 in CBA hosts (Hutchings 
et al. 1992, Braley-Mullen, Sharp 1997) perhaps reflecting dose and route of 
administration differences in peptide delivery. The strong anti-Tg responses observed in 
T4p2553-primed NOD.H2h4 mice were not detected in age-matched mice challenged 
with OVA, indicating that they are not spontaneously generated but rather reflect access 
of the T4p2553 site on the surface of the Tg molecule by peptide-specific IgG. In view of 
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this, the lack of spontaneous IgG response to T4p2553 in ISAT was surprising, 
demonstrating that existing T4p2553-specifc B cell clones do not contribute to the Tg 
autoantibody repertoire that characterizes ISAT. This suggests that Tg-specific IgG 
response is driven against other immunodominant B cell epitopes or by Tg fragments that 
lack the T4p2553 sequence. Nevertheless, T4p2553-specific B cells could bind to and 
internalize intact Tg, playing an APC role, as previously suggested in the NOD.H2h4 
model (Braley-Mullen, Yu 2000). 
 
In conclusion, this study identifies for the first time a Tg T-cell epitope as a spontaneous 
target in ISAT. It also highlights the fact that iodine, as a dietary element that accelerates 
an autoimmune process, becomes itself an integral part of a target self-epitope recognized 
by pathogenic T cells. Our ability to activate and monitor autoreactive T cells of a 
defined specificity provides a new read-out system to study effects of immune 
intervention in this animal model. It also generates new opportunities for the construction 
of TCR-transgenic mice in this model which will be useful in studies of 
immunoregulation. 
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6.1. Abstract 
Recent studies have shown that high salt intake exacerbates EAE and have raised the 
possibility that a HSD may comprise a risk factor for autoimmune diseases in general. In 
this report, we have examined whether a HSD regimen could exacerbate murine 
autoimmune thyroiditis, including SAT in NOD.H2h4 mice, EAT in C57BL/6J mice 
challenged with Tg and EAT in CBA/J mice challenged with the Tg peptide (2549-2560).  
The physiological impact of high salt intake was confirmed by enhanced water 
consumption and suppressed aldosterone levels in all strains. However, the high salt 
treatment failed to significantly affect the incidence and severity of SAT or EAT or Tg-
specific IgG levels, relative to control mice maintained on a normal salt diet. These data 
demonstrate that high salt intake does not exacerbate autoimmune thyroiditis in three 
experimental models indicating that a HSD is not a risk factor for all autoimmune 
diseases. 
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6.2. Introduction 
 
Recently, two independent studies have reported that a HSD can exacerbate the severity 
of EAE in mice, as compared to the level of severity developed in mice fed a normal diet 
(Wu et al. 2013, Kleinewietfeld et al. 2013). These findings were fascinating as well as 
intriguing in view of the fact that data generated by the World Health Organization 
(WHO) do not support a direct correlation between salt intake and prevalence of multiple 
sclerosis in humans (Croxford et al. 2013, Elliott, Brown). Nevertheless, the reported 
dramatic exacerbation of EAE in mice on HSD, has highlighted the possibility that 
increased salt intake may aggravate clinical symptoms in individuals genetically 
predisposed to MS and most importantly, has raised the question whether HSD might 
represent a risk factor for the development of other autoimmune diseases.  
 
In this report, we have examined potential HSD effects on the development of 
autoimmune thyroiditis in mice. The experimental design was made to monitor incidence 
and severity of disease in three mouse models that have been used extensively to study 
pathogenetic mechanisms analogous to those operating in HT in humans. In the first 
group, we used NOD.H2h4 mice which are known to develop SAT with age (Kolypetri et 
al. 2010, Braley-Mullen et al. 1999, Burek et al. 2003). In the second and third groups, 
we asked whether mild forms of EAT, induced after challenge with thyroid antigen in 
adjuvant, could be exacerbated by concomitant high salt intake. To this purpose, we 
challenged C57BL/6 mice with Tg and CBA/J mice, with the known pathogenic Tg 
peptide (2549 – 2560) containing T4 at amino acid position 2553 ((T4)2553) (Champion 
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et al. 1991, Hutchings et al. 1992). We also monitored Tg-specific serum IgG responses 
as an index of autoreactivity in all strains.  
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6.3. Results and Discussion 
 
Following placement of NOD.H2h4, C57BL/6 and CBA/J mice on HSD (n=10, per strain) 
or control diet (n=10 per strain), water intake was monitored weekly over the 5-week 
observation period, as an index of response to the dietary regimen (Veress et al. 1995). 
Mice on HSD showed a highly significant increase of water intake with average (mean ± 
S.E.) daily consumption rates 15.5 ± 0.71, 9.1 ± 0.3 and 7.3 ± 0.2 g/mouse for 
NOD.H2h4, C57BL/6 and CBA/J strains, respectively, while control values ranged 
between 3.2 – 4.3 g/day (Figure 6.1a). At the end of the study period, the effectiveness 
of the HSD was further assessed by measurement of serum aldosterone levels to check 
for the high salt-induced suppression reported by others (Kim et al. 2008, Makhanova et 
al. 2008). A profound suppression of serum aldosterone was observed in the experimental 
vs. the control groups in all strains: 13 vs. 381 pg/ml in NOD.H2h4, 13 vs. 254 pg/ml in 
C57BL/6, and 21 vs. 386 pg/ml in CBA/J mice (Figure 6.1b).  
NOD.H2h4 mice, developed by Dr. L. Wicker and colleagues for studies on diabetes 
(Podolin et al. 1993), were chosen as a first animal model for our study because it is the 
only mouse strain known to develop SAT at an increasing incidence and severity with 
age. In our colony, the first signs of spontaneous thyroiditis appear in 12-14 week-old 
male or female mice (Kolypetri et al. 2010) and at 55 weeks of age, practically all mice 
exhibit SAT of advanced severity and seropositivity for Tg-specific IgG  (unpublished 
observations). While thyroiditis incidence and severity may differ among various 
colonies, analogous age-dependent effects on SAT have been reported by others (Braley-
Mullen et al. 1999, Burek et al. 2003). In this report, our aim was to test whether HSD, 
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initiated at the early stages of SAT, would influence the development of disease. As 
shown in Table 6.1, placement of 12 week-old NOD.H2h4 mice on HSD for five weeks 
did not significantly raise the incidence (6/10 vs. 9/10) or severity (I.I.= 1.3 vs. 1.6) of 
SAT vs. those of the controls. In addition, there was no significant increase in the number 
of mice spontaneously developing IgG antibodies to Tg (Figure 6.1c). 
 
In a second series of experiments, we followed the experimental design of Wu et al (Wu 
et al. 2013) and Kleinewietfeld et al (Kleinewietfeld et al. 2013) by placing C57BL/6 
mice on the same high salt regimen (4% NaCl in chow, 1% NaCl in drinking water) that 
exacerbates EAE in this strain and a similar period of observation (5 weeks). An added 
attractive feature was that, in the field of EAT, this strain is well known to develop 
relatively low levels of thyroiditis after challenge with Tg in adjuvant (Vladutiu, Rose 
1971), thus favoring investigation into possible enhancing effects of high salt intake on 
pathology in this model. The results showed that a dietary regimen of high salt, continued 
throughout the period of antigenic challenge, did not increase the EAT incidence (9/10 
vs. 6/10) or mean severity (I.I. = 1.2 vs. 0.9) vs. that of the controls (Table 6.1). 
Moreover, strong, but not significantly different Tg-specific IgG responses were detected 
in both the high salt and control groups (Figure 6.1c).   
In a third experimental model, we challenged the EAT-susceptible strain CBA/J 
(Vladutiu, Rose 1971) with the 12-mer T-cell epitope (T4)2553 of Tg (Champion et al. 
1991, Hutchings et al. 1992) at doses that are mildly pathogenic. Mice in the 
experimental group were placed on HSD during the 5 week induction phase of EAT. The 
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high salt regimen had again no significant effect either on the incidence (6/10 vs. 4/10) or 
mean severity (I.I. = 0.9 vs. 0.5) of disease (Table 6.1). The (T4)2553 peptide elicited a 
Tg-specific IgG response of similar relative strength in both groups, which was, as 
expected, lower than that obtained in C57BL/6 mice immunized with intact Tg (Figure 
6.1c).  
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                                                             Figure 6.1 
Effects of HSD vs. control diet (CD) on physiological and immunological parameters in 
mice developing autoimmune thyroiditis.  (a) Water intake (g/day) in mice placed on 
HSD or CD for 5 weeks expressed as mean ± SE of values (n=10 per group). Asterisks 
denote statistical significance assessed by a t-test (p values for all groups <10-7). (b) 
Serum aldosterone levels measured by RIA at the end of 5-week observation period. Five 
samples were run for each experimental and control group, with each sample being 
pooled from two randomly selected mice within a group. The data represent the mean ± 
SE values in each group and asterisks denote statistical significance assessed by a t-test 
(p<0.036 for NOD.H2h4; p<10-4 for C57BL/6 and CBA/J). (c) ELISA-based Tg-specific 
IgG responses from individual mouse sera, observed spontaneously (NOD.H2h4 mice) or 
after antigenic challenge as described in Materials and Methods (C57BL/6 and CBA/J 
mice). Serum dilutions for the assay were 1:25 for NOD.H2h4, 1:50 for C57BL/6 and 
1:100 for CBA/J mice. Data represent the mean ± S.D. optical density values of triplicate 
wells. 
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Table 6.1. Thyroiditis incidence and severity in NOD.H2h4, C57BL/6 and CBA/J mice 
 
 
 
 
 
 
 
 
 
Strain NaCl a Immunizing 
antigen 
Thyroiditis 
p value b 
Incidence 
Severity (score) 
Mean 
0 1 2 3 4 
c
 NOD.H2h4 + - 6/10 4 1 4  1 1.3 
0.63 
 - - 9/10 1 5 2 1 1 1.6 
d
 C57BL6/J + Tg 9/10 1 7 1 1  1.2 
0.39 
 - Tg 6/10 4 4 1 1  0.9 
e CBA/J + T4p2553 6/10 4 3 3   0.9 0.35 
 - T4p2553 4/10 6 3 1   0.5 
a) Mice received normal chow and water ad libitum or chow containing 4% NaCl and water containing 1% 
NaCl ad libitum, over a 5 week period, as described in section 2.1 
b) Statistical significance was assessed by the non-parametric Mann-Whitney test. 
c) Each group consisted of 5 female and five male 12-wk old thyroiditis-prone NOD.H2h4 mice. 
d) Female C57BL/6J mice (n= 10 per group) were s.c. challenged with 100 µg Tg in CFA and the 
experimental group was simultaneously placed on HSD. Three weeks later, all mice received 50 µg Tg in 
IFA. EAT was determined 5 weeks after the initial antigenic challenge. 
e) Female CBA/J mice (n = 10 per group) were s.c. challenged s.c. with 100 nmol of T4p2553 peptide in 
CFA and the experimental group was simultaneously placed on HSD. Three weeks later, all mice received 
50 nmol of the same peptide in IFA. EAT was determined 5 weeks after the initial antigenic challenge. 
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The focus of the current work was to examine the thesis that there is a tangible link 
between HSD and autoimmune disease other than EAE, using mouse models of 
autoimmune thyroiditis. The data provided demonstrate strongly that dietary salt does not 
promote either antigen-induced or spontaneous thyroid autoimmune disease. The report 
that C57BL/6 mice on high salt intake develop enhanced EAE after challenge with an 
encephalitogenic MOG peptide in CFA (Wu et al. 2013, Kleinewietfeld et al. 2013) is in 
apparent contrast with our finding that delivery of a thyroiditogenic molecule (Tg) to the 
same strain via the same route and under the same high salt conditions does not lead to 
enhanced EAT. To the extent that the studies of Wu et al. (Wu et al. 2013), and 
Kleinewietfeld et al. (Kleinewietfeld et al. 2013) have assigned a pivotal role to 
pathogenic Th17 cells for the exacerbation of EAE, our data suggest that either a) Th17 
cells are not as critical in EAT/SAT development as in EAE, or b) additional pleiotropic 
physiological, hormonal and metabolic factors, triggered by HSD, mediate EAE 
exacerbation in a unique manner that is not necessarily duplicated in EAT/SAT. 
 
EAT and SAT are well known to be mediated by Th1 cells (Yu et al. 2002) – but a role 
for Th17 cells in pathogenesis remains possible. Interleukin 17 (IL-17)-/- NOD.H2h4 mice 
have been reported to exhibit reduced iodide-accelerated SAT and diminished Tg-specific 
titers as compared to WT controls, while intrathyroidal cytokine mRNA analysis has 
suggested the presence of both Th1 and Th17 cells in thyroidal lymphocyte infiltrates of 
WT NOD.H2h4 mice (Horie et al. 2009). In humans, an increased frequency of Th17 cells 
has been reported in the peripheral blood of patients with HT (Figueroa-Vega et al. 2010, 
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Qin et al. 2012, Shi et al. 2010) or autoimmune thyroid disease (AITD) (HT and Graves’ 
disease) (Nanba et al. 2009, Hayashi et al. 2009) and it has been recently suggested that T 
cell derived-leptin may contribute to the increased frequency of Th17 cells in HT (Wang 
et al. 2013). Associations of single nucleotide polymorphisms in AITD have been 
described for the IL-23R gene in Japanese (Ban et al. 2009) and for the IL-17A and IL-
17F genes in Chinese populations (Yan et al. 2012). However, since IL-17 is produced by 
several cell types including CD8+ cells and γδ T cells (Hirota et al. 2011, Ivanov et al. 
2006, O'Shea, Jones 2013), association data from both mouse and human studies may not 
necessarily reflect a cause-and-effect relationship between Th17 cells and thyroid 
pathology. Lastly, it is noteworthy that even in the pivotal EAE studies (Wu et al. 2013, 
Kleinewietfeld et al. 2013), exacerbating effects of HSD on disease were demonstrable in 
WT mice during the first twenty days of the dietary regimen. When monitoring continued 
until day 25 in one of the studies, no significant differences between HSD and control 
groups were found (Wu et al. 2013). In the work presented here, while no significant 
effects on HSD on EAT were observed using a well-established 5 wk disease induction 
protocol, we cannot exclude the possibility that high salt intake might have had transient, 
non-sustained effects on EAT that were not apparent after 5 weeks. Also, we cannot 
exclude the possibility that the effects of high salt intake on thyroiditis could reach 
statistical significance if a larger sample size is analyzed. 
 
Regardless of the mechanism involved, our data clearly demonstrate that excess salt in 
diet should not be expected to be an environmental risk factor that broadly influences 
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induction of autoimmune disease. Enhanced salt intake is accompanied by fluid, ionic 
and hormonal changes including suppression of the renin-angiotensin system (de la Sierra 
et al. 1996, van der Meer, Netea 2013) which could differentially influence autoimmune 
responses depending on the anatomical site and metabolic status of the target organ. The 
planning of clinical trials to investigate low-salt diets for treating or preventing 
autoimmune disease should proceed with caution, taking into account relevant data from 
diverse animal model studies. 
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SUMMARY AND FUTURE DIRECTIONS 
 
 
The thesis describes studies on the immunoregulation of autoimmune thyroiditis using 
murine models of EAT, SAT and ISAT. In this section, a brief summary of, and future 
directions related to each chapter are outlined.  
 
Chapter 3 
We examined whether immunopathogenic and/or immunodominant Tg epitopes could be 
located adjacent to proteolytic sites using the EAT model. We predicted possible 
cathepsin B, D and L cleavage sites in mTg and we identified H2-Ak binding motifs 
adjacent to the proteolytic sites. Peptides encompassing these motifs were synthesized 
and two of them, p2369 (a.a. 2369-2380) and p2439 (a.a. 2439-2450) located close to 
cathepsin L cleavage sites, were found to be immunopathogenic but not 
immunodominant in CBA/J mice. This finding raised the number of pathogenic, cryptic 
peptides to 27.  
 
Hypothesis #1: Tg epitopes, previously defined as “cryptic”, become dominant after 
processing of Tg fragments by DC. 
The reasons behind the inability to identify a dominant Tg epitope are unknown. A 
plausible hypothesis is that Tg epitopes, previously identified as cryptic, may become 
immunodominant after processing of Tg fragments rather than intact Tg. To test this 
premise, intact Tg will be partially digested with cathepsins B and L and the reaction will 
140 
 
be irreversibly blocked by a cysteine protease inhibitor. Tg fragmentation will be 
confirmed by SDS-PAGE. The protein solution will be then subjected to reverse phase 
HPLC and the fractions will be pooled and concentrated. BM-derived DC from CBA/J 
mice will be incubated with titrating amounts of the Tg fragment concentrate or intact Tg 
(as negative control) or a known free cryptic Tg peptide such as T4p2553 (as positive 
control). Peptide-primed T cells or peptide-specific T cell hybridomas will be added to 
the wells and their activation will be used as a readout system. As additional control, 
chloroquine-treated DC will be used to exclude the possibility that the peptide binds 
exogenously to the MHC molecules. If our hypothesis is correct, we expect to detect T 
activation in the presence of the Tg fragment concentrate but not in the presence of intact 
Tg.  
Pitfalls: Inability to detect a T cell response could be attributed to: a) wrong choice of 
epitope to test the concept. In this case, the experiment can be repeated with other kwown 
pathogenic Tg peptides; b) epitopes generated after processing of Tg fragments may be 
expressed at levels below the required T cell activation threshold. 
 
Hypothesis #2: Tg epitopes, previously defined as “cryptic”, are constitutively generated 
and expressed on DC within the thyroid gland. 
Previous studies have shown that Tg peptide-activated T cells selectively home to the 
thyroid after direct challenge of mice with peptide in CFA or after adoptive transfers to 
naïve recipients. These observations made us hypothesize that cryptic Tg peptides are 
constitutively generated and expressed on intrathyroidal DC. To address this concept, 
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intrathyroidal DC will be sorted from SJL fresh thyrocyte suspensions via anti-CD11c Ab 
staining. Then, DC will be cultured with Tg peptide-primed T cells or Tg peptide-specific 
T cell hybridomas without the addition of exogenous peptide for 72 hours. The peptide 
used in this design will be a randomly chosen Tg cryptic epitope in the first experiment 
but the presence of 4 more cryptic epitopes will be examined using the similar design. As 
additional control, in some wells exogenous peptide will be added. T cell proliferation 
will be assessed by thymidine uptake and the production of IL-2 and IFN-γ in the 
supernatant will be examined by sandwich ELISA. T cell hybridoma activation will be 
assessed by the proliferation of CTLL cells. If we detect significant T cell proliferation or 
activation in the absence of exogenous peptide that would indicate that this cryptic 
peptide was generated and expressed on the surface of DC.  
Pitfalls: a) A large number of animals, as thyroid donors, will be required because the 
intrathyroidal DC yield is low; b) T-cell activation may not be observed if Tg peptides 
are endogenously generated on DC at levels insufficient to trigger a T cell response in 
vitro. 
 
Chapter 4 
We showed that iodide-treated NOD.H2h4 thyrocytes undergo apoptosis at significantly 
higher levels than CBA/J thyrocytes and that was associated with an impaired control of 
oxidative stress mechanisms. Since the majority of the molecular events involved in 
iodide-mediated apoptosis remain unknown, the following experiments could be 
performed. 
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Hypothesis #1: The mitochondrial pathway is involved in the early stages of iodide-
induced apoptosis of NOD.H2h4 thyrocytes. 
Previous studies have reported that mitochondria are involved in the early events of 
apoptosis triggered by high iodide doses in FRTL-5 cells (Yao et al. 2012). To examine 
whether this organelle participates in the initial events in iodide-induced apoptosis of 
NOD.H2h4 thyrocytes, we will perform a kinetic analysis of the production of superoxide 
as well as the release of apoptogenic factors from mitochondria. Thyrocytes from 
NOD.H2h4 and CBA/J mice will be cultured for 9 days in vitro. On day 9, 4 x 10-6 M NaI 
or medium will be added to the wells and 2, 4, 6 and 8 hours later, the cells will be 
stained with MitoSOX Red, a mitochondrial superoxide indicator and they will be 
analyzed by flow cytometry. As additional control, cells will be stained only with 
propidium iodide to verify the integrity of the membrane. If our hypothesis is correct, we 
expect to detect an increased production of mitochondrial superoxide after 2-8 hours in 
iodide-treated NOD.H2h4 thyrocytes compared to all control groups. Furthermore, we 
will examine the release of the proteins cytochrome c and apoptosis-inducing factor in 
the cytoplasm. Cells will be treated with or without 4 x 10-6 M NaI for 2, 4, 6 and 8 
hours. Then, thyrocytes will be lysed and centrifuged to separate the cytosolic and 
mitochondrial fractions. The concentration of cytochrome c in the cytosolic and 
mitochondrial fractions will be estimated by an ELISA kit while the presence of 
apoptosis-inducing factor will be examined by Western blot analysis. If our hypothesis is 
correct, we expect increased concentrations of one or both proteins to be detected in the 
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cytoplasm during the first 2-8 hours after iodide treatment. The data will indicate the 
involvement of mitochondria during early stages of iodide-mediated apoptosis but they 
will not answer whether the mitochondrial changes are the cause or the effect of the 
apoptotic cascade in iodide-treated thyrocytes. 
 
Hypothesis #2: NOD.H2h4 thyrocytes are highly susceptible to iodide-mediated apoptosis 
due to defective expression and/or function of the transcription factor Nrf-2. 
The nuclear factor erythroid 2 (Nrf-2) is a basic region-leucine zipper-type protein that 
acts as the master regulator of genes involved in anti-oxidant defense mechanisms (Uruno 
et al. 2013). Under normal conditions, Nrf-2 tightly interacts with the adaptor protein 
Keap-1 in the cytoplasm, facilitating ubiquitination and degradation of Nrf-2 by 
proteasomes (Ma 2013). Under stress conditions, electrophiles or ROS can interact and 
modify the cysteine residues of Keap1, leading to conformational changes in the Keap1- 
Nrf-2 complex. These changes allow Nrf-2 to escape cytosolic degradation and 
translocate to the nucleus where it induces the expression of itself as well as of several 
genes with anti-oxidant function or ROS metabolism (Ma 2013). The Nrf-2 anti-oxidant 
signaling pathway has been shown to have a critical role in the survival of mammary 
epithelial cells (Gorrini et al. 2013) and protect pancreatic β-cells from ROS-mediated 
damage (Yagishita et al. 2014). 
 
 In Figure 4.4, the expression of 10 Nrf-2 regulated genes (Sod1, Gpx2, 7, 4, Prx1, 2, 5, 
Park7, Fth1 and Nqo1) (Ma 2013) was significantly upregulated in CBA/J thyrocytes 
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whereas only 2 Nrf-2 regulated genes (Gpx2, Nqo1) had higher expression in NOD.H2h4 
thyrocytes after iodide treatment. To examine whether there is a defect in the expression 
levels of Nrf-2 in NOD.H2h4 mice, NOD.H2h4 and CBA/J primary thyrocytes will be 
cultured for 9 days. On day 9, cells will be treated with 4 x 10-6 M NaI or medium for 24 
hours. Then, mRNA will be isolated from all groups and the expression levels of the Nrf-
2 will be analyzed by qPCR. If there is a defect at the expression level, then we expect to 
detect significantly higher levels of Nrf-2 mRNA expression in the CBA/J vs the 
NOD.H2h4 thyrocytes after iodide treatment. Our findings will also be examined at the 
protein level by Western blot analysis.  
 
To examine whether there is a defect in the regulation of the Nrf-2 protein, its interaction 
with the protein Keap-1 will be examined under normal and stress conditions by 
immunofluorescence staining. Thyrocytes from both strains will be cultured with or 
without 4 x 10-6 M NaI for 24 hours and then cells will be fixed, stained with a FITC-
conjugated anti-Nrf-2, PE-conjugated anti-Keap1 mAb and DAPI and they will be 
analysed by immunofluorescence microscopy. If the regulation of the Nrf-2 protein in the 
iodide-treated NOD.H2h4 group is defective then we expect to detect the two proteins co-
localized in the cytoplasm whereas in the iodide-treated CBA/J group the Keap1 protein 
will be in the cytoplasm and the Nrf-2 will have been translocated to the nucleus. The 
pitfall in this approach is that Nrf-2 may translocate to the nucleus in iodide-treated 
NOD.H2h4 thyrocytes but still have an impaired capacity to regulate the transcription of 
genes due to strain-specific polymorphisms in the Nrf-2 protein. 
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Hypothesis #3: Ex vivo detection of iodide-induced apoptosis of NOD.H2h4 thyrocytes.  
Previous studies in the NOD mouse have highlighted that spontaneous apoptosis in 
pancreatic sections has been difficult to detect due to the rapid clearance of apoptotic 
cells as well as their low frequency even at peak times (4-13%) (Mathis et al. 2001). To 
examine if in our model, administration of iodide-rich diet could cause a significant 
increase in the number of apoptotic thyrocytes within the gland to allow their detection, 
we will perform the following experiment. Six to eight week old NOD.H2h4 and CBA/J 
mice will be placed on normal or 0.05% NaI containing water for 2-10 days and a kinetic 
analysis of apoptosis on a daily basis will be performed using the NIR-FLIVOTM 690. 
FLIVOTM is a cell-permeable tracer that circulates throughout the body and binds 
irreversibly to activated caspases. Apoptotic cells can be visualized using live animals in 
a whole animal imager or thyroid glands can be isolated and cell suspensions analyzed by 
fluorescence microscopy or flow cytometry to quantify the number of apoptotic cells. If 
our hypothesis is correct, we expect to detect a significant number of apoptotic thyrocytes 
in glands from iodide-treated NOD.H2h4 mice compared to all control groups. 
Pitfalls:  The difference in the number of apoptotic cells between the iodide-fed and 
control group may be small and not reach statistical significance. 
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Chapter 5 
 We have reported that the Tg peptide T4p2553 is a natural T cell target recognized at 
early stages - before ISAT onset - in NOD.H2h4 mice. This observation as well as the 
generation of the T4p2553-specific T-cell hybridoma clone KC1 are quite advantageous 
for further studies in the NOD.H2h4 model. Cloning of the VJ and VDJ sequences of the 
TCR of the KC1 hybridoma clone will allow us to construct the KC1 TCR transgenic 
mouse in the NOD.H2h4 background. The existence of such a transgenic mouse will help 
us overcome the problem of the low frequency of ag-specific T cells and facilitate the 
design of our experiments as in the NOD system with the BDC2.5 and 8.3 TCR 
transgenic mice. 
 
Our data have also shown that even though T4p2553 was detected on the surface of CLN 
DC regardless of iodide ingestion, spontaneous T cell activation against the peptide was 
recorded only in CLNC of mice receiving iodide-rich diet. This observation made us 
speculate that a high rate of iodide-induced apoptosis of thyrocytes (as described in 
Chapter 4) inside the gland may have altered the tolerogenic function of DC to 
immunogenic leading to T cell activation in the draining lymph nodes. To shed more 
light on the events triggered by iodide that lead to T cell activation in CLN, we will test 
the following hypotheses: 
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Hypothesis #1: Iodide-mediated apoptosis of thyrocytes abrogates the tolerogenic 
phenotype of tissue-draining migratory DC. 
The tissue-draining LN contain two groups of DC. The LN-resident DC - plasmacytoid, 
CD8+, CD8- DC- as well as the tissue draining migratory DC - CD103+ and CD11b+ DC 
that have migrated to the nodes from the drained tissue (Miller et al. 2012). Recent 
studies have shown that the tissue-draining, migratory DC, have a crucial role in 
peripheral tolerance induction through the activation of Treg cells (Yamazaki et al. 2008, 
Idoyaga et al. 2013). Interestingly, the molecular signature of this DC subset - which is 
not shared with LN-resident DC - has been identified by the Immunological Genome 
Consortium (Miller et al. 2012). Under steady state, migratory DC express immune 
response-dampening molecules like Itgb8 (encoding TGF-β-activating integrin β8) and 
Socs2 (encoding a TLR-responsive molecule that regulates the release of cytokines from 
DCs) whereas under inflammatory conditions they express Cxcl10, Ccl3, Cxcl9, Il6, Il1b, 
and Il1a (Miller et al. 2012). 
 
To test hypothesis #1, we will follow an in vitro and an in vivo approach. In the in vitro 
experiment, NOD.H2h4 thyrocytes will be cultured with titrating concentrations of NaI 
for 24 hours. During this incubation period, cells will become apoptotic as shown in 
Chapter 4. Then, thyrocytes will be washed and cultured for 1, 2 and 3 days with 
syngeneic migratory DCs (or resident DC as controls) purified from pooled LN (cervical, 
brachial, axillary, inguinal) as described by (Miller et al. 2012). Additional control 
groups will include migratory or resident DC cultured either with medium alone (steady 
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state DC) or with poly (I:C) (activated DC). Subsequently, CD11c+ cells will be 
recovered and their cDNA will be analyzed by real-time RT-PCR using appropriate 
primers for the above-mentioned genes. If our hypothesis is correct, we expect that 
migratory DC incubated with apoptotic thyrocytes will reduce expression of Itgb8 and 
Socs2 while they will increase expression of genes encoding the inflammatory molecules 
described above. 
 
 In the in vivo approach, six to eight week old NOD.H2h4 mice will be placed on NaI 
containing water or normal water for 7-9 days i.e. at a time point before the onset of 
ISAT. Migratory DC and control resident DC from CLNC will be isolated and mRNA 
will be used for Real-Time PCR analysis. Corresponding DCs from thyroid-non draining 
LN (inguinal) will be used as controls. If our hypothesis is correct, we expect that only 
migratory DC from CLNC of mice on iodide-rich diet will have reduced expression of 
Itgb8 and Socs2 and increased expression of genes encoding the inflammatory molecules 
described above. 
 
Hypothesis #2: The migratory CD11b+ DC is the APC subset carrying the T4p2553 from 
the thyroid to CLN. 
Previous studies in the NOD mouse have suggested that β cell antigens are transported 
from the pancreas to the pancreatic LN by DC before insulitis onset. Interestingly, the 
relevant DC subset was characterized as CD11c+CD11b+CD8α- (Turley et al. 2003). In 
our system, the majority of intrathyroidal DC have been characterized as 
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CD11clowCD11b+CD8α- cells (Klein, Wang 2004). To examine whether this DC subset 
carries the T4p2553 peptide from the thyroid to the CLN, migratory CD103+, migratory 
CD11b+, resident CD8α+, CD8α- DC subsets will be purified from the CLN of 6-8 week 
old NOD.H2h4 mice. These subsets of DC will be cultured for 24 hours with the 
T4p2553-specific KC1 T cell hybridoma without addition of exogenous T4p2553. 
Activation of the hybridoma will be assessed by the IL-2 production in a CTLL assay. Ex 
vivo obtained migratory and resident DC subsets from thyroid-non draining (inguinal) LN 
will be used as additional controls. In some cultures, exogenous p2495 will also be added 
as positive control. If our hypothesis is correct, we expect to detect significant T cell 
activation only in the presence of migratory CD11b+ cell from CLN. These data will 
indicate that this subset only expresses the T4p2553 endogenously on its surface. These 
data would also imply that this is the DC subset transporting the peptide from the thyroid 
to CLN. The pitfall in this design is that if T4p2553 is transferred via the lymph to the 
CLN and not by a specific DC subset then it should be present in resident DC as well. 
 
Hypothesis #3: Tolerogenic semimature DC pulsed with T4p2553 can suppress ISAT 
Previous studies from our laboratory have shown that tolerogenic semimature DC pulsed 
with Tg can activate CD4+CD25+ Treg cells and suppress EAT (Verginis et al. 2005). 
Studies with NOD mice have shown that tolerogenic DC, presenting a single 
autoantigenic peptide (mimotope), can activate CD4+CD25+ Treg cells and suppress 
autoimmune diabetes (Tarbell et al. 2004). To examine whether tolerogenic DC pulsed 
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with only one Tg epitope, the T4p2553, can suppress ISAT via activation of Treg in 
NOD.H2h4 mice, the following experimental design will be followed.  
 
NOD.H2h4 bone marrow cells will be cultured for 9 days in the presence of GM-CSF and 
TNF-α (40 ng/ml) or LPS (1 µg/ml) or medium will be added for an additional 24 hours 
of culture. Non adherent cells will be examined for DC generation based on CD11c 
expression, and they will be monitored for phenotypic expression of MHC class II, 
CD80, CD86, and CD40 molecules. Sandwich ELISA in DC culture supernatants will 
test for the levels of IL-12, IL-1β, and IL-6 secretion. TNF-α treated DC would be 
expected to acquire a semi-mature phenotype, i.e. increased expression of MHC class II, 
CD80, CD86, and CD40 molecules compared to DC generated only with GM-CSF as 
well as low levels of IL-12, IL-1β, and IL-6 secretion compared to LPS-treated DC. 
 
To assay the tolerogenic function of TNF-α treated DC in vivo, DC will be pulsed with 
T4p2553, intact Tg or ovalbumin (antigen control) for 6 hours, treated with TNF-α for 24 
hours, and then adoptively transferred i.v. into naïve 6-8 wk old NOD.H2h4 mice in three 
injections (days 0, 2 and 4, 3x106 cells/mouse). On day 0, mice (n= 10) will be placed on 
NaI/H20 for 28 days to develop ISAT while a control group will be placed on normal 
diet. Additional controls will be CBA/J mice that receive T4p2553-pulsed tolerogenic 
DC to suppress T4p2553-induced or Tg-induced EAT, as previously (Verginis et al. 
2005). If TNF-α-treated, semi-mature Tg-pulsed or T4p2553-pulsed DC turn out to 
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suppress ISAT in NOD.H2h4 mice, this will support the view that Tg-specific and/or 
T4p2553-specific Treg cells exist in this strain and can be expanded by this protocol.  
 
To seek evidence that CD4+CD25+ T cells from mice injected with Tg- or T4p2553- 
pulsed DC have the characteristics of the Treg cell subset, the expression levels of CD25, 
CD62L, Foxp3 and glucocorticoid-induced TNF receptor (GITR) in CD4+CD25+ and 
CD4+CD25- T cells will be examined by flow cytometry. Treg cell function will be tested 
by mixing experiments in vivo or in vitro. The induced CD4+CD25+Foxp3+ cells will be 
purified by flow cytometry and their putative suppressive function will be tested in vitro 
as described (Yamazaki et al. 2008). CFSE-labelled responder CD4+ CD25- T cells from 
WT NOD.H2h4 mice will be stimulated with anti-CD3 mAb and spleen APCs. In these 
wells, titrated numbers of Treg cells – purified from mice injected with Tg, T4p2553 or 
ova pulsed DC - will be added and 3 days later, CFSE dilution will be analyzed by flow 
cytometry. Evidence of suppressive function in vitro will prompt the design of adoptive 
transfer experiments to ascertain whether this Treg population from Tg- and/or T4p2553- 
pulsed DC can prevent ISAT development. To this end, CD4+CD25+Foxp3+ cells will be 
purified from mice injected with Tg, T4p2553 or OVA pulsed DC. Treg cells or PBS will 
be transferred to naïve recipients and one day later mice will start receiving iodide-rich 
diet for 28 days. Thyroids will be removed at the end of this 28 day period. Additional 
control groups will include mice that will receive Treg cells from all groups but they will 
be administered normal water for 28 days.   
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Hypothesis #4: Spontaneous T cell activation against other Tg epitopes can be detected in 
CLN during the initial stages of ISAT. 
Previous studies in EAT have identified several pathogenic Ak-binding Tg peptides in 
CBA/J mice. To examine whether these peptides - I-p117, I-p179, I-p304, I-p1931, I-
p2529, I-p2540 and their non-iodinated analogs (Li, Carayanniotis 2006, Li et al. 2007) 
as well as the peptides p306, p1579, p1826, p2102, and p2596 (Verginis et al. 2002) - are 
recognized by CD4+ CLNC after NaI admininistration in NOD.H2h4 mice, the following 
experiment will be performed. CD4+ cells will be purified from CLN and splenocytes 7, 
11 and 15 days after initiation of the iodide-rich diet and their proliferative responses 
against the peptide panel described above will be tested. Splenic CD11c+ cells will be 
used as APC. CD4+ cells from CLN and splenocytes of mice on a normal water diet will 
be used as controls. If our hypothesis is correct, we expect to detect significant 
proliferative responses against other Tg epitopes only in CLN of iodide treated mice.  
 
Chapter 6  
We examined whether HSD exacerbates autoimmune thyroiditis using three animal 
models of the disease. Our data showed that there was no significant difference in the 
incidence and severity of thyroiditis between animals on high salt and normal diet as 
previously shown in the EAE model (Wu et al. 2013, Kleinewietfeld et al. 2013). This 
study however, raised the question of whether Th17 cells have a pathogenic role in 
thyroiditis, a concept that has not been studied extensively before. To examine this 
concept, we will make use of a TCR transgenic SJL mouse model specific for the 
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pathogenic Tg peptide p2495 (LINRAKAVK) (a.a. 2495-2503) that was generated in our 
laboratory. The p2495-specific TCR was obtained from the As-restricted T cell 
hybridoma clone 9.13 which secretes IL-2 upon specific activation with p2495. The VJ 
and VDJ sequences of the 9.13 TCR were cloned and microinjected into fertilized (B6 x 
SJL) F1 oocytes. Successful production of a fertile founder was followed by backcrossing 
to SJL for 10 generations and subsequent brother-sister mating. 9.13 TcR transgene-
positive mice were further crossed with SJL Rag+/- mice (kindly provided by Dr. V. 
Kuchroo), and via selective breeding, 9.13 TCR-positive Rag-/- progeny (9.13 T/R-) mice 
were obtained.  The 9.13 T/R-/- will be used as donors of naïve T cells. 
 
Hypothesis #1: p2495-specific Th17 cells are thyroidogenic in SJL mice. 
Previous studies have shown that EAT and SAT are mediated by Th1 cells (Yu et al. 
2002, Stafford, Rose 2000). In the ISAT model however, it was reported that IFN-γ and 
IL-17 mRNA were detected in thyroidal lymphocyte infiltrates of WT NOD.H2h4 mice. 
Also, IL-17-/- NOD.H2h4 mice were reported to have reduced ISAT symptoms (Horie et 
al. 2009). To examine whether Th17 cells are pathogenic in autoimmune thyroiditis, 
CD4+ T cells from 9.13 T/R-/- mice will be purified from spleen and LN and will be 
further sorted as naïve CD4+ CD25- CD62Lhi CD44lo T cells. These naive cells will be 
cultured in the presence of anti-CD3/CD28 microbeads for 4 days under Th17 or Th1 
skewing conditions. The Th17 skewing conditions would include addition of IL-23 alone 
(McGeachy et al. 2007) or IL-23 +IL-6 +IL1β (Lee et al. 2012, Singh et al. 2013) in the 
wells to generate highly pathogenic Th17 cells as well as IL-23 + IL-6 +TGF-β1 
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(Ghoreschi et al. 2010) to generate the classical Th17 cells. The Th1 conditions will 
include addition of IL-12 and anti-IL-4 Ab. 
 
After the 4-day culture, mRNA will be purified and the expression levels of Il-17a, Il-
17f, Ifn-g, Il-21, Il-22, Il-23r, Il-4, Il-10, Tbx21 (encodes T-bet), Rorc (encodes RORγt), 
Csf2 (encodes GM-CSF), Foxp3 and Gata3 will be analyzed by qPCR to confirm the 
differentiation towards the Th17 or Th1 lineage. Also, the presence of IL-17, GM-CSF, 
IL-22, IFN-γ, IL-4 and IL-10 at the protein level will be verified by intracellular cytokine 
staining. Once we have confirmed the in vitro differentiation towards the Th17 lineage, 
cells will be adoptively transferred i.v. to WT SJL recipient mice and EAT will be 
examined 2-3 weeks later. As positive control, mice will receive similarly treated T cells 
skewed towards the Th1 lineage i.v. If our hypothesis is correct, we expect that at least 
one group of in vitro Th17 differentiated cells will be thyroidogenic in SLJ mice. A 
pitfall in this approach is that Th17 may convert to Th1 cells in vivo due to plasticity. To 
examine this possibility, thyroidal T cell infiltrates will be stained, gated on CD4+ Vb4+ 
cells, a subset expected to be enriched with 9.13 T cells, and analyzed by intracellular 
cytokine staining for IL-17 and IFN-γ production.  
 
 
 
 
 
155 
 
In summary, our studies on the immunoregulation of autoimmune thyroiditis examined: 
 1) The immunopathogenicity and/or immunodominance of putative Ak-binding epitopes 
located close to possible cathepsin B, D and L cleavage sites in mTg. Two new 
immunopathogenic but cryptic Tg peptides, p2369 and p2439 were identified. This 
increased the number of known pathogenic Tg epitopes to 27 and we proposed possible 
explanations for the inability to find a dominant epitope in Tg; 2) The effect of iodide on 
the apoptosis of NOD.H2h4 thyrocytes. Our data showed high susceptibility of NOD.H2h4 
vs CBA/J thyrocytes to iodide-induced apoptosis which was associated with an impaired 
control of oxidative stress mechanisms in the iodide-treated NOD.H2h4 group. These 
results suggested that iodide-mediated apoptosis of NOD.H2h4 thyrocytes may be the 
trigger of ISAT onset in this strain; 3) The effect of iodide on the spontaneous activation 
of thyroid-antigen specific T cells in iodide-fed animals. Activated T4p2553-specific T 
cells were detected in CLN of NOD.H2h4 mice before ISAT onset as well as in 
intrathyroidal infiltrates. Our work identified for the first time a Tg epitope, T4p2553, as 
a spontaneous T cell target in ISAT providing opportunities for the construction of a TCR 
transgenic system in this strain; 4) The role of high salt diet in autoimmune thyroiditis 
development. Mice on a high salt diet did not develop significantly higher levels of the 
disease compared to mice on normal diet using three models of thyroiditis. These data 
suggested that high salt diet is not a risk factor for autoimmune thyroiditis and 
autoimmune diseases in general. 
 
 
156 
 
REFERENCES 
Adamczyk, M., Fino, L., Fishpaugh, J.R., Johnson, D.D. & Mattingly, P.G. 1994, 
"Immunoassay reagents for thyroid testing. 1. Synthesis of thyroxine conjugates", 
Bioconjugate chemistry, vol. 5, no. 5, pp. 459-462.  
Allen, E.M., Appel, M.C. & Braverman, L.E. 1986, "The effect of iodide ingestion on the 
development of spontaneous lymphocytic thyroiditis in the diabetes-prone BB/W rat", 
Endocrinology, vol. 118, no. 5, pp. 1977-1981.  
Allen, P.M., McKean, D.J., Beck, B.N., Sheffield, J. & Glimcher, L.H. 1985, "Direct 
evidence that a class II molecule and a simple globular protein generate multiple 
determinants", The Journal of experimental medicine, vol. 162, no. 4, pp. 1264-1274.  
Altuvia, Y., Berzofsky, J.A., Rosenfeld, R. & Margalit, H. 1994, "Sequence features that 
correlate with MHC restriction", Molecular immunology, vol. 31, no. 1, pp. 1-19.  
Anderson, M.S. & Bluestone, J.A. 2005, "The NOD mouse: a model of immune 
dysregulation", Annual Review of Immunology, vol. 23, pp. 447-485.  
Anderton, S.M., Viner, N.J., Matharu, P., Lowrey, P.A. & Wraith, D.C. 2002, "Influence 
of a dominant cryptic epitope on autoimmune T cell tolerance", Nature immunology, vol. 
3, no. 2, pp. 175-181.  
157 
 
Arvan, P. & Di Jeso, B. 2005, "Thyroglobulin structure, function, and biosynthesis" in 
Werner & Ingbar's The Thyroid A Fundamental and Clinical Text, eds. L.E. Braverman 
& R.D. Utiger, Lippincott Williams & Wilkins, Philadelphia, USA, pp. 77.  
Asamoto, H., Oishi, M., Akazawa, Y. & Tochino, Y. 1986, "Histological and 
immunological changes in the thymus and other organs in NOD mice." in Insulitis and 
Type 1 diabetes - Lessons from the NOD mouse., eds. S. Tarui, Y. Tochino & K. Nonaka, 
Academic Press, Tokyo, pp. 61.  
Bagchi, N., Brown, T.R., Herdegen, D.M., Dhar, A. & Sundick, R.S. 1990, "Antioxidants 
delay the onset of thyroiditis in obese strain chickens", Endocrinology, vol. 127, no. 4, 
pp. 1590-1595.  
Bagchi, N., Brown, T.R. & Sundick, R.S. 1995, "Thyroid cell injury is an initial event in 
the induction of autoimmune thyroiditis by iodine in obese strain chickens", 
Endocrinology, vol. 136, no. 11, pp. 5054-5060.  
Bagchi, N., Brown, T.R., Urdanivia, E. & Sundick, R.S. 1985, "Induction of autoimmune 
thyroiditis in chickens by dietary iodine", Science (New York, N.Y.), vol. 230, no. 4723, 
pp. 325-327.  
Balasa, B. & Carayanniotis, G. 1993, "Immunotargeting of thyroglobulin on antigen 
presenting cells abrogates natural tolerance in the absence of adjuvant", Cellular 
immunology, vol. 150, no. 2, pp. 453-458.  
158 
 
Ban, Y., Tozaki, T., Taniyama, M., Nakano, Y., Yoneyama, K., Ban, Y. & Hirano, T. 
2009, "Association studies of the IL-23R gene in autoimmune thyroid disease in the 
Japanese population", Autoimmunity, vol. 42, no. 2, pp. 126-130.  
Barin, J.G., Talor, M.V., Sharma, R.B., Rose, N.R. & Burek, C.L. 2005, "Iodination of 
murine thyroglobulin enhances autoimmune reactivity in the NOD.H2 mouse", Clinical 
and experimental immunology, vol. 142, no. 2, pp. 251-259.  
Beers, C., Honey, K., Fink, S., Forbush, K. & Rudensky, A. 2003, "Differential 
regulation of cathepsin S and cathepsin L in interferon gamma-treated macrophages", The 
Journal of experimental medicine, vol. 197, no. 2, pp. 169-179.  
Beisel, K.W., David, C.S., Giraldo, A.A., Kong, Y.M. & Rose, N.R. 1982, "Regulation of 
experimental autoimmune thyroiditis: mapping of susceptibility to the I-A subregion of 
the mouse H-2", Immunogenetics, vol. 15, no. 4, pp. 427-430.  
Bernard, N.F., Ertug, F. & Margolese, H. 1992, "High incidence of thyroiditis and anti-
thyroid autoantibodies in NOD mice", Diabetes, vol. 41, no. 1, pp. 40-46.  
Berndorfer, U., Wilms, H. & Herzog, V. 1996, "Multimerization of thyroglobulin (TG) 
during extracellular storage: isolation of highly cross-linked TG from human thyroids", 
The Journal of clinical endocrinology and metAbolism, vol. 81, no. 5, pp. 1918-1926.  
Bernstein, S.E. 2007, "Chapter 16: Physiological Characteristics" in Biology of the 
LAboratory Mouse, ed. E.L. Green, Second edn, Dover Publications, Inc., New York.  
159 
 
Bigazzi, P.E. & Rose, N.R. 1975, "Spontaneous autoimmune thyroiditis in animals as a 
model of human disease", Progress in allergy, vol. 19, pp. 245-274.  
Bogner, U., Schleusener, H. & Wall, J.R. 1984, "Antibody-dependent cell mediated 
cytotoxicity against human thyroid cells in Hashimoto's thyroiditis but not Graves' 
disease", The Journal of clinical endocrinology and metAbolism, vol. 59, no. 4, pp. 734-
738.  
Bonita, R.E., Rose, N.R., Rasooly, L., Caturegli, P. & Burek, C.L. 2003, "Kinetics of 
mononuclear cell infiltration and cytokine expression in iodine-induced thyroiditis in the 
NOD-H2h4 mouse", Experimental and molecular pathology, vol. 74, no. 1, pp. 1-12.  
Bottazzo, G.F., Pujol-Borrell, R., Hanafusa, T. & Feldmann, M. 1983, "Role of aberrant 
HLA-DR expression and antigen presentation in induction of endocrine autoimmunity", 
Lancet, vol. 2, no. 8359, pp. 1115-1119.  
Boulard, O., Damotte, D., Deruytter, N., Fluteau, G., Carnaud, C. & Garchon, H.J. 2002, 
"An interval tightly linked to but distinct from the H2 complex controls both overt 
diabetes (Idd16) and chronic experimental autoimmune thyroiditis (Ceat1) in nonobese 
diabetic mice", Diabetes, vol. 51, no. 7, pp. 2141-2147.  
Bournaud, C. & Orgiazzi, J.J. 2003, "Iodine excess and thyroid autoimmunity", Journal 
of endocrinological investigation, vol. 26, no. 2 Suppl, pp. 49-56.  
160 
 
Braley-Mullen, H., Johnson, M., Sharp, G.C. & Kyriakos, M. 1985, "Induction of 
experimental autoimmune thyroiditis in mice with in vitro activated splenic T cells", 
Cellular immunology, vol. 93, no.1, pp. 132-143.  
Braley-Mullen, H. & Sharp, G.C. 1997, "A thyroxine-containing thyroglobulin peptide 
induces both lymphocytic and granulomatous forms of experimental autoimmune 
thyroiditis", Journal of Autoimmunity, vol. 10, no. 6, pp. 531-540.  
Braley-Mullen, H., Sharp, G.C., Bickel, J.T. & Kyriakos, M. 1991, "Induction of severe 
granulomatous experimental autoimmune thyroiditis in mice by effector cells activated in 
the presence of anti-interleukin 2 receptor antibody", The Journal of experimental 
medicine, vol. 173, no. 4, pp. 899-912.  
Braley-Mullen, H., Sharp, G.C., Medling, B. & Tang, H. 1999, "Spontaneous 
autoimmune thyroiditis in NOD.H-2h4 mice", Journal of Autoimmunity, vol. 12, no. 3, 
pp. 157-165.  
Braley-Mullen, H. & Yu, S. 2000, "Early requirement for B cells for development of 
spontaneous autoimmune thyroiditis in NOD.H-2h4 mice", Journal of immunology 
(Baltimore, Md.: 1950), vol. 165, no. 12, pp. 7262-7269.  
Brown, N.K., McCormick, D.J., Brusic, V., David, C.S. & Kong, Y.C. 2008a, "A novel 
H2A-E+ transgenic model susceptible to human but not mouse thyroglobulin-induced 
autoimmune thyroiditis: identification of mouse pathogenic epitopes", Cellular 
immunology, vol. 251, no. 1, pp. 1-7.  
161 
 
Brown, N.K., McCormick, D.J., David, C.S. & Kong, Y.C. 2008b, "H2E-derived 
Ealpha52-68 peptide presented by H2Ab interferes with clonal deletion of autoreactive T 
cells in autoimmune thyroiditis", Journal of immunology (Baltimore, Md.: 1950), vol. 
180, no. 10, pp. 7039-7046.  
Burek, C.L. & Rose, N.R. 2008, "Autoimmune thyroiditis and ROS", Autoimmunity 
reviews, vol. 7, no. 7, pp. 530-537.  
Burek, C.L., Sharma, R.B. & Rose, N.R. 2003, "NKT cell regulation of autoimmune 
thyroiditis", Autoimmunity, vol. 36, no. 6-7, pp. 405-408.  
Burek, C.L. & Talor, M.V. 2009, "Environmental triggers of autoimmune thyroiditis", 
Journal of Autoimmunity, vol. 33, no. 3-4, pp. 183-189.  
Burgi, H. 2010, "Iodine excess", Best practice & research.Clinical endocrinology & 
metabolism, vol. 24, no. 1, pp. 107-115.  
Calderon, B., Suri, A., Miller, M.J. & Unanue, E.R. 2008, "Dendritic cells in islets of 
Langerhans constitutively present beta cell-derived peptides bound to their class II MHC 
molecules", Proceedings of the National Academy of Sciences of the United States of 
America, vol. 105, no. 16, pp. 6121-6126.  
Calderon, B. & Unanue, E.R. 2012, "Antigen presentation events in autoimmune 
diabetes", Current opinion in immunology, vol. 24, no. 1, pp. 119-128.  
162 
 
Camargo, R., Knobel, M. & Medeiros-Neto, G. 2007, "Iodine nutrition: more is better?", 
Arquivos Brasileiros de Endocrinologia e Metabologia, vol. 51, no. 4, pp. 639-640.  
Canning, M.O., Ruwhof, C. & Drexhage, H.A. 2003, "Aberrancies in antigen-presenting 
cells and T cells in autoimmune thyroid disease. A role in faulty tolerance induction", 
Autoimmunity, vol. 36, no. 6-7, pp. 429-442.  
Carayanniotis, G. 2011, "Molecular parameters linking thyroglobulin iodination with 
autoimmune thyroiditis", Hormones, vol. 10, no. 1, pp. 11-19.  
Carayanniotis, G. 2007, "Recognition of thyroglobulin by T cells: the role of iodine", 
Thyroid : official journal of the American Thyroid Association, vol. 17, no. 10, pp. 963-
973.  
Carayanniotis, G. 2003, "The cryptic self in thyroid autoimmunity: the paradigm of 
thyroglobulin", Autoimmunity, vol. 36, no. 6-7, pp. 423-428.  
Carayanniotis, G., Chronopoulou, E. & Rao, V.P. 1994, "Distinct genetic pattern of 
mouse susceptibility to thyroiditis induced by a novel thyroglobulin peptide", 
Immunogenetics, vol. 39, no. 1, pp. 21-28.  
Carayanniotis, G. & Rao, V.P. 1997, "Searching for pathogenic epitopes in thyroglobulin: 
parameters and caveats", Immunology today, vol. 18, no. 2, pp. 83-88.  
Caturegli, P., De Remigis, A. & Rose, N.R. 2014, "Hashimoto thyroiditis: Clinical and 
diagnostic criteria", Autoimmunity reviews, vol. 13, no. 4-5, pp. 391-397.  
163 
 
Caturegli, P., Vidalain, P.O., Vali, M., guilera-Galaviz, L.A. & Rose, N.R. 1997, 
"Cloning and characterization of murine thyroglobulin cDNA", Clinical immunology and 
immunopathology, vol. 85, no. 2, pp. 221-226.  
Cavalieri, R.R. 1997, "Iodine metabolism and thyroid physiology: current concepts", 
Thyroid : official journal of the American Thyroid Association, vol. 7, no. 2, pp. 177-181.  
Champion, B.R., Page, K.R., Parish, N., Rayner, D.C., Dawe, K., Biswas-Hughes, G., 
Cooke, A., Geysen, M. & Roitt, I.M. 1991, "Identification of a thyroxine-containing self-
epitope of thyroglobulin which triggers thyroid autoreactive T cells", The Journal of 
experimental medicine, vol. 174, no. 2, pp. 363-370.  
Champion, B.R., Rayner, D.C., Byfield, P.G., Page, K.R., Chan, C.T. & Roitt, I.M. 1987, 
"Critical role of iodination for T cell recognition of thyroglobulin in experimental murine 
thyroid autoimmunity", Journal of immunology (Baltimore, Md.: 1950), vol. 139, no. 11, 
pp. 3665-3670.  
Charreire, J. & Michel-Bechet, M. 1982, "Syngeneic sensitization of mouse lymphocytes 
on monolayers of thyroid epithelial cells. III. Induction of thyroiditis by thyroid-
sensitized T lymphoblasts", European journal of immunology, vol. 12, no. 5, pp. 421-
425.  
Chen, W., Man, N., Shan, Z. & Teng, W. 2011, "Effects of long-term exposure to iodine 
excess on the apoptosis of thyrocytes in Wistar rats", Experimental and clinical 
endocrinology & diabetes, vol. 119, no. 1, pp. 1-8.  
164 
 
Chen, C.R., Hamidi, S., Braley-Mullen, H., Nagayama, Y., Bresee, C., Aliesky, H.A., 
Rapoport, B. & McLachlan, S.M. 2010, "Antibodies to thyroid peroxidase arise 
spontaneously with age in NOD.H-2h4 mice and appear after thyroglobulin antibodies", 
Endocrinology, vol. 151, no. 9, pp. 4583-4593.  
Chi, H.C., Chen, C.Y., Tsai, M.M., Tsai, C.Y. & Lin, K.H. 2013, "Molecular functions of 
thyroid hormones and their clinical significance in liver-related diseases", BioMed 
research international, vol. 2013, pp. 601361.  
Chiovato, L., Bassi, P., Santini, F., Mammoli, C., Lapi, P., Carayon, P. & Pinchera, A. 
1993, "Antibodies producing complement-mediated thyroid cytotoxicity in patients with 
atrophic or goitrous autoimmune thyroiditis", The Journal of clinical endocrinology and 
metabolism, vol. 77, no. 6, pp. 1700-1705.  
Chronopoulou, E. & Carayanniotis, G. 1993, "H-2E(k) expression influences thyroiditis 
induction by the thyroglobulin peptide (2495-2511)", Immunogenetics, vol. 38, no. 2, pp. 
150-153.  
Chronopoulou, E. & Carayanniotis, G. 1992, "Identification of a thyroiditogenic 
sequence within the thyroglobulin molecule", Journal of immunology (Baltimore, Md. : 
1950), vol. 149, no. 3, pp. 1039-1044.  
Cihakova, D., Talor, M.V., Barin, J.G., Baldeviano, G.C., Fairweather, D., Rose, N.R. & 
Burek, C.L. 2009, "Sex differences in a murine model of Sjogren's syndrome", Annals of 
the New York Academy of Sciences, vol. 1173, pp. 378-383.  
165 
 
Clements, C.M., McNally, R.S., Conti, B.J., Mak, T.W. & Ting, J.P. 2006, "DJ-1, a 
cancer- and Parkinson's disease-associated protein, stabilizes the antioxidant 
transcriptional master regulator Nrf2", Proceedings of the National Academy of Sciences 
of the United States of America, vol. 103, no. 41, pp. 15091-15096.  
Cohen, S.B. & Weetman, A.P. 1988, "The effect of iodide depletion and supplementation 
in the Buffalo strain rat", Journal of endocrinological investigation, vol. 11, no. 8, pp. 
625-627.  
Cole, R.K., Kite, J.H.,Jr & Witebsky, E. 1968, "Hereditary autoimmune thyroiditis in the 
fowl", Science (New York, N.Y.), vol. 160, no. 3834, pp. 1357-1358.  
Costagliola, S., Many, M.C., Stalmans-Falys, M., Tonacchera, M., Vassart, G. & 
Ludgate, M. 1994, "Recombinant thyrotropin receptor and the induction of autoimmune 
thyroid disease in BALB/c mice: a new animal model", Endocrinology, vol. 135, no. 5, 
pp. 2150-2159.  
Creemers, P., Rose, N.R. & Kong, Y.M. 1983, "Experimental autoimmune thyroiditis. In 
vitro cytotoxic effects of T lymphocytes on thyroid monolayers", The Journal of 
experimental medicine, vol. 157, no. 2, pp. 559-571.  
Croizet, K., RAbilloud, R., Kostrouch, Z., Nicolas, J.F. & Rousset, B. 2000, "Culture of 
dendritic cells from a nonlymphoid organ, the thyroid gland: evidence for TNF alpha-
dependent phenotypic changes of thyroid-derived dendritic cells", Laboratory 
166 
 
investigation; a journal of technical methods and pathology, vol. 80, no. 8, pp. 1215-
1225.  
Croizet, K., Trouttet-Masson, S., RAbilloud, R., Nicolas, J.F., Bernier-Valentin, F. & 
Rousset, B. 2001, "Signaling from epithelial to dendritic cells of the thyroid gland: 
evidence for thyrocyte-derived factors controlling the survival, multiplication, and 
endocytic activity of dendritic cells", Laboratory investigation; a journal of technical 
methods and pathology, vol. 81, no. 12, pp. 1601-1613.  
Croxford, A.L., Waisman, A. & Becher, B. 2013, "Does dietary salt induce 
autoimmunity?", Cell research, vol. 23, no. 7, pp. 872-873.  
Czarnocka, B., Ruf, J., Ferrand, M., Carayon, P. & Lissitzky, S. 1985, "Purification of the 
human thyroid peroxidase and its identification as the microsomal antigen involved in 
autoimmune thyroid diseases", FEBS letters, vol. 190, no. 1, pp. 147-152.  
Dai, G., Levy, O. & Carrasco, N. 1996, "Cloning and characterization of the thyroid 
iodide transporter", Nature, vol. 379, no. 6564, pp. 458-460.  
Dai, Y.D., Eliades, P., Carayanniotis, K.A., McCormick, D.J., Kong, Y.C., Magafa, V., 
Cordopatis, P., Lymberi, P. & Carayanniotis, G. 2005, "Thyroxine-binding antibodies 
inhibit T cell recognition of a pathogenic thyroglobulin epitope", Journal of immunology 
(Baltimore, Md.: 1950), vol. 174, no. 5, pp. 3105-3110.  
167 
 
Dai, Y.D., Rao, V.P. & Carayanniotis, G. 2002, "Enhanced iodination of thyroglobulin 
facilitates processing and presentation of a cryptic pathogenic peptide 19", Journal of 
immunology (Baltimore, Md. : 1950), vol. 168, no. 11, pp. 5907-5911.  
Damotte, D., Colomb, E., Cailleau, C., Brousse, N., Charreire, J. & Carnaud, C. 1997, 
"Analysis of susceptibility of NOD mice to spontaneous and experimentally induced 
thyroiditis", European journal of immunology, vol. 27, no. 11, pp. 2854-2862.  
Dawe, K.I., Hutchings, P.R., Geysen, M., Champion, B.R., Cooke, A. & Roitt, I.M. 1996, 
"Unique role of thyroxine in T cell recognition of a pathogenic peptide in experimental 
autoimmune thyroiditis", European journal of immunology, vol. 26, no. 4, pp. 768-772.  
de la Sierra, A., Lluch, M.M., Coca, A., Aguilera, M.T., Giner, V., Bragulat, E. & 
Urbano-Marquez, A. 1996, "Fluid, ionic and hormonal changes induced by high salt 
intake in salt-sensitive and salt-resistant hypertensive patients", Clinical science (London, 
England : 1979), vol. 91, no. 2, pp. 155-161.  
Dedieu, A., Gaillard, J.C., Pourcher, T., Darrouzet, E. & Armengaud, J. 2011, "Revisiting 
iodination sites in thyroglobulin with an organ-oriented shotgun strategy", Journal of 
Biological Chemistry, vol. 286, no. 1, pp. 259-269.  
Dugrillon, A., Bechtner, G., Uedelhoven, W.M., Weber, P.C. & Gartner, R. 1990, 
"Evidence that an iodolactone mediates the inhibitory effect of iodide on thyroid cell 
proliferation but not on adenosine 3',5'-monophosphate formation", Endocrinology, vol. 
127, no. 1, pp. 337-343.  
168 
 
Dugrillon, A., Uedelhoven, W.M., Pisarev, M.A., Bechtner, G. & Gartner, R. 1994, 
"Identification of delta-iodolactone in iodide treated human goiter and its inhibitory effect 
on proliferation of human thyroid follicles", Hormone and metabolic research = 
Hormon- und Stoffwechselforschung = Hormones et metabolisme, vol. 26, no. 10, pp. 
465-469.  
Dunn J.T. & Dunn A.D. 2000, "Thyroglobulin:Chemistry, Biosynthesis and Proteolysis" 
in Werner & Ingbar's The Thyroid A Fundamental and Clinical Text, eds. Braverman 
L.E. & Utiger R.D., Lipincott Williams & Wilkins, Philadephia, pp. 91-104.  
Dunn, A.D., Crutchfield, H.E. & Dunn, J.T. 1991, "Thyroglobulin processing by 
thyroidal proteases. Major sites of cleavage by cathepsins B, D, and L", Journal of 
Biological Chemistry, vol. 266, no. 30, pp. 20198-20204.  
Dunn, A.D. & Dunn, J.T. 1982, "Thyroglobulin degradation by thyroidal proteases: 
action of purified cathepsin D", Endocrinology, vol. 111, no. 1, pp. 280-289.  
Dunn, A.D., Myers, H.E. & Dunn, J.T. 1996, "The combined action of two thyroidal 
proteases releases T4 from the dominant hormone-forming site of thyroglobulin", 
Endocrinology, vol. 137, no. 8, pp. 3279-3285.  
Elliott, P. & Brown, I., World Health 
Organization. http://www.who.int/dietphysicalactivity/Elliot-brown-2007.pdf. [25 Nov 
2013].  
169 
 
Ellis, J.S., Hong, S.H., Zaghouani, H. & Braley-Mullen, H. 2013, "Reduced effectiveness 
of CD4+Foxp3+ regulatory T cells in CD28-deficient NOD.H-2h4 mice leads to 
increased severity of spontaneous autoimmune thyroiditis", Journal of immunology 
(Baltimore, Md.: 1950), vol. 191, no. 10, pp. 4940-4949.  
Eirehewy, M., Kong, Y.M., Giraldo, A.A. & Rose, N.R. 1981, "Syngeneic thyroglobulin 
is immunogenic in good responder mice", European journal of immunology, vol. 11, no. 
2, pp. 146-151.  
Esquivel, P.S., Kong, Y.C. & Rose, N.R. 1978, "Evidence for thyroglobulin-reactive T 
cells in good responder mice", Cellular immunology, vol. 37, no. 1, pp. 14-19.  
Esquivel, P.S., Rose, N.R. & Kong, Y.C. 1977, "Induction of autoimmunity in good and 
poor responder mice with mouse thyroglobulin and lipopolysaccharide", The Journal of 
experimental medicine, vol. 145, no. 5, pp. 1250-1263.  
Farid, N.R., Sampson, L., Moens, H. & Barnard, J.M. 1981, "The association of goitrous 
autoimmune thyroiditis with HLA-DR5", Tissue antigens, vol. 17, no. 3, pp. 265-268.  
Farwell, A.P. & Braverman, L.E. 1996, "Inflammatory thyroid disorders", 
Otolaryngologic clinics of North America, vol. 29, no. 4, pp. 541-556.  
Figueroa-Vega, N., Alfonso-Perez, M., Benedicto, I., Sanchez-Madrid, F., Gonzalez-
Amaro, R. & Marazuela, M. 2010, "Increased circulating pro-inflammatory cytokines and 
170 
 
Th17 lymphocytes in Hashimoto's thyroiditis", The Journal of clinical endocrinology and 
metabolism, vol. 95, no. 2, pp. 953-962.  
Flogel, U., Godecke, A., Klotz, L.O. & Schrader, J. 2004, "Role of myoglobin in the 
antioxidant defense of the heart", FASEB journal : official publication of the Federation 
of American Societies for Experimental Biology, vol. 18, no. 10, pp. 1156-1158.  
Flynn, J.C., Conaway, D.H., Cobbold, S., Waldmann, H. & Kong, Y.C. 1989, "Depletion 
of L3T4+ and Lyt-2+ cells by rat monoclonal antibodies alters the development of 
adoptively transferred experimental autoimmune thyroiditis", Cellular immunology, vol. 
122, no. 2, pp. 377-390.  
Flynn, J.C., McCormick, D.J., Brusic, V., Wan, Q., Panos, J.C., Giraldo, A.A., David, 
C.S. & Kong, Y.C. 2004, "Pathogenic human thyroglobulin peptides in HLA-DR3 
transgenic mouse model of autoimmune thyroiditis", Cellular immunology, vol. 229, no. 
2, pp. 79-85.  
Follis, R.H.,Jr 1959, "Thyroiditis resulting from administration of excess iodine to 
hamsters with hyperplastic goiters", Proceedings of the Society for Experimental Biology 
and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.), vol. 
102, pp. 425-429.  
Forster, I. & Lieberam, I. 1996, "Peripheral tolerance of CD4 T cells following local 
activation in adolescent mice", European journal of immunology, vol. 26, no.12, pp. 
3194-3202.  
171 
 
Friedrichs, B., Tepel, C., Reinheckel, T., Deussing, J., von, F.K., Herzog, V., Peters, C., 
Saftig, P. & Brix, K. 2003, "Thyroid functions of mouse cathepsins B, K, and L", The 
Journal of clinical investigation, vol. 111, no. 11, pp. 1733-1745.  
Gagnerault, M.C., Luan, J.J., Lotton, C. & Lepault, F. 2002, "Pancreatic lymph nodes are 
required for priming of beta cell reactive T cells in NOD mice", The Journal of 
experimental medicine, vol. 196, no. 3, pp. 369-377.  
Ganesh, B.B., Cheatem, D.M., Sheng, J.R., Vasu, C. & PrAbhakar, B.S. 2009, "GM-
CSF-induced CD11c+CD8a- dendritic cells facilitate Foxp3+ and IL-10+ regulatory T 
cell expansion resulting in suppression of autoimmune thyroiditis", International 
immunology, vol. 21, no. 3, pp. 269-282.  
Gartner, R. 2009, "Autoregulation of thyroid growth and function by iodine: Independent 
regulation of the thyroid gland by iodocompounds." in Comprehensive handbook of 
iodine. Nutritional, biochemical, pathological and therapeutic aspects, eds. V.R. Preedy, 
G.N. Burrow & R.R. Watson, First edn, Academic Press, USA, pp. 243.  
Gartner, R., Rank, P. & Ander, B. 2010, "The role of iodine and delta-iodolactone in 
growth and apoptosis of malignant thyroid epithelial cells and breast cancer cells", 
Hormones (Athens, Greece), vol. 9, no. 1, pp. 60-66.  
Gentile, F., Conte, M. & Formisano, S. 2004, "Thyroglobulin as an autoantigen: what can 
we learn about immunopathogenicity from the correlation of antigenic properties with 
protein structure?", Immunology, vol. 112, no. 1, pp. 13-25.  
172 
 
Gentile, F., Palumbo, G. & Salvatore, G. 1992, "The origin of the electrophoretic doublet 
of thyroglobulin", Biochemical and biophysical research communications, vol. 186, no. 
3, pp. 1185-1191.  
Gentile, F. & Salvatore, G. 1993, "Preferential sites of proteolytic cleavage of bovine, 
human and rat thyroglobulin. The use of limited proteolysis to detect solvent-exposed 
regions of the primary structure", European journal of biochemistry / FEBS, vol. 218, no. 
2, pp. 603-621.  
Ghoreschi, K., Laurence, A., Yang, X.P., Tato, C.M., McGeachy, M.J., Konkel, J.E., 
Ramos, H.L., Wei, L., Davidson, T.S., Bouladoux, N., Grainger, J.R., Chen, Q., Kanno, 
Y., Watford, W.T., Sun, H.W., Eberl, G., Shevach, E.M., Belkaid, Y., Cua, D.J., Chen, 
W. & O'Shea, J.J. 2010, "Generation of pathogenic T(H)17 cells in the absence of TGF-
beta signalling", Nature, vol. 467, no. 7318, pp. 967-971.  
Golden, B., Levin, L., Ban, Y., Concepcion, E., Greenberg, D.A. & Tomer, Y. 2005, 
"Genetic analysis of families with autoimmune diabetes and thyroiditis: evidence for 
common and unique genes", The Journal of clinical endocrinology and metabolism, vol. 
90, no. 8, pp. 4904-4911.  
Golstein, J. & Dumont, J.E. 1996, "Cytotoxic effects of iodide on thyroid cells: difference 
between rat thyroid FRTL-5 cell and primary dog thyrocyte responsiveness", Journal of 
endocrinological investigation, vol. 19, no. 2, pp. 119-126.  
173 
 
Gopisetty, A., Bhattacharya, P., Haddad, C., Bruno, J.C.,Jr, Vasu, C., Miele, L. & 
Prabhakar, B.S. 2013, "OX40L/Jagged1 cosignaling by GM-CSF-induced bone marrow-
derived dendritic cells is required for the expansion of functional regulatory T cells", 
Journal of immunology (Baltimore, Md.: 1950), vol. 190, no. 11, pp. 5516-5525.  
Gornicka, A., Morris-Stiff, G., Thapaliya, S., Papouchado, B.G., Berk, M. & Feldstein, 
A.E. 2011, "Transcriptional profile of genes involved in oxidative stress and antioxidant 
defense in a dietary murine model of steatohepatitis", Antioxidants & redox signaling, 
vol. 15, no. 2, pp. 437-445.  
Gorrini, C., Baniasadi, P.S., Harris, I.S., Silvester, J., Inoue, S., Snow, B., Joshi, P.A., 
Wakeham, A., Molyneux, S.D., Martin, B., Bouwman, P., Cescon, D.W., Elia, A.J., 
Winterton-Perks, Z., Cruickshank, J., Brenner, D., Tseng, A., Musgrave, M., Berman, 
H.K., Khokha, R., Jonkers, J., Mak, T.W. & Gauthier, M.L. 2013, "BRCA1 interacts with 
Nrf2 to regulate antioxidant signaling and cell survival", The Journal of experimental 
medicine, vol. 210, no. 8, pp. 1529-1544.  
Guncar, G., Pungercic, G., Klemencic, I., Turk, V. & Turk, D. 1999, "Crystal structure of 
MHC class II-associated p41 Ii fragment bound to cathepsin L reveals the structural basis 
for differentiation between cathepsins L and S", The EMBO journal, vol. 18, no. 4, pp. 
793-803.  
Hajdu, A. & Rona, G. 1969, "Spontaneous thyroiditis in laboratory rats", Experientia, 
vol. 25, no. 12, pp. 1325-1327.  
174 
 
Hanafusa, T., Pujol-Borrell, R., Chiovato, L., Russell, R.C., Doniach, D. & Bottazzo, 
G.F. 1983, "Aberrant expression of HLA-DR antigen on thyrocytes in Graves' disease: 
relevance for autoimmunity", Lancet, vol. 2, no. 8359, pp. 1111-1115.  
Harach, H.R., Escalante, D.A., Onativia, A., Lederer Outes, J., Saravia Day, E. & 
Williams, E.D. 1985, "Thyroid carcinoma and thyroiditis in an endemic goitre region 
before and after iodine prophylaxis", Acta Endocrinologica, vol. 108, no. 1, pp. 55-60.  
Hasham, A. & Tomer, Y. 2012, "Genetic and epigenetic mechanisms in thyroid 
autoimmunity", Immunologic research, vol. 54, no. 1-3, pp. 204-213.  
Hashimoto, H. 1912, "Zur Kenntniss der lymphomatösen Veränderung der Schilddrüse 
(Struma lymphomatosa)", Arch Klin Chir, vol. 97, pp. 219.  
Hayashi, F., WatanAbe, M., Nanba, T., Inoue, N., Akamizu, T. & Iwatani, Y. 2009, 
"Association of the -31C/T functional polymorphism in the interleukin-1beta gene with 
the intractability of Graves' disease and the proportion of T helper type 17 cells", Clinical 
and experimental immunology, vol. 158, no. 3, pp. 281-286.  
Hedinger, C. 1981, "Geographic pathology of thyroid diseases", Pathology, research and 
practice, vol. 171, no. 3-4, pp. 285-292.  
Herzog, V., Berndorfer, U. & Saber, Y. 1992, "Isolation of insoluble secretory product 
from bovine thyroid: extracellular storage of thyroglobulin in covalently cross-linked 
form", The Journal of cell biology, vol. 118, no. 5, pp. 1071-1083.  
175 
 
Hintze, K.J. & Theil, E.C. 2005, "DNA and mRNA elements with complementary 
responses to hemin, antioxidant inducers, and iron control ferritin-L expression", 
Proceedings of the National Academy of Sciences of the United States of America, vol. 
102, no. 42, pp. 15048-15052.  
Hirota, K., Duarte, J.H., Veldhoen, M., Hornsby, E., Li, Y., Cua, D.J., Ahlfors, H., 
Wilhelm, C., Tolaini, M., Menzel, U., Garefalaki, A., Potocnik, A.J. & Stockinger, B. 
2011, "Fate mapping of IL-17-producing T cells in inflammatory responses", Nature 
immunology, vol. 12, no. 3, pp. 255-263.  
Höglund, P., Mintern, J., Waltzinger, C., Heath, W., Benoist, C. & Mathis, D. 1999, 
"Initiation of autoimmune diabetes by developmentally regulated presentation of islet cell 
antigens in the pancreatic lymph nodes", The Journal of experimental medicine, vol. 189, 
no. 2, pp. 331.  
Hong, S.H. & Braley-Mullen, H. 2014, "Follicular B cells in thyroids of mice with 
spontaneous autoimmune thyroiditis contribute to disease pathogenesis and are targets of 
anti-CD20 antibody therapy", Journal of immunology (Baltimore, Md.: 1950), vol. 192, 
no. 3, pp. 897-905.  
Horie, I., Abiru, N., Nagayama, Y., Kuriya, G., Saitoh, O., Ichikawa, T., Iwakura, Y. & 
Eguchi, K. 2009, "T helper type 17 immune response plays an indispensable role for 
development of iodine-induced autoimmune thyroiditis in non-obese diabetic-H2h4 
mice", Endocrinology, vol. 150, no. 11, pp. 5135-5142.  
176 
 
Horie, I., Abiru, N., Sakamoto, H., Iwakura, Y. & Nagayama, Y. 2011, "Induction of 
autoimmune thyroiditis by depletion of CD4+CD25+ regulatory T cells in thyroiditis-
resistant IL-17, but not interferon-gamma receptor, knockout nonobese diabetic-H2h4 
mice", Endocrinology, vol. 152, no. 11, pp. 4448-4454.  
Hoshioka, A., Kohno, Y., Katsuki, T., Shimojo, N., Maruyama, N., Inagaki, Y., Yokochi, 
T., Tarutani, O., Hosoya, T. & Niimi, H. 1993, "A common T-cell epitope between 
human thyroglobulin and human thyroid peroxidase is related to murine experimental 
autoimmune thyroiditis", Immunology letters, vol. 37, no. 2-3, pp. 235-239.  
Hurtenbach, U. & Maurer, C. 1989, "Type I diabetes in NOD mice is not associated with 
insulin-specific, autoreactive T cells", Journal of Autoimmunity, vol. 2, no. 2, pp. 151-
161.  
Hutchings, P.R., Cooke, A., Dawe, K., Champion, B.R., Geysen, M., Valerio, R. & Roitt, 
I.M. 1992, "A thyroxine-containing peptide can induce murine experimental autoimmune 
thyroiditis", The Journal of experimental medicine, vol. 175, no. 3, pp. 869-872.  
Hutchings, P.R., Verma, S., Phillips, J.M., Harach, S.Z., Howlett, S. & Cooke, A. 1999, 
"Both CD4(+) T cells and CD8(+) T cells are required for iodine accelerated thyroiditis 
in NOD mice", Cellular immunology, vol. 192, no. 2, pp. 113-121.  
Idoyaga, J., Fiorese, C., Zbytnuik, L., Lubkin, A., Miller, J., Malissen, B., Mucida, D., 
Merad, M. & Steinman, R.M. 2013, "Specialized role of migratory dendritic cells in 
177 
 
peripheral tolerance induction", The Journal of clinical investigation, vol. 123, no. 2, pp. 
844-854.  
Ivanov, I.I., McKenzie, B.S., Zhou, L., Tadokoro, C.E., Lepelley, A., Lafaille, J.J., Cua, 
D.J. & Littman, D.R. 2006, "The orphan nuclear receptor RORgammat directs the 
differentiation program of proinflammatory IL-17+ T helper cells", Cell, vol. 126, no. 6, 
pp. 1121-1133.  
Jacobson, D.L., Gange, S.J., Rose, N.R. & Graham, N.M. 1997, "Epidemiology and 
estimated population burden of selected autoimmune diseases in the United States", 
Clinical immunology and immunopathology, vol. 84, no. 3, pp. 223-243.  
Jacobson, E.M., Yang, H., Menconi, F., Wang, R., Osman, R., Skrabanek, L., Li, C.W., 
Fadlalla, M., Gandhi, A., Chaturvedi, V., Smith, E.P., Schwemberger, S., Osterburg, A., 
Babcock, G.F. & Tomer, Y. 2009, "Employing a recombinant HLA-DR3 expression 
system to dissect major histocompatibility complex II-thyroglobulin peptide dynamism: a 
genetic, biochemical, and reverse immunological perspective", Journal of Biological 
Chemistry, vol. 284, no. 49, pp. 34231-34243.  
Jaeckel, E., Lipes, M.A. & von Boehmer, H. 2004, "Recessive tolerance to preproinsulin 
2 reduces but does not abolish type 1 diabetes", Nature immunology, vol. 5, no. 10, pp. 
1028-1035.  
Jankovic, B.D. & Mitrovic, K. 1963, "Experimental Allergic Thyroiditis in the Chicken", 
Nature, vol. 200, pp. 186-187.  
178 
 
Jeker, L.T., Hejazi, M., Burek, C.L., Rose, N.R. & Caturegli, P. 1999, "Mouse thyroid 
primary culture", Biochemical and biophysical research communications, vol. 257, no. 2, 
pp. 511-515.  
Jenkins, D., Penny, M.A., Fletcher, J.A., Jacobs, K.H., Mijovic, C.H., Franklyn, J.A. & 
Sheppard, M.C. 1992, "HLA class II gene polymorphism contributes little to Hashimoto's 
thyroiditis", Clinical endocrinology, vol. 37, no. 2, pp. 141-145.  
Jiang, H.Y., Li, H.S., Carayanniotis, K. & Carayanniotis, G. 2007, "Variable influences 
of iodine on the T-cell recognition of a single thyroglobulin epitope", Immunology, vol. 
121, no. 3, pp. 370-376.  
Jones, H.E. & Roitt, I.M. 1961, "Experimental auto-immune thyroiditis in the rat", British 
journal of experimental pathology, vol. 42, pp. 546-557.  
Jordans, S., Jenko-Kokalj, S., Kuhl, N.M., Tedelind, S., Sendt, W., Bromme, D., Turk, D. 
& Brix, K. 2009, "Monitoring compartment-specific substrate cleavage by cathepsins B, 
K, L, and S at physiological pH and redox conditions", BMC biochemistry, vol. 10, no. 
1471-2091; 1471-2091, pp. 23.  
Kabel, P.J., Voorbij, H.A., De Haan, M., van der Gaag, R.D. & Drexhage, H.A. 1988, 
"Intrathyroidal dendritic cells", The Journal of clinical endocrinology and metabolism, 
vol. 66, no. 1, pp. 199-207.  
179 
 
Karras, E., Carayanniotis, G. & Lymberi, P. 2003, "Induction of murine thyroiditis by a 
non dominant E(k)-restricted peptide of human thyroglobulin", Immunology, vol. 108; 
no. 4, pp. 556-561.  
Karras, E., Yang, H., Lymberi, P. & Christadoss, P. 2005, "Human thyroglobulin peptide 
p2340 induces autoimmune thyroiditis in HLA-DR3 transgenic mice", Journal of 
Autoimmunity, vol. 24; no.  4, pp. 291-296.  
Kaufman, D.L., Tisch, R., Sarvetnick, N., Chatenoud, L., Harrison, L.C., Haskins, K., 
Quinn, A., Sercarz, E., Singh, B., von Herrath, M., Wegmann, D., Wen, L. & Zekzer, D. 
2001, "Report from the 1st International NOD Mouse T-Cell Workshop and the follow-
up mini-workshop", Diabetes, vol. 50, no. 11, pp. 2459-2463.  
Kawashima, A., Yamazaki, K., Hara, T., Akama, T., Yoshihara, A., Sue, M., Tanigawa, 
K., Wu, H., Ishido, Y., Takeshita, F., Ishii, N., Sato, K. & Suzuki, K. 2013, 
"Demonstration of innate immune responses in the thyroid gland: potential to sense 
danger and a possible trigger for autoimmune reactions", Thyroid : official journal of the 
American Thyroid Association, vol. 23, no. 4, pp. 477-487.  
Kim, P.S., Hossain, S.A., Park, Y.N., Lee, I., Yoo, S.E. & Arvan, P. 1998, "A single 
amino acid change in the acetylcholinesterase-like domain of thyroglobulin causes 
congenital goiter with hypothyroidism in the cog/cog mouse: a model of human 
endoplasmic reticulum storage diseases", Proceedings of the National Academy of 
Sciences of the United States of America, vol. 95; no. 17, pp. 9909-9913.  
180 
 
Kim, S.M., Eisner, C., Faulhaber-Walter, R., Mizel, D., Wall, S.M., Briggs, J.P. & 
Schnermann, J. 2008, "Salt sensitivity of blood pressure in NKCC1-deficient mice", 
American journal of physiology.Renal physiology, vol. 295, no. 4, pp. F1230-8.  
Kimura, H., Kimura, M., Tzou, S.C., Chen, Y.C., Suzuki, K., Rose, N.R. & Caturegli, P. 
2005, "Expression of class II major histocompatibility complex molecules on thyrocytes 
does not cause spontaneous thyroiditis but mildly increases its severity after 
immunization", Endocrinology, vol. 146, no. 3, pp. 1154-1162.  
Klein, J.R. & Wang, H.C. 2004, "Characterization of a novel set of resident intrathyroidal 
bone marrow-derived hematopoietic cells: potential for immune-endocrine interactions in 
thyroid homeostasis", The Journal of experimental biology, vol. 207, no. Pt 1, pp. 55-65.  
Kleinewietfeld, M., Manzel, A., Titze, J., Kvakan, H., Yosef, N., Linker, R.A., Muller, 
D.N. & Hafler, D.A. 2013, "Sodium chloride drives autoimmune disease by the induction 
of pathogenic TH17 cells", Nature, vol. 496, no. 7446, pp. 518-522.  
Knight, S.C., Farrant, J., Chan, J., Bryant, A., Bedford, P.A. & Bateman, C. 1988, 
"Induction of autoimmunity with dendritic cells: studies on thyroiditis in mice", Clinical 
immunology and immunopathology, vol. 48, no. 3, pp. 277-289.  
Kohrle, J., Jakob, F., Contempre, B. & Dumont, J.E. 2005, "Selenium, the thyroid, and 
the endocrine system", Endocrine reviews, vol. 26, no. 7, pp. 944-984.  
181 
 
Kolypetri, P., Noel, N.A., Carayanniotis, K.A. & Carayanniotis, G. 2010, "Iodine content 
of thyroglobulin in Nod.H2h4 mice developing iodine-accelerated autoimmune 
thyroiditis", Hormones (Athens, Greece), vol. 9, no. 2, pp. 151-160.  
Kong, Y., David, C.S., Giraldo, A.A., Elrehewy, M. & Rose, N.R. 1979, "Regulation of 
autoimmune response to mouse thyroglobulin: influence of H-2D-end genes", Journal of 
immunology (Baltimore, Md.: 1950), vol. 123, no. 1, pp. 15-18.  
Kong, Y.C., Audibert, F., Giraldo, A.A., Rose, N.R. & Chedid, L. 1985, "Effects of 
natural or synthetic microbial adjuvants on induction of autoimmune thyroiditis", 
Infection and immunity, vol. 49, no. 1, pp. 40-45.  
Kong, Y.C., Flynn, J.C., Banga, J.P. & David, C.S. 2007, "Application of HLA class II 
transgenic mice to study autoimmune regulation", Thyroid : official journal of the 
American Thyroid Association, vol. 17, no. 10, pp. 995-1003.  
Kong, Y.C., Lomo, L.C., Motte, R.W., Giraldo, A.A., Baisch, J., Strauss, G., 
Hammerling, G.J. & David, C.S. 1996, "HLA-DRB1 polymorphism determines 
susceptibility to autoimmune thyroiditis in transgenic mice: definitive association with 
HLA-DRB1*0301 (DR3) gene", The Journal of experimental medicine, vol. 184, no. 3, 
pp. 1167-1172.  
Kong, Y.C., McCormick, D.J., Wan, Q., Motte, R.W., Fuller, B.E., Giraldo, A.A. & 
David, C.S. 1995, "Primary hormonogenic sites as conserved autoepitopes on 
182 
 
thyroglobulin in murine autoimmune thyroiditis. Secondary role of iodination", Journal 
of immunology (Baltimore, Md.: 1950), vol. 155, no. 12, pp. 5847-5854.  
Kong, Y.M., David, C.S., Lomo, L.C., Fuller, B.E., Motte, R.W. & Giraldo, A.A. 1997, 
"Role of mouse and human class II transgenes in susceptibility to and protection against 
mouse autoimmune thyroiditis", Immunogenetics, vol. 46; no. 4, pp. 312-317.  
Konno, N., Makita, H., Yuri, K., Iizuka, N. & Kawasaki, K. 1994, "Association between 
dietary iodine intake and prevalence of subclinical hypothyroidism in the coastal regions 
of Japan", The Journal of clinical endocrinology and metabolism, vol. 78, no. 2, pp. 393-
397.  
Kotani, T., Umeki, K., Hirai, K. & Ohtaki, S. 1990, "Experimental murine thyroiditis 
induced by porcine thyroid peroxidase and its transfer by the antigen-specific T cell line", 
Clinical and experimental immunology, vol. 80, no. 1, pp. 11-18.  
Kotani, T., Umeki, K., Yagihashi, S., Hirai, K. & Ohtaki, S. 1992, "Identification of 
thyroiditogenic epitope on porcine thyroid peroxidase for C57BL/6 mice", Journal of 
immunology (Baltimore, Md.: 1950), vol. 148, no. 7, pp. 2084-2089.  
Kurts, C., Kosaka, H., Carbone, F.R., Miller, J.F. & Heath, W.R. 1997, "Class I-restricted 
cross-presentation of exogenous self-antigens leads to deletion of autoreactive CD8(+) T 
cells", The Journal of experimental medicine, vol. 186, no. 2, pp. 239-245.  
183 
 
Langer, R., Burzler, C., Bechtner, G. & Gartner, R. 2003, "Influence of iodide and 
iodolactones on thyroid apoptosis. Evidence that apoptosis induced by iodide is mediated 
by iodolactones in intact porcine thyroid follicles", Experimental and clinical 
endocrinology & diabetes : official journal, German Society of Endocrinology [and] 
German Diabetes Association, vol. 111, no. 6, pp. 325-329.  
Latz, E., Xiao, T.S. & Stutz, A. 2013, "Activation and regulation of the inflammasomes", 
Nature reviews.Immunology, vol. 13, no. 6, pp. 397-411.  
Lee, Y., Awasthi, A., Yosef, N., Quintana, F.J., Xiao, S., Peters, A., Wu, C., 
Kleinewietfeld, M., Kunder, S., Hafler, D.A., Sobel, R.A., Regev, A. & Kuchroo, V.K. 
2012, "Induction and molecular signature of pathogenic TH17 cells", Nature 
immunology, vol. 13, no. 10, pp. 991-999.  
Lehmann, P., Rank, P., Hallfeldt, K.L., Krebs, B. & Gartner, R. 2006, "Dose-related 
influence of sodium selenite on apoptosis in human thyroid follicles in vitro induced by 
iodine, EGF, TGF-beta, and H2O2", Biological trace element research, vol. 112, no. 2, 
pp. 119-130.  
Leoni, S.G., Galante, P.A., Ricarte-Filho, J.C. & Kimura, E.T. 2008, "Differential gene 
expression analysis of iodide-treated rat thyroid follicular cell line PCCl3", Genomics, 
vol. 91, no. 4, pp. 356-366.  
184 
 
Leoni, S.G., Kimura, E.T., Santisteban, P. & De la Vieja, A. 2011, "Regulation of thyroid 
oxidative state by thioredoxin reductase has a crucial role in thyroid responses to iodide 
excess", Molecular endocrinology (Baltimore, Md.), vol. 25, no. 11, pp. 1924-1935.  
Li, D., Chen, X.Q., Li, W.J., Yang, Y.H., Wang, J.Z. & Yu, A.C. 2007, "Cytoglobin up-
regulated by hydrogen peroxide plays a protective role in oxidative stress", 
Neurochemical research, vol. 32, no. 8, pp. 1375-1380.  
Li, H.S. & Carayanniotis, G. 2007, "Induction of goitrous hypothyroidism by dietary 
iodide in SJL mice", Endocrinology, vol. 148, no. 6, pp. 2747-2752.  
Li, H.S. & Carayanniotis, G. 2006, "Iodination of tyrosyls in thyroglobulin generates 
neoantigenic determinants that cause thyroiditis", Journal of immunology (Baltimore, 
Md. : 1950), vol. 176, no. 7, pp. 4479-4483.  
Li, H.S. & Carayanniotis, G. 2005, "Detection of thyroglobulin mRNA as truncated 
isoform(s) in mouse thymus", Immunology, vol. 115, no. 1, pp. 85-89.  
Li, H.S., Jiang, H.Y. & Carayanniotis, G. 2007, "Modifying effects of iodine on the 
immunogenicity of thyroglobulin peptides", Journal of Autoimmunity, vol. 28, no. 4, pp. 
171-176.  
Li, H.S., Verginis, P. & Carayanniotis, G. 2006, "Maturation of dendritic cells by 
necrotic thyrocytes facilitates induction of experimental autoimmune thyroiditis", 
Clinical and experimental immunology, vol. 144, no. 3, pp. 467-474.  
185 
 
Li, M. & Boyages, S.C. 1994, "Iodide induced lymphocytic thyroiditis in the BB/W rat: 
evidence of direct toxic effects of iodide on thyroid subcellular structure", Autoimmunity, 
vol. 18, no. 1, pp. 31-40.  
Li, Y.S., Kanamoto, N., Hataya, Y., Moriyama, K., Hiratani, H., Nakao, K. & Akamizu, 
T. 2004, "Transgenic mice producing major histocompatibility complex class II 
molecules on thyroid cells do not develop apparent autoimmune thyroid diseases", 
Endocrinology, vol. 145, no. 5, pp. 2524-2530.  
Liu, J., Li, J., Li, W.J. & Wang, C.M. 2013, "The role of uncoupling proteins in diabetes 
mellitus", Journal of diabetes research, vol. 2013, pp. 585897.  
Londei, M., Lamb, J.R., Bottazzo, G.F. & Feldmann, M. 1984, "Epithelial cells 
expressing aberrant MHC class II determinants can present antigen to cloned human T 
cells", Nature, vol. 312, no. 5995, pp. 639-641.  
Ma, Q. 2013, "Role of nrf2 in oxidative stress and toxicity", Annual Review of 
Pharmacology and Toxicology, vol. 53, pp. 401-426.  
Mahmoud, I., Colin, I., Many, M.C. & Denef, J.F. 1986, "Direct toxic effect of iodide in 
excess on iodine-deficient thyroid glands: epithelial necrosis and inflammation associated 
with lipofuscin accumulation", Experimental and molecular pathology, vol. 44, no. 3, pp. 
259-271.  
186 
 
Makhanova, N., Hagaman, J., Kim, H.S. & Smithies, O. 2008, "Salt-sensitive blood 
pressure in mice with increased expression of aldosterone synthase", Hypertension, vol. 
51, no. 1, pp. 134-140.  
Manoury, B., Mazzeo, D., Fugger, L., Viner, N., Ponsford, M., Streeter, H., Mazza, G., 
Wraith, D.C. & Watts, C. 2002, "Destructive processing by asparagine endopeptidase 
limits presentation of a dominant T cell epitope in MBP 1", Nature immunology, vol. 3, 
no. 2, pp. 169-174.  
Many, M.C., Maniratunga, S., Varis, I., Dardenne, M., Drexhage, H.A. & Denef, J.F. 
1995, "Two-step development of Hashimoto-like thyroiditis in genetically autoimmune 
prone non-obese diabetic mice: effects of iodine-induced cell necrosis", The Journal of 
endocrinology, vol. 147, no. 2, pp. 311-320.  
Many, M.C., Mestdagh, C., van den Hove, M.F. & Denef, J.F. 1992, "In vitro study of 
acute toxic effects of high iodide doses in human thyroid follicles", Endocrinology, vol. 
131, no. 2, pp. 621-630.  
Maree, A.F., Komba, M., Finegood, D.T. & Edelstein-Keshet, L. 2008, "A quantitative 
comparison of rates of phagocytosis and digestion of apoptotic cells by macrophages 
from normal (BALB/c) and diabetes-prone (NOD) mice", Journal of applied physiology 
(Bethesda, Md.: 1985), vol. 104, no. 1, pp. 157-169.  
187 
 
Marino, M., Pinchera, A., McCluskey, R.T. & Chiovato, L. 2001, "Megalin in thyroid 
physiology and pathology", Thyroid : official journal of the American Thyroid 
Association, vol. 11, no. 1, pp. 47-56.  
Markou, K., Georgopoulos, N., Kyriazopoulou, V. & Vagenakis, A.G. 2001, "Iodine-
Induced hypothyroidism", Thyroid : official journal of the American Thyroid Association, 
vol. 11, no. 5, pp. 501-510.  
Maron, R. & Cohen, I.R. 1979, "Mutation at H-2K locus influences susceptibility to 
autoimmune thyroiditis", Nature, vol. 279, no. 5715, pp. 715-716.  
Maron, R., Zerubavel, R., Friedman, A. & Cohen, I.R. 1983, "T lymphocyte line specific 
for thyroglobulin produces or vaccinates against autoimmune thyroiditis in mice", 
Journal of immunology (Baltimore, Md. : 1950), vol. 131, no. 5, pp. 2316-2322.  
Mathis, D., Vence, L. & Benoist, C. 2001, "beta-Cell death during progression to 
diabetes", Nature, vol. 414, no. 6865, pp. 792-798.  
McGeachy, M.J., Bak-Jensen, K.S., Chen, Y., Tato, C.M., Blumenschein, W., 
McClanahan, T. & Cua, D.J. 2007, "TGF-beta and IL-6 drive the production of IL-17 and 
IL-10 by T cells and restrain T(H)-17 cell-mediated pathology", Nature immunology, vol. 
8, no. 12, pp. 1390-1397.  
McLachlan, S.M. & Rapoport, B. 2007, "Thyroid peroxidase as an autoantigen", Thyroid 
: official journal of the American Thyroid Association, vol. 17, no. 10, pp. 939-948.  
188 
 
Mendive, F.M., Rivolta, C.M., Moya, C.M., Vassart, G. & Targovnik, H.M. 2001, 
"Genomic organization of the human thyroglobulin gene: the complete intron-exon 
structure", European journal of endocrinology / European Federation of Endocrine 
Societies, vol. 145, no. 4, pp. 485-496.  
Menges, M., Rossner, S., Voigtlander, C., Schindler, H., Kukutsch, N.A., Bogdan, C., 
Erb, K., Schuler, G. & Lutz, M.B. 2002, "Repetitive injections of dendritic cells matured 
with tumor necrosis factor alpha induce antigen-specific protection of mice from 
autoimmunity", The Journal of experimental medicine, vol. 195, no. 1, pp. 15-21.  
Mihelic, M. & Turk, D. 2007, "Two decades of thyroglobulin type-1 domain research", 
Biological chemistry, vol. 388, no. 11, pp. 1123-1130.  
Miller, J.C., Brown, B.D., Shay, T., Gautier, E.L., Jojic, V., Cohain, A., Pandey, G., 
Leboeuf, M., Elpek, K.G., Helft, J., Hashimoto, D., Chow, A., Price, J., Greter, M., 
Bogunovic, M., Bellemare-Pelletier, A., Frenette, P.S., Randolph, G.J., Turley, S.J., 
Merad, M. & Immunological Genome Consortium 2012, "Deciphering the transcriptional 
network of the dendritic cell lineage", Nature immunology, vol. 13, no. 9, pp. 888-899.  
Mohan, J.F., Levisetti, M.G., Calderon, B., Herzog, J.W., Petzold, S.J. & Unanue, E.R. 
2010, "Unique autoreactive T cells recognize insulin peptides generated within the islets 
of Langerhans in autoimmune diabetes", Nature immunology, vol. 11, no. 4, pp. 350-354.  
189 
 
Molina, F., Pau, B. & Granier, C. 1996, "The type-1 repeats of thyroglobulin regulate 
thyroglobulin degradation and T3, T4 release in thyrocytes 3", FEBS letters, vol. 391, no. 
3, pp. 229-231.  
Morand, S., Chaaraoui, M., Kaniewski, J., Deme, D., Ohayon, R., Noel-Hudson, M.S., 
Virion, A. & Dupuy, C. 2003, "Effect of iodide on nicotinamide adenine dinucleotide 
phosphate oxidase activity and Duox2 protein expression in isolated porcine thyroid 
follicles", Endocrinology, vol. 144, no. 4, pp. 1241-1248.  
Morgan, D.J., Kreuwel, H.T. & Sherman, L.A. 1999, "Antigen concentration and 
precursor frequency determine the rate of CD8+ T cell tolerance to peripherally 
expressed antigens", Journal of immunology (Baltimore, Md.: 1950), vol. 163, no. 2, pp. 
723-727.  
Mori, N., Itoh, N. & Salvaterra, P.M. 1987, "Evolutionary origin of cholinergic 
macromolecules and thyroglobulin", Proceedings of the National Academy of Sciences of 
the United States of America, vol. 84, no. 9, pp. 2813-2817.  
Muixi, L., Alvarez, I. & Jaraquemada, D. 2008a, "Peptides presented in vivo by HLA-DR 
in thyroid autoimmunity", Advances in Immunology, vol. 99, pp. 165-209.  
Muixi, L., Carrascal, M., Alvarez, I., Daura, X., Marti, M., Armengol, M.P., Pinilla, C., 
Abian, J., Pujol-Borrell, R. & Jaraquemada, D. 2008b, "Thyroglobulin peptides associate 
in vivo to HLA-DR in autoimmune thyroid glands", Journal of immunology (Baltimore, 
Md.: 1950), vol. 181, no. 1, pp. 795-807.  
190 
 
Muller, K., Krohn, K., Eszlinger, M., Ludgate, M. & Fuhrer, D. 2011, "Effect of iodine 
on early stage thyroid autonomy", Genomics, vol. 97, no. 2, pp. 94-100.  
Nagataki, S. 1974, "Effect of excess quantities of iodide." in Handbook of Physiology, 
eds. R.O. Greep & E.B. Astwwood, American Physiological Society, Washington, pp. 
329-344.  
Nagayama, Y., Horie, I., Saitoh, O., Nakahara, M. & Abiru, N. 2007, "CD4+CD25+ 
naturally occurring regulatory T cells and not lymphopenia play a role in the 
pathogenesis of iodide-induced autoimmune thyroiditis in NOD-H2h4 mice", Journal of 
Autoimmunity, vol. 29, no. 2-3, pp. 195-202.  
Nakagawa, H. & Ohtaki, S. 1984, "Partial purification and characterization of two thiol 
proteases from hog thyroid lysosomes", Endocrinology, vol. 115, no. 1, pp. 33-40.  
Nakagawa, T., Roth, W., Wong, P., Nelson, A., Farr, A., Deussing, J., Villadangos, J.A., 
Ploegh, H., Peters, C. & Rudensky, A.Y. 1998, "Cathepsin L: critical role in Ii 
degradation and CD4 T cell selection in the thymus", Science (New York, N.Y.), vol. 280, 
no. 5362, pp. 450-453.  
Nakagawa, T.Y., Brissette, W.H., Lira, P.D., Griffiths, R.J., Petrushova, N., Stock, J., 
McNeish, J.D., Eastman, S.E., Howard, E.D., Clarke, S.R., Rosloniec, E.F., Elliott, E.A. 
& Rudensky, A.Y. 1999, "Impaired invariant chain degradation and antigen presentation 
and diminished collagen-induced arthritis in cathepsin S null mice", Immunity, vol. 10, 
no. 2, pp. 207-217.  
191 
 
Nanba, T., Watanabe, M., Inoue, N. & Iwatani, Y. 2009, "Increases of the Th1/Th2 cell 
ratio in severe Hashimoto's disease and in the proportion of Th17 cells in intractable 
Graves' disease", Thyroid : official journal of the American Thyroid Association, vol. 19, 
no. 5, pp. 495-501.  
Ng, H.P. & Kung, A.W. 2006, "Induction of autoimmune thyroiditis and hypothyroidism 
by immunization of immunoactive T cell epitope of thyroid peroxidase", Endocrinology, 
vol. 147, no. 6, pp. 3085-3092.  
Nioi, P., McMahon, M., Itoh, K., Yamamoto, M. & Hayes, J.D. 2003, "Identification of a 
novel Nrf2-regulated antioxidant response element (ARE) in the mouse 
NAD(P)H:quinone oxidoreductase 1 gene: reassessment of the ARE consensus 
sequence", The Biochemical journal, vol. 374, no. Pt 2, pp. 337-348.  
O'Brien, B.A., Geng, X., Orteu, C.H., Huang, Y., Ghoreishi, M., Zhang, Y., Bush, J.A., 
Li, G., Finegood, D.T. & Dutz, J.P. 2006, "A deficiency in the in vivo clearance of 
apoptotic cells is a feature of the NOD mouse", Journal of Autoimmunity, vol. 26, no. 2, 
pp. 104-115.  
Oppenheim, Y., Kim, G., Ban, Y., Unger, P., Concepcion, E., Ando, T. & Tomer, Y. 
2003, "The effects of alpha interferon on the development of autoimmune thyroiditis in 
the NOD H2h4 mouse", Clinical & developmental immunology, vol. 10, no. 2-4, pp. 161-
165.  
192 
 
O'Shea, J.J. & Jones, R.G. 2013, "Autoimmunity: Rubbing salt in the wound", Nature, 
vol. 496, no. 7446, pp. 437-439.  
Perkins, D.L., Berriz, G., Kamradt, T., Smith, J.A. & Gefter, M.L. 1991, 
"Immunodominance: intramolecular competition between T cell epitopes", Journal of 
immunology (Baltimore, Md.: 1950), vol. 146, no. 7, pp. 2137-2144.  
Petanceska, S. & Devi, L. 1992, "Sequence analysis, tissue distribution, and expression of 
rat cathepsin S", The Journal of biological chemistry, vol. 267, no. 36, pp. 26038-26043.  
Pi, J., Zhang, Q., Fu, J., Woods, C.G., Hou, Y., Corkey, B.E., Collins, S. & Andersen, 
M.E. 2010, "ROS signaling, oxidative stress and Nrf2 in pancreatic beta-cell function", 
Toxicology and applied pharmacology, vol. 244, no. 1, pp. 77-83.  
Podolin, P.L., Pressey, A., DeLarato, N.H., Fischer, P.A., Peterson, L.B. & Wicker, L.S. 
1993, "I-E+ nonobese diabetic mice develop insulitis and diabetes", The Journal of 
experimental medicine, vol. 178, no. 3, pp. 793-803.  
Polytarchou, C., Pfau, R., Hatziapostolou, M. & Tsichlis, P.N. 2008, "The JmjC domain 
histone demethylase Ndy1 regulates redox homeostasis and protects cells from oxidative 
stress", Molecular and cellular biology, vol. 28, no. 24, pp. 7451-7464.  
Provenzano, M.J., Domann, F. & Hefley, L. 2009, "Chapter 21. Cellular iodine transport: 
Body distribution of the human sodium iodide symporter." in Comprehensive handbook 
193 
 
of iodine. Nutritional, biochemical, pathological and therapeutic aspects., eds. V.R. 
Preedy, G.N. Burrow & R.R. Watson, 1st edn, Academic Press, USA, pp. 207.  
Qin, Q., Liu, P., Liu, L., Wang, R., Yan, N., Yang, J., Wang, X., Pandey, M. & Zhang, 
J.A. 2012, "The increased but non-predominant expression of Th17- and Th1-specific 
cytokines in Hashimoto's thyroiditis but not in Graves' disease", Brazilian journal of 
medical and biological research, vol. 45, no. 12, pp. 1202-1208.  
Quaratino, S., Feldmann, M., Dayan, C.M., Acuto, O. & Londei, M. 1996, "Human self-
reactive T cell clones expressing identical T cell receptor beta chains differ in their ability 
to recognize a cryptic self-epitope", The Journal of experimental medicine, vol. 183, no. 
2, pp. 349-358.  
Rao, V.P., Balasa, B. & Carayanniotis, G. 1994, "Mapping of thyroglobulin epitopes: 
presentation of a 9mer pathogenic peptide by different mouse MHC class II isotypes", 
Immunogenetics, vol. 40, no. 5, pp. 352-359.  
Rao, V.P. & Carayanniotis, G. 1997, "Contrasting immunopathogenic properties of 
highly homologous peptides from rat and human thyroglobulin", Immunology, vol. 90, 
no. 2, pp. 244-249.  
Rao, V.P., Kajon, A.E., Spindler, K.R. & Carayanniotis, G. 1999, "Involvement of 
epitope mimicry in potentiation but not initiation of autoimmune disease", Journal of 
immunology (Baltimore, Md. : 1950), vol. 162, no. 10, pp. 5888-5893.  
194 
 
Rapoport, B. 2000, "The thyrotropin receptor" in Werner & Ingbar's The Thyroid A 
Fundamental and Clinical Text, eds. L.E. Braverman & R.D. Utiger, Lippincott Williams 
& Wilkins, USA, pp. 219.  
Rapoport, B. & McLachlan, S.M. 2007, "The thyrotropin receptor in Graves' disease", 
Thyroid : official journal of the American Thyroid Association, vol. 17, no. 10, pp. 911-
922.  
Rasmussen, L.B., Andersen, S., Ovesen, L. & Laurberg, P. 2009, "Iodine intake and food 
choice" in Comprehensive handbook of iodine. Nutritional, biochemical, pathological 
and theurapeutic aspects, eds. V.R. Preedy, G.N. Burrow & R.R. Watson, Academic 
Press, USA, pp. 333.  
Rasooly, L., Burek, C.L. & Rose, N.R. 1996, "Iodine-induced autoimmune thyroiditis in 
NOD-H-2h4 mice", Clinical immunology and immunopathology, vol. 81, no. 3, pp. 287-
292.  
Riese, R.J., Mitchell, R.N., Villadangos, J.A., Shi, G.P., Palmer, J.T., Karp, E.R., De 
Sanctis, G.T., Ploegh, H.L. & Chapman, H.A. 1998, "Cathepsin S activity regulates 
antigen presentation and immunity", The Journal of clinical investigation, vol. 101, no. 
11, pp. 2351-2363.  
Roitt I.M., Doniach D., Campell P.N. & Hudson R.V. 1956, "Autoantibodies in 
Hashimoto's disease", Lancet, vol. 2, pp. 820-821.  
195 
 
Romball, C.G. & Weigle, W.O. 1987, "Transfer of experimental autoimmune thyroiditis 
with T cell clones", Journal of immunology (Baltimore, Md. : 1950), vol. 138, no. 4, pp. 
1092-1098.  
Rose, N.R. 2011, "The genetics of autoimmune thyroiditis: the first decade", Journal of 
Autoimmunity, vol. 37, no. 2, pp. 88-94.  
Rose, N.R., Bonita, R. & Burek, C.L. 2002, "Iodine: an environmental trigger of 
thyroiditis", Autoimmunity reviews, vol. 1, no. 1-2, pp. 97-103.  
Rose, N.R., Rasooly, L., SAboori, A.M. & Burek, C.L. 1999, "Linking iodine with 
autoimmune thyroiditis", Environmental health perspectives, vol. 107 Suppl 5, pp. 749-
752.  
Rose, N.R., SAboori, A.M., Rasooly, L. & Burek, C.L. 1997, "The role of iodine in 
autoimmune thyroiditis", Critical reviews in immunology, vol. 17, no. 5-6, pp. 511-517.  
Rose, N.R., Skelton, F.R., Kite, J.H.,Jr & Witebsky, E. 1966, "Experimental thyroiditis in 
the rhesus monkey. 3. Course of the disease", Clinical and experimental immunology, 
vol. 1, no. 2, pp. 171-188.  
Rose, N.R., Twarog, F.J. & Crowle, A.J. 1971, "Murine thyroiditis: importance of 
adjuvant and mouse strain for the induction of thyroid lesions", Journal of immunology 
(Baltimore, Md. : 1950), vol. 106, no. 3, pp. 698-704.  
196 
 
Rose, N.R. & Witebsky, E. 1956, "Studies on organ specificity. V. Changes in the thyroid 
glands of rabbits following active immunization with rabbit thyroid extracts", Journal of 
immunology (Baltimore, Md.: 1950), vol. 76, no. 6, pp. 417-427.  
Rosenberg, I.N. & Goswami, A. 1979, "Purification and characterization of a 
flavoprotein from bovine thyroid with iodotyrosine deiodinase activity", The Journal of 
biological chemistry, vol. 254, no. 24, pp. 12318-12325.  
Roti, E. & Uberti, E.D. 2001, "Iodine excess and hyperthyroidism", Thyroid : official 
journal of the American Thyroid Association, vol. 11, no. 5, pp. 493-500.  
Rousset, B., Selmi, S., Bornet, H., Bourgeat, P., Rabilloud, R. & Munari-Silem, Y. 1989, 
"Thyroid hormone residues are released from thyroglobulin with only limited alteration 
of the thyroglobulin structure", The Journal of biological chemistry, vol. 264, no. 21, pp. 
12620-12626.  
Rovere, P., Vallinoto, C., Bondanza, A., Crosti, M.C., Rescigno, M., Ricciardi-
Castagnoli, P., Rugarli, C. & Manfredi, A.A. 1998, "Bystander apoptosis triggers 
dendritic cell maturation and antigen-presenting function", Journal of immunology 
(Baltimore, Md.: 1950), vol. 161, no. 9, pp. 4467-4471.  
Rubio, I.G. & Medeiros-Neto, G. 2009, "Mutations of the thyroglobulin gene and its 
relevance to thyroid disorders", Current opinion in endocrinology, diabetes, and obesity, 
vol. 16, no. 5, pp. 373-378.  
197 
 
Ruwhof, C. & Drexhage, H.A. 2001, "Iodine and thyroid autoimmune disease in animal 
models", Thyroid : official journal of the American Thyroid Association, vol. 11, no. 5, 
pp. 427-436.  
Saller, B., Fink, H. & Mann, K. 1998, "Kinetics of acute and chronic iodine excess", 
Experimental and clinical endocrinology & diabetes : official journal, German Society of 
Endocrinology [and] German Diabetes Association, vol. 106 Suppl 3, pp. S34-8.  
Santisteban, P. 2005, "Development and anatomy of the hypothalamic-pituitary-thyroid 
axis" in Werner & Ingbar's The Thyroid A Fundamental and Clinical Text, eds. L.E. 
Braverman & R.D. Utiger, Lippincott Williams & Wilkins, Philadelphia, pp. 8.  
Saranac, L., Zivanovic, S., Bjelakovic, B., Stamenkovic, H., Novak, M. & Kamenov, B. 
2011, "Why is the thyroid so prone to autoimmune disease?", Hormone research in 
paediatrics, vol. 75, no. 3, pp. 157-165.  
Scheinecker, C., McHugh, R., Shevach, E.M. & Germain, R.N. 2002, "Constitutive 
presentation of a natural tissue autoantigen exclusively by dendritic cells in the draining 
lymph node", The Journal of experimental medicine, vol. 196, no. 8, pp. 1079-1090.  
Schneider, S.C., Ohmen, J., Fosdick, L., Gladstone, B., Guo, J., Ametani, A., Sercarz, 
E.E. & Deng, H. 2000, "Cutting edge: introduction of an endopeptidase cleavage motif 
into a determinant flanking region of hen egg lysozyme results in enhanced T cell 
determinant display 1", Journal of immunology (Baltimore, Md. : 1950), vol. 165, no. 1, 
pp. 20-23.  
198 
 
Schuppert, F., Rambusch, E., Kirchner, H., Atzpodien, J., Kohn, L.D. & von zur Muhlen, 
A. 1997, "Patients treated with interferon-alpha, interferon-beta, and interleukin-2 have a 
different thyroid autoantibody pattern than patients suffering from endogenous 
autoimmune thyroid disease", Thyroid : official journal of the American Thyroid 
Association, vol. 7, no. 6, pp. 837-842.  
Schweizer, U., Chiu, J. & Kohrle, J. 2008, "Peroxides and peroxide-degrading enzymes 
in the thyroid", Antioxidants & redox signaling, vol. 10, no. 9, pp. 1577-1592.  
Sercarz, E.E., Lehmann, P.V., Ametani, A., Benichou, G., Miller, A. & Moudgil, K. 
1993, "Dominance and crypticity of T cell antigenic determinants", Annual Review of 
Immunology, vol. 11, pp. 729-766.  
Sharma, R., Traore, K., Trush, M.A., Rose, N.R. & Burek, C.L. 2008, "Intracellular 
adhesion molecule-1 up-regulation on thyrocytes by iodine of non-obese diabetic.H2(h4) 
mice is reactive oxygen species-dependent", Clinical and experimental immunology, vol. 
152, no. 1, pp. 13-20.  
Sharma, R.B., Fan, X., Caturegli, P., Rose, N.R. & Burek, C.L. 2011, "Invariant NKT 
Cell Lines Derived from the NOD.H2 Mouse Enhance Autoimmune Thyroiditis", 
Journal of thyroid research, vol. 2011, pp. 895923.  
Shi, G.P., Villadangos, J.A., Dranoff, G., Small, C., Gu, L., Haley, K.J., Riese, R., 
Ploegh, H.L. & Chapman, H.A. 1999, "Cathepsin S required for normal MHC class II 
peptide loading and germinal center development", Immunity, vol. 10, no. 2, pp. 197-206.  
199 
 
Shi, Y., Wang, H., Su, Z., Chen, J., Xue, Y., Wang, S., Xue, Y., He, Z., Yang, H., Zhou, 
C., Kong, F., Liu, Y., Yang, P., Lu, L., Shao, Q., Huang, X. & Xu, H. 2010, 
"Differentiation imbalance of Th1/Th17 in peripheral blood mononuclear cells might 
contribute to pathogenesis of Hashimoto's thyroiditis", Scandinavian journal of 
immunology, vol. 72, no. 3, pp. 250-255.  
Simons, P.J., Delemarre, F.G. & Drexhage, H.A. 2000, "A functional and phenotypic 
study on immune accessory cells isolated from the thyroids of Wistar and autoimmune-
prone BB-DP rats", Journal of Autoimmunity, vol. 15, no. 4, pp. 417-424.  
Singh, B., Schwartz, J.A., Sandrock, C., Bellemore, S.M. & Nikoopour, E. 2013, 
"Modulation of autoimmune diseases by interleukin (IL)-17 producing regulatory T 
helper (Th17) cells", The Indian journal of medical research, vol. 138, no. 5, pp. 591-
594.  
Smyth, P.P. 2003, "Role of iodine in antioxidant defence in thyroid and breast disease", 
BioFactors (Oxford, England), vol. 19, no. 3-4, pp. 121-130.  
Spindel, O.N., World, C. & Berk, B.C. 2012, "Thioredoxin interacting protein: redox 
dependent and independent regulatory mechanisms", Antioxidants & redox signaling, 
vol. 16, no. 6, pp. 587-596.  
Stafford, E.A. & Rose, N.R. 2000, "Newer insights into the pathogenesis of experimental 
autoimmune thyroiditis", International reviews of immunology, vol. 19, no. 6, pp. 501-
533.  
200 
 
Steinman, R.M., Turley, S., Mellman, I. & InAba, K. 2000, "The induction of tolerance 
by dendritic cells that have captured apoptotic cells", The Journal of experimental 
medicine, vol. 191, no. 3, pp. 411-416.  
Sternthal, E., Like, A.A., Sarantis, K. & Braverman, L.E. 1981, "Lymphocytic thyroiditis 
and diabetes in the BB/W rat. A new model of autoimmune endocrinopathy", Diabetes, 
vol. 30, no. 12, pp. 1058-1061.  
Strieder, T.G., Wenzel, B.E., Prummel, M.F., Tijssen, J.G. & Wiersinga, W.M. 2003, 
"Increased prevalence of antibodies to enteropathogenic Yersinia enterocolitica virulence 
proteins in relatives of patients with autoimmune thyroid disease", Clinical and 
experimental immunology, vol. 132, no. 2, pp. 278-282.  
Sundick, R.S., Herdegen, D.M., Brown, T.R. & Bagchi, N. 1987, "The incorporation of 
dietary iodine into thyroglobulin increases its immunogenicity", Endocrinology, vol. 120, 
no. 5, pp. 2078-2084.  
Suzuki, H. 1980, "Etiology of endemic goiter and iodide excess" in Endemic Goiter and 
Endemic Cretinism. Iodine Nutrition in Health and Disease, eds. J.B. Stanbury & B.S. 
Hetzel, J. Wiley and Sons, New York, pp. 237-53.  
Suzuki, K., Lavaroni, S., Mori, A., Ohta, M., Saito, J., Pietrarelli, M., Singer, D.S., 
Kimura, S., Katoh, R., Kawaoi, A. & Kohn, L.D. 1998, "Autoregulation of thyroid-
specific gene transcription by thyroglobulin", Proceedings of the National Academy of 
Sciences of the United States of America, vol. 95, no. 14, pp. 8251-8256.  
201 
 
Tandon, N., Mehra, N.K., Taneja, V., Vaidya, M.C. & Kochupillai, N. 1990, "HLA 
antigens in Asian Indian patients with Graves' disease", Clinical endocrinology, vol. 33, 
no. 1, pp. 21-26.  
Tarbell, K.V., Yamazaki, S., Olson, K., Toy, P. & Steinman, R.M. 2004, "CD25+ CD4+ 
T cells, expanded with dendritic cells presenting a single autoantigenic peptide, suppress 
autoimmune diabetes", The Journal of experimental medicine, vol. 199, no. 11, pp. 1467-
1477.  
Taurog A., C.I.L. 1946, "On the determination of plasma iodine", The Journal of 
biological chemistry, vol. 163, pp. 313.  
Taurog, A.M. 2000, "Hormone synthesis: Thyroid iodine metabolism" in Werner & 
Ingbar's The Thyroid A Fundamental and Clinical Text, eds. L.E. Braverman & R.D. 
Utiger, Lippincott Williams & Wilkins, USA, pp. 61.  
Teng, X., Shan, Z., Teng, W., Fan, C., Wang, H. & Guo, R. 2009, "Experimental study 
on the effects of chronic iodine excess on thyroid function, structure, and autoimmunity 
in autoimmune-prone NOD.H-2h4 mice", Clinical and experimental medicine, vol. 9, no. 
1, pp. 51-59.  
Teng, X., Shi, X., Shan, Z., Jin, Y., Guan, H., Li, Y., Yang, F., Wang, W., Tong, Y. & 
Teng, W. 2008, "Safe range of iodine intake levels: a comparative study of thyroid 
diseases in three women population cohorts with slightly different iodine intake levels", 
Biological trace element research, vol. 121, no. 1, pp. 23-30.  
202 
 
Terplan, K.L., Witebsky, E., Rose, N.R., Paine, J.R. & Egan, R.W. 1960, "Experimental 
thyroiditis in rabbits, guinea pigs and dogs, following immunization with thyroid extracts 
of their own and of heterologous species", The American journal of pathology, vol. 36, 
pp. 213-239.  
Testa, A., Castaldi, P., Fant, V., Fiore, G.F., Grieco, V., De Rosa, A., Pazardjiklian, M.G. 
& De Rosa, G. 2006, "Prevalence of HCV antibodies in autoimmune thyroid disease", 
European review for medical and pharmacological sciences, vol. 10, no. 4, pp. 183-186.  
Texier, B., Bedin, C., Tang, H., Camoin, L., Laurent-Winter, C. & Charreire, J. 1992, 
"Characterization and sequencing of a 40-amino-acid peptide from human thyroglobulin 
inducing experimental autoimmune thyroiditis", Journal of immunology (Baltimore, Md. 
: 1950), vol. 148, no. 11, pp. 3405-3411.  
Thompson, C. & Farid, N.R. 1985, "Post-partum thyroiditis and goitrous (Hashimoto's) 
thyroiditis are associated with HLA-DR4", Immunology letters, vol. 11, no. 5-6, pp. 301-
303.  
Thomsen, M., Ryder, L.P., Bech, K., Bliddal, H., Feldt-Rasmussen, U., Molholm, J., 
Kappelgaard, E., Nielsen, H. & Svejgaard, A. 1983, "HLA-D in Hashimoto's thyroiditis", 
Tissue antigens, vol. 21, no. 2, pp. 173-175.  
Tomazic, V., Rose, N.R. & Shreffler, D.C. 1974, "Autoimmune murine thyroiditis. IV. 
Localization of genetic control of the immune response", Journal of immunology 
(Baltimore, Md.: 1950), vol. 112, no. 3, pp. 965-969.  
203 
 
Tsatsoulis, A. 2006, "The role of stress in the clinical expression of thyroid 
autoimmunity", Annals of the New York Academy of Sciences, vol. 1088, pp. 382-395.  
Turley, S., Poirot, L., Hattori, M., Benoist, C. & Mathis, D. 2003, "Physiological beta cell 
death triggers priming of self-reactive T cells by dendritic cells in a type-1 diabetes 
model", The Journal of experimental medicine, vol. 198, no. 10, pp. 1527-1537.  
Uruno, A., Furusawa, Y., Yagishita, Y., Fukutomi, T., Muramatsu, H., Negishi, T., 
Sugawara, A., Kensler, T.W. & Yamamoto, M. 2013, "The Keap1-Nrf2 system prevents 
onset of diabetes mellitus", Molecular and cellular biology, vol. 33, no. 15, pp. 2996-
3010.  
Vali, M., Rose, N.R. & Caturegli, P. 2000, "Thyroglobulin as autoantigen: structure-
function relationships", Reviews in endocrine & metAbolic disorders, vol. 1, no. 1-2, pp. 
69-77.  
van de Graaf, S.A., Ris-Stalpers, C., Pauws, E., Mendive, F.M., Targovnik, H.M. & de 
Vijlder, J.J. 2001, "Up to date with human thyroglobulin", The Journal of endocrinology, 
vol. 170, no. 2, pp. 307-321.  
van der Meer, J.W. & Netea, M.G. 2013, "A salty taste to autoimmunity", The New 
England journal of medicine, vol. 368, no. 26, pp. 2520-2521.  
204 
 
Vasu, C., Holterman, M.J. & Prabhakar, B.S. 2003, "Modulation of dendritic cell 
function and cytokine production to prevent thyroid autoimmunity", Autoimmunity, vol. 
36, no. 6-7, pp. 389-396.  
Vecchiatti, S.M., Guzzo, M.L., Caldini, E.G., Bisi, H., Longatto-Filho, A. & Lin, C.J. 
2013, "Iodine increases and predicts incidence of thyroiditis in NOD mice: 
Histopathological and ultrastructural study", Experimental and therapeutic medicine, vol. 
5, no. 2, pp. 603-607.  
Veress, A.T., Chong, C.K., Field, L.J. & Sonnenberg, H. 1995, "Blood pressure and 
fluid-electrolyte balance in ANF-transgenic mice on high- and low-salt diets", The 
American Journal of Physiology, vol. 269, no. 1 Pt 2, pp. R186-92.  
Verginis, P., Li, H.S. & Carayanniotis, G. 2005, "Tolerogenic semimature dendritic cells 
suppress experimental autoimmune thyroiditis by activation of thyroglobulin-specific 
CD4+CD25+ T cells", Journal of immunology (Baltimore, Md.: 1950), vol. 174, no. 11, 
pp. 7433-7439.  
Verginis, P., Stanford, M.M. & Carayanniotis, G. 2002, "Delineation of five 
thyroglobulin T cell epitopes with pathogenic potential in experimental autoimmune 
thyroiditis", Journal of immunology (Baltimore, Md. : 1950), vol. 169, no. 9, pp. 5332-
5337.  
Verma, S., Hutchings, P., Guo, J., McLachlan, S., Rapoport, B. & Cooke, A. 2000, "Role 
of MHC class I expression and CD8(+) T cells in the evolution of iodine-induced 
205 
 
thyroiditis in NOD-H2(h4) and NOD mice", European journal of immunology, vol. 30, 
no. 4, pp. 1191-1202.  
Vitale, M., Di Matola, T., D'Ascoli, F., Salzano, S., Bogazzi, F., Fenzi, G., Martino, E. & 
Rossi, G. 2000, "Iodide excess induces apoptosis in thyroid cells through a p53-
independent mechanism involving oxidative stress", Endocrinology, vol. 141, no. 2, pp. 
598-605.  
Vladutiu, A.O. & Rose, N.R. 1975, "Cellular basis of the genetic control of immune 
responsiveness to murine thyroglobulin in mice", Cellular immunology, vol. 17, no. 1, pp. 
106-113.  
Vladutiu, A.O. & Rose, N.R. 1971, "Autoimmune murine thyroiditis relation to 
histocompatibility (H-2) type", Science, vol. 174, no. 14, pp. 1137-1139.  
Vladutiu, A.O. & Steinman, L. 1987, "Inhibition of experimental autoimmune thyroiditis 
in mice by anti-I-A antibodies", Cellular immunology, vol. 109, no. 1, pp. 169-180.  
Voorby, H.A., Kabel, P.J., de Haan, M., Jeucken, P.H., van der Gaag, R.D., de Baets, 
M.H. & Drexhage, H.A. 1990, "Dendritic cells and class II MHC expression on 
thyrocytes during the autoimmune thyroid disease of the BB rat", Clinical immunology 
and immunopathology, vol. 55, no. 1, pp. 9-22.  
Wan, Q., McCormick, D.J., David, C.S. & Kong, Y.C. 1998, "Thyroglobulin peptides of 
specific primary hormonogenic sites can generate cytotoxic T cells and serve as target 
206 
 
autoantigens in experimental autoimmune thyroiditis", Clinical immunology and 
immunopathology, vol. 86, no. 1, pp. 110-114.  
Wan, Q., Motte, R.W., McCormick, D.J., Fuller, B.E., Giraldo, A.A., David, C.S. & 
Kong, Y.M. 1997, "Primary hormonogenic sites as conserved autoepitopes on 
thyroglobulin in murine autoimmune thyroiditis: role of MHC class II", Clinical 
immunology and immunopathology, vol. 85, no. 2, pp. 187-194.  
Wang, S., Baidoo, S.E., Liu, Y., Zhu, C., Tian, J., Ma, J., Tong, J., Chen, J., Tang, X., 
Xu, H. & Lu, L. 2013, "T cell-derived leptin contributes to increased frequency of T 
helper type 17 cells in female patients with Hashimoto's thyroiditis", Clinical and 
experimental immunology, vol. 171, no. 1, pp. 63-68.  
Watanabe, H., Inaba, M., Adachi, Y., Sugiura, K., Hisha, H., Iguchi, T., Ito, T., 
Yasumizu, R., Inaba, K., Yamashita, T. & Ikehara, S. 1999, "Experimental autoimmune 
thyroiditis induced by thyroglobulin-pulsed dendritic cells", Autoimmunity, vol. 31, no. 4, 
pp. 273-282.  
Weatherall, D., Sarvetnick, N. & Shizuru, J.A. 1992, "Genetic control of diabetes 
mellitus", Diabetologia, vol. 35 Suppl 2, pp. S1-7.  
Weaver, D.K., Nishiyama, R.H., Burton, W.D. & Batsakis, J.G. 1966, "Surgical thyroid 
disease. A survey before and after iodine prophylaxis", Archives of surgery (Chicago, 
Ill.: 1960), vol. 92, no. 5, pp. 796-801.  
207 
 
Weetman, A.P. 1996, "Chronic autoimmune thyroiditis" in Werner & Ingbar's The 
Thyroid A Fundamental and Clinical Text, eds. L.E. Braverman & R.D. Utiger, 
Lippincott-Raven, Philadelphia, pp. 738.  
Weetman, A.P. & McGregor, A.M. 1994, "Autoimmune thyroid disease: further 
developments in our understanding", Endocrine reviews, vol. 15, no. 6, pp. 788-830.  
Weissel, M., Hofer, R., Zasmeta, H. & Mayr, W.R. 1980, "HLA-DR and Hashimoto's 
thyroiditis", Tissue antigens, vol. 16, no. 3, pp. 256-257.  
WHO, 2004, "Iodine" in Vitamin and mineral requirements in human nutrition, ed. 
Report of a joint FAO/WHO expert consultation,Bangkok, Thailand, pp. 305.  
Wick, G., Sundick, R.S. & Albini, B. 1974, "A review: The obese strain (OS) of 
chickens: an animal model with spontaneous autoimmune thyroiditis", Clinical 
immunology and immunopathology, vol. 3, no. 2, pp. 272-300.  
Wicker, L.S. 1997, "Major histocompatibility complex-linked control of autoimmunity", 
The Journal of experimental medicine, vol. 186, no. 7, pp. 973-975.  
Wicker, L.S., Todd, J.A. & Peterson, L.B. 1995, "Genetic control of autoimmune 
diabetes in the NOD mouse", Annual Review of Immunology, vol. 13, pp. 179-200.  
Wu, C., Yosef, N., Thalhamer, T., Zhu, C., Xiao, S., Kishi, Y., Regev, A. & Kuchroo, 
V.K. 2013, "Induction of pathogenic TH17 cells by inducible salt-sensing kinase SGK1", 
Nature, vol. 496, no. 7446, pp. 513-517.  
208 
 
Xue, H., Wang, W., Shan, Z., Li, Y., Li, Y., Teng, X., Gao, Y., Fan, C. & Teng, W. 2011, 
"Dynamic changes of CD4+CD25 + regulatory T cells in NOD.H-2h4 mice with iodine-
induced autoimmune thyroiditis", Biological trace element research, vol. 143, no. 1, pp. 
292-301.  
Yagishita, Y., Fukutomi, T., Sugawara, A., Kawamura, H., Takahashi, T., Pi, J., Uruno, 
A. & Yamamoto, M. 2014, "Nrf2 protects pancreatic beta-cells from oxidative and 
nitrosative stress in diabetic model mice", Diabetes, vol. 63, no. 2, pp. 605-618.  
Yamazaki, S., Dudziak, D., Heidkamp, G.F., Fiorese, C., Bonito, A.J., Inaba, K., 
Nussenzweig, M.C. & Steinman, R.M. 2008, "CD8+ CD205+ splenic dendritic cells are 
specialized to induce Foxp3+ regulatory T cells", Journal of immunology (Baltimore, 
Md.: 1950), vol. 181, no. 10, pp. 6923-6933.  
Yan, N., Yu, Y.L., Yang, J., Qin, Q., Zhu, Y.F., Wang, X., Song, R.H. & Zhang, J.A. 
2012, "Association of interleukin-17A and -17F gene single-nucleotide polymorphisms 
with autoimmune thyroid diseases", Autoimmunity, vol. 45, no. 7, pp. 533-539.  
Yao, X., Li, M., He, J., Zhang, G., Wang, M., Ma, J., Sun, Y., Zhang, W. & Li, L. 2012, 
"Effect of early acute high concentrations of iodide exposure on mitochondrial 
superoxide production in FRTL cells", Free radical biology & medicine, vol. 52, no. 8, 
pp. 1343-1352.  
Yu, L., Robles, D.T., Abiru, N., Kaur, P., Rewers, M., Kelemen, K. & Eisenbarth, G.S. 
2000, "Early expression of antiinsulin autoantibodies of humans and the NOD mouse: 
209 
 
evidence for early determination of subsequent diabetes", Proceedings of the National 
Academy of Sciences of the United States of America, vol. 97, no. 4, pp. 1701-1706.  
Yu, S., Dunn, R., Kehry, M.R. & Braley-Mullen, H. 2008, "B cell depletion inhibits 
spontaneous autoimmune thyroiditis in NOD.H-2h4 mice", Journal of immunology 
(Baltimore, Md.: 1950), vol. 180, no. 11, pp. 7706-7713.  
Yu, S., Ellis, J.S., Dunn, R., Kehry, M.R. & Braley-Mullen, H. 2012, "Transient 
depletion of B cells in young mice results in activation of regulatory T cells that inhibit 
development of autoimmune disease in adults", International immunology, vol. 24, no. 4, 
pp. 233-242.  
Yu, S., Maiti, P.K., Dyson, M., Jain, R. & Braley-Mullen, H. 2006, "B cell-deficient 
NOD.H-2h4 mice have CD4+CD25+ T regulatory cells that inhibit the development of 
spontaneous autoimmune thyroiditis", The Journal of experimental medicine, vol. 203, 
no. 2, pp. 349-358.  
Yu, S., Medling, B., Yagita, H. & Braley-Mullen, H. 2001, "Characteristics of 
inflammatory cells in spontaneous autoimmune thyroiditis of NOD.H-2h4 mice", Journal 
of Autoimmunity, vol. 16, no. 1, pp. 37-46.  
Yu, S., Sharp, G.C. & Braley-Mullen, H. 2002, "Dual roles for IFN-gamma, but not for 
IL-4, in spontaneous autoimmune thyroiditis in NOD.H-2h4 mice", Journal of 
immunology (Baltimore, Md.: 1950), vol. 169, no. 7, pp. 3999-4007.  
210 
 
Zhang, L., Sharma, S., Zhu, L.X., Kogai, T., Hershman, J.M., Brent, G.A., Dubinett, 
S.M. & Huang, M. 2003, "Nonradioactive iodide effectively induces apoptosis in 
genetically modified lung cancer cells", Cancer research, vol. 63, no. 16, pp. 5065-5072.  
Zhang, Y., O'Brien, B., Trudeau, J., Tan, R., Santamaria, P. & Dutz, J.P. 2002, "In situ 
beta cell death promotes priming of diabetogenic CD8 T lymphocytes", Journal of 
immunology (Baltimore, Md.: 1950), vol. 168, no. 3, pp. 1466-1472.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
211 
 
 
 
 
 
 
 
Appendices 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
212 
 
Appendix 1. Gene expression profile of apoptosis-related genes in iodide-treated NOD.H2h4 and CBA/J 
thyrocytes. 
RefSeq Symbol Description Fold change ( + NaI / - NaI) 
CBA/J NOD.H2h4 
NM_009594 Abl1 C-Abl oncogene 1, non-receptor tyrosine kinase -2.07 -1.47 
NM_012019 Aifm1 Apoptosis-inducing factor, mitochondrion-associated 1 1.49 1.07 
NM_009652 Akt1 Thymoma viral proto-oncogene 1 -1.69 -1.70 
NM_009673 Anxa5 Annexin A5 -1.18 1.23 
NM_009684 Apaf1 Apoptotic peptidase activating factor 1 -1.82 -1.29 
NM_007466 Api5 Apoptosis inhibitor 5 -1.38 -1.04 
NM_030693 Atf5 Activating transcription factor 5 -2.26 -1.84 
NM_007522 Bad BCL2-associated agonist of cell death 1.18 1.10 
NM_009736 Bag1 Bcl2-associated athanogene 1 1.18 -1.01 
NM_013863 Bag3 Bcl2-associated athanogene 3 -1.11 -1.16 
NM_007523 Bak1 BCL2-antagonist/killer 1 -1.33 -1.14 
NM_007527 Bax Bcl2-associated X protein -1.28 1.03 
NM_009740 Bcl10 B-cell leukemia/lymphoma 10 -1.55 -1.18 
NM_009741 Bcl2 B-cell leukemia/lymphoma 2 -1.57 1.72 
NM_009742 Bcl2a1a B-cell leukemia/lymphoma 2 related protein A1a    -1.29 a 1.12 
NM_009743 Bcl2l1 Bcl2-like 1 -1.61 -1.20 
NM_013479 Bcl2l10 Bcl2-like 10 -2.15 -1.51 
NM_009754 Bcl2l11 BCL2-like 11 (apoptosis facilitator) -1.37 1.15 
NM_007537 Bcl2l2 Bcl2-like 2 -1.73 -1.38 
NM_007544 Bid BH3 interacting domain death agonist -1.49 1.31 
NM_007465 Birc2 Baculoviral IAP repeat-containing 2 -1.39 1.27 
NM_007464 Birc3 Baculoviral IAP repeat-containing 3 -1.46 1.47 
NM_009689 Birc5 Baculoviral IAP repeat-containing 5 1.43 1.36 
NM_016787 Bnip2 BCL2/adenovirus E1B interacting protein 2 -1.27 -1.03 
NM_009760 Bnip3 BCL2/adenovirus E1B interacting protein 3 -1.16 1.27 
NM_009761 Bnip3l BCL2/adenovirus E1B interacting protein 3-like -1.38 1.15 
NM_016778 Bok BCL2-related ovarian killer protein -4.06 -527.93 
NM_130859 Card10 Caspase recruitment domain family, member 10 -3.80 -1.07 
NM_009807 Casp1 Caspase 1 -1.50 -1.16 
NM_009808 Casp12 Caspase 12 -1.29 1.05 
NM_009809 Casp14 Caspase 14 1.69   -2.19 a 
NM_007610 Casp2 Caspase 2 -1.18 -1.08 
NM_009810 Casp3 Caspase 3 -1.55 -1.21 
NM_007609 Casp4 Caspase 4, apoptosis-related cysteine peptidase -1.23 1.27 
NM_009811 Casp6 Caspase 6 -1.20 1.33 
NM_007611 Casp7 Caspase 7 -1.22 1.03 
NM_009812 Casp8 Caspase 8 -1.33 1.45 
NM_015733 Casp9 Caspase 9 -2.47 1.01 
NM_011611 Cd40 CD40 antigen 1.12 1.99 
NM_011616 Cd40lg CD40 ligand    -3.68 c   -1.92 c 
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NM_011617 Cd70 CD70 antigen      -1.58 b -1.18 
NM_009805 Cflar CASP8 and FADD-like apoptosis regulator -1.68 -1.25 
NM_007702 Cidea Cell death-inducing DNA fragmentation factor, alpha 
subunit-like effector A 1.19 1.76 
NM_009894 Cideb Cell death-inducing DNA fragmentation factor, alpha 
subunit-like effector B 1.07 1.19 
NM_009950 Cradd CASP2 and RIPK1 domain containing adaptor with death domain -1.43 1.24 
NM_010015 Dad1 Defender against cell death 1 1.31 1.41 
NM_029653 Dapk1 Death associated protein kinase 1 -1.69 -1.00 
NM_010044 Dffa DNA fragmentation factor, alpha subunit -1.74 -1.07 
NM_007859 Dffb DNA fragmentation factor, beta subunit -2.13 1.61 
NM_023232 DiAblo Diablo homolog (Drosophila) -1.03 1.16 
NM_010175 Fadd Fas (TNFRSF6)-associated via death domain -1.81 -1.08 
NM_007987 Fas Fas (TNF receptor superfamily member 6) -1.61 1.09 
NM_010177 Fasl Fas ligand (TNF superfamily, member 6)     -1.44 b    -1.92 c 
NM_007836 Gadd45a Growth arrest and DNA-damage-inducible 45 alpha -1.57 1.09 
NM_010513 Igf1r Insulin-like growth factor I receptor -1.74 -1.17 
NM_010548 Il10 Interleukin 10 -2.67 -1.83 
NM_010712 Lhx4 LIM homeobox protein 4    -3.68 c -3.48 
NM_010736 Ltbr Lymphotoxin B receptor -1.94 -1.27 
NM_011949 Mapk1 Mitogen-activated protein kinase 1 -1.35 1.03 
NM_008562 Mcl1 Myeloid cell leukemia sequence 1 -1.83 -1.46 
NM_008670 Naip1 NLR family, apoptosis inhibitory protein 1    -17.00 b -1.67 
NM_010872 Naip2 NLR family, apoptosis inhibitory protein 2 1.27 1.02 
NM_008689 Nfkb1 Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1, p105 -1.55 1.02 
NM_080637 Nme5 Non-metastatic cells 5, protein expressed in (nucleoside-diphosphate kinase) -1.43 1.79 
NM_172729 Nod1 Nucleotide-binding oligomerization domain containing 1 -1.22 -1.08 
NM_030152 Nol3 Nucleolar protein 3 (apoptosis repressor with CARD domain) 1.19 1.04 
NM_011130 Polb Polymerase (DNA directed), beta -1.16 1.02 
NM_011563 Prdx2 Peroxiredoxin 2 1.08 1.20 
NM_023258 Pycard PYD and CARD domain containing 1.02 1.31 
NM_009068 Ripk1 Receptor (TNFRSF)-interacting serine-threonine kinase 1 -2.11 -1.09 
NM_013693 Tnf Tumor necrosis factor 1.23 -1.18 
NM_020275 Tnfrsf10b Tumor necrosis factor receptor superfamily, member 10b -1.59 1.14 
NM_008764 Tnfrsf11b Tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin) -1.76 -1.26 
NM_011609 Tnfrsf1a Tumor necrosis factor receptor superfamily, member 1a -1.34 -1.24 
NM_009425 Tnfsf10 Tumor necrosis factor (ligand) superfamily, member 10 2.36 1.22 
NM_011614 Tnfsf12 Tumor necrosis factor (ligand) superfamily, member 12 -1.22 1.08 
NM_009421 Traf1 Tnf receptor-associated factor 1 1.34 1.10 
NM_009422 Traf2 Tnf receptor-associated factor 2 -1.43 1.18 
NM_011632 Traf3 Tnf receptor-associated factor 3 -1.63 -1.20 
NM_011640 Trp53 Transformation related protein 53 -1.26 1.12 
NM_173378 Trp53bp2 Transformation related protein 53 binding protein 2 -1.51 1.04 
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For certain indicated genes expression analysis was not made possible due to: (a) nonspecific 
amplification of the product as indicated by the melting curve analysis; (b) a high threshold cycle 
(30-35 cycles) in both control and test samples; and (c) an undetermined threshold cycle i.e. 
greater than the defined cutoff (35 cycles) in both control and test samples. 
 
 
 
 
NM_011641 Trp63 Transformation related protein 63 -1.62 1.57 
NM_011642 Trp73 Transformation related protein 73   -2.10 a 1.06 
NM_009688 Xiap X-linked inhibitor of apoptosis -1.62 -1.16 
NM_007393 Actb Actin, beta -1.22 -1.36 
NM_009735 B2m Beta-2 microglobulin 1.56 1.41 
NM_008084 Gapdh Glyceraldehyde-3-phosphate dehydrogenase 1.03 -1.33 
NM_010368 Gusb Glucuronidase, beta -1.14 1.12 
NM_008302 Hsp90Ab1 Heat shock protein 90 alpha (cytosolic), class B member 1 -1.15 1.14 
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Appendix 2. Gene expression profile of oxidative stress-related genes in NaI-treated NOD.H2h4 
and CBA/J thyrocytes. 
 
RefSeq Symbol Description 
Fold change 
 (+ NaI / - NaI) 
CBA/J NOD.H2h4 
NM_009654 Alb Albumin 
   -2.43 c    -3.31 b 
NM_028717 Als2 Amyotrophic lateral sclerosis 2 (juvenile) homolog 
(human) -1.42 -1.19 
NM_009676 Aox1 Aldehyde oxidase 1 -1.34 1.37 
NM_007462 Apc Adenomatosis polyposis coli 1.04 1.02 
NM_009696 Apoe Apolipoprotein E 1.80 1.34 
NM_019864 Atr Ataxia telangiectasia and rad3 related 1.09 1.24 
NM_009804 Cat Catalase 1.42 1.14 
NM_013653 Ccl5 Chemokine (C-C motif) ligand 5 2.26 1.17 
NM_016892 Ccs Copper chaperone for superoxide dismutase 1.38 -1.18 
NM_007798 Ctsb Cathepsin B 1.23 -1.27 
NM_007806 Cyba Cytochrome b-245, alpha polypeptide 1.29 1.08 
NM_030206 Cygb Cytoglobin 1.47 -2.19 
NM_001039520 Dnm2 Dynamin 2 -1.01 -1.82 
NM_001099297 Duox1 Dual oxidase 1 1.48 -1.17 
NM_153068 Ehd2 EH-domain containing 2 1.28 -1.77 
NM_007946 Epx Eosinophil peroxidase     -1.91 b     -1.07 b 
NM_007949 Ercc2 Excision repair cross-complementing rodent repair 
deficiency, complementation group 2 -1.11 -1.60 
NM_001081221 Ercc6 Excision repair cross-complementing rodent repair 
deficiency, complementation group 6 1.25 -1.18 
NM_007985 Fancc Fanconi anemia, complementation group C -1.09 -1.20 
NM_018881 Fmo2 Flavin containing monooxygenase 2 2.07 -1.13 
NM_010239 Fth1 Ferritin heavy chain 1 2.05 -1.02 
NM_010295 Gclc Glutamate-cysteine ligase, catalytic subunit 1.47 1.22 
NM_008129 Gclm Glutamate-cysteine ligase, modifier subunit 1.69 1.28 
NM_008160 Gpx1 Glutathione peroxidase 1 1.76 -1.07 
NM_030677 Gpx2 Glutathione peroxidase 2 3.14 2.55 
NM_008161 Gpx3 Glutathione peroxidase 3 1.64 -1.56 
NM_008162 Gpx4 Glutathione peroxidase 4 2.03 -1.04 
NM_010343 Gpx5 Glutathione peroxidase 5    -1.07 b     2.34 b 
NM_145451 Gpx6 Glutathione peroxidase 6    1.74 b     2.57 b 
NM_024198 Gpx7 Glutathione peroxidase 7 2.64 -1.04 
NM_010344 Gsr Glutathione reductase 1.69 -1.06 
NM_008180 Gss Glutathione synthetase 1.48 -1.05 
NM_029555 Gstk1 Glutathione S-transferase kappa 1 1.72 1.12 
NM_013541 Gstp1 Glutathione S-transferase, pi 1 1.81 1.08 
NM_010442 Hmox1 Heme oxygenase (decycling) 1 1.99 1.20 
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NM_010479 Hspa1a Heat shock protein 1A 1.96 1.02 
NM_010497 Idh1 Isocitrate dehydrogenase 1 (NADP+), soluble 1.86 1.05 
NM_026298 Ift172 Intraflagellar transport 172 homolog (Chlamydomonas) 1.03 -1.33 
NM_001009940 Il19 Interleukin 19    -1.03 b     1.02 b 
NM_016971 Il22 Interleukin 22 
     2.16 b -1.22 
NM_008473 Krt1 Keratin 1 
   1.09 a -3.64 
NM_080420 Lpo Lactoperoxidase     1.02 a      2.57 b 
NM_013593 Mb Myoglobin 2.01 -1.49 
NM_010824 Mpo Myeloperoxidase 3.20 -1.40 
NM_010876 Ncf1 Neutrophil cytosolic factor 1 1.28 -1.77 
NM_010877 Ncf2 Neutrophil cytosolic factor 2 2.96 -1.03 
NM_022414 Ngb Neuroglobin 1.38 -1.94 
NM_010927 Nos2 Nitric oxide synthase 2, inducible 
  -1.05 a     -5.40 a 
NM_172203 Nox1 NADPH oxidase 1 
    2.30 b     1.26 b 
NM_015760 Nox4 NADPH oxidase 4 1.92 -1.54 
NM_172204 Noxa1 NADPH oxidase activator 1    4.11 a     2.97 a 
NM_027988 Noxo1 NADPH oxidase organizer 1 1.42 2.09 
NM_008706 Nqo1 NAD(P)H dehydrogenase, quinone 1 2.89 2.37 
NM_020569 Park7 Parkinson disease (autosomal recessive, early onset) 7 2.49 -1.03 
NM_011034 Prdx1 Peroxiredoxin 1 2.97 1.12 
NM_011563 Prdx2 Peroxiredoxin 2 2.43 -1.03 
NM_007452 Prdx3 Peroxiredoxin 3 1.82 1.02 
NM_016764 Prdx4 Peroxiredoxin 4 1.91 -1.16 
NM_012021 Prdx5 Peroxiredoxin 5 2.27 -1.03 
NM_007453 Prdx6 Peroxiredoxin 6 1.91 -1.17 
NM_011170 Prnp Prion protein 1.48 -1.21 
NM_011186 Psmb5 Proteasome (prosome, macropain) subunit, beta type 5 2.18 1.04 
NM_008969 Ptgs1 Prostaglandin-endoperoxide synthase 1 1.42 -1.31 
NM_011198 Ptgs2 Prostaglandin-endoperoxide synthase 2 1.37 -1.30 
NM_009020 Rag2 Recombination activating gene 2 1.08 1.91 
NM_058214 Recql4 RecQ protein-like 4 1.53 -1.55 
NM_009127 Scd1 Stearoyl-Coenzyme A desaturase 1 1.92 -1.12 
NM_173052 Serpinb1b Serine (or cysteine) peptidase inhibitor, clade B, 
member 1b 2.87 1.08 
NM_134086 Slc38a1 Solute carrier family 38, member 1 1.19 -1.39 
NM_011434 Sod1 Superoxide dismutase 1, soluble 3.57 1.02 
NM_013671 Sod2 Superoxide dismutase 2, mitochondrial 1.38 -1.35 
NM_011435 Sod3 Superoxide dismutase 3, extracellular 1.20 -1.56 
NM_011018 Sqstm1 Sequestosome 1 1.18 1.20 
NM_029688 Srxn1 Sulfiredoxin 1 homolog (S. cerevisiae) 1.22 1.04 
NM_009417 Tpo Thyroid peroxidase 5.77 1.65 
NM_011660 Txn1 Thioredoxin 1 2.13 1.40 
NM_023719 Txnip Thioredoxin interacting protein 2.62 1.40 
NM_015762 Txnrd1 Thioredoxin reductase 1 1.63 -1.26 
NM_013711 Txnrd2 Thioredoxin reductase 2 1.93 -1.09 
NM_153162 Txnrd3 Thioredoxin reductase 3 1.41 -1.21 
NM_011671 Ucp2 Uncoupling protein 2 (mitochondrial, proton carrier) 2.01 -1.24 
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NM_009464 Ucp3 Uncoupling protein 3 (mitochondrial, proton carrier) 2.15 -1.67 
NM_011701 Vim Vimentin 1.88 -1.21 
NM_011728 Xpa Xeroderma pigmentosum, complementation group A 1.51 -1.00 
NM_007393 Actb Actin, beta -1.10 -1.36 
NM_009735 B2m Beta-2 microglobulin -1.19 1.31 
NM_008084 Gapdh Glyceraldehyde-3-phosphate dehydrogenase 1.27 -1.16 
NM_010368 Gusb Glucuronidase, beta 1.03 1.21 
NM_008302 Hsp90ab1 Heat shock protein 90 alpha (cytosolic), class B member 
1 1.00 -1.00 
 
 
 
 
For certain indicated genes expression analysis was not made possible due to: (a) nonspecific 
amplification of the product as indicated by the melting curve analysis; (b) a high threshold cycle 
(30-35 cycles) in both control and test samples; and (c) an undetermined threshold cycle i.e. 
greater than the defined cutoff (35 cycles) in both control and test samples.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
